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ABSTRACT 
Diphosphoinositol polyphosphates (PP-InsPy) represent a novel group of 
secondary messengers that regulate diverse important cellular processes, including 
signal transduction, vesicle trafficking and apoptosis. The concentration of PP-InsPy in 
cells is very low which makes their isolation from biological sources difficult. An 
alternative is the preparation of PP-InsPy by enzymatic reactions. However, this method 
does not permit to obtain large amounts of material and it is not suitable for the 
preparation of non-natural isomers and analogs. Therefore, an efficient method to 
prepare scalable amounts of different PP-InsPy is essential for the study of functions of 
PP-InsPy. The preparation of PP-InsPy by chemical synthesis holds promise to access 
these required amounts. Additionally, such a method can also provide access to several 
non-natural derivatives that can be used as chemical tools to study the metabolism of 
PP-InsPy. In order to achieve such a synthesis, novel efficient synthetic routes and 
methods are in high demand. 
We will report a novel total synthesis of unsymmetric diphosphoinositol 
polyphosphates. An efficient synthetic route has been developed based on reagent 
controlled asymmetric phosphorylation using a C2-symmetric phosphoramidite. This novel 
phosphorylating reagent enabled us to target all four possible unsymmetric X-PP-InsP5 
(1-PP-InsP5, 3-PP-InsP5, 4-PP-InsP5 and 6-PP-InsP5). Moreover, we developed an 
outstanding one-flask procedure for the formation of the pyrophosphate moiety that is 
characteristic of all PP-InsPy. Unsymmetric 1,5-(PP)2-InsP4 and 3,5-(PP)2-InsP4 were 
prepared for the first time adapting these methods. A novel synthesis of the two 
symmetric 5-PP-InsP5 and 5-PPP-InsP5 (contains a triphosphate) will be also reported. 
These results are a new approach to obtain PP-InsPy on multimilligram scale. 
Additionally, it is the starting point for the development of efficient reagents for 
asymmetric phosphorylation and pyrophosphorylation. These methods have been 
applied already in the synthesis of chemical tools that can be used to decipher inositol 
related cellular signalling pathways. 
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ZUSAMMENFASSUNG 
Diphosphoinositol Polyphosphate (PP-InsPy) verkörpern eine neue Gruppe von 
sekundären Botenstoffen, welche diverse wichtige zelluläre Prozesse wie 
Signalübermittlung, Vesikel-Transport und Apoptose regulieren. Kürzlich wurde berichtet, 
dass PP-InsPy Proteine phosphorylieren in einem Prozess bekannt als 
Pyrophosphorylierung. Diese neue Art der posttranslationalen Modifikation findet in vitro 
statt; jedoch ist immer noch unklar, ob es auch in vivo erfolgt. Die Konzentration von PP-
InsPy in Zellen ist sehr tief, was ihre Gewinnung aus biologischen Quellen erschwert. PP-
InsPy wurden enzymatisch hergestellt. Auf diesem Weg kann jedoch nicht genügend 
Material für biologische Studien gewonnen werden. Zusätzlich ist die Herstellung der 
nicht-natürlichen Isomere nicht möglich und die Stereochemie der hergestellten 
Molekülen kann nicht bestimmt werden. Daher ist eine effiziente Methode, um einen 
skalierbare Mengen an PP-InsPy zu erhalten, entscheidend für Studien bezüglich der 
Struktur und Funktionen der PP-InsPy. Die Gewinnung von PP-InsPy mittels chemischer 
Synthese offeriert die beste Chancen, um eine skalierbare Menge an Material mit 
bekannter Stereochemie zu produzieren. Diese Methode liefert zusätzlich den Zugang zu 
einigen unnatürlichen Derivaten, welche als chemische Hilfsmittel in der Analyse des 
Metabolismus der PP-InsPy verwendet werden können. Verschiedene Synthesen von 
enantiomerenreinen Inositol Polyphosphaten wurden publiziert, aber PP-InsPy sind nicht 
kommerziell erhältlich und die Qualität der früheren Zubereitungen wurden in Frage 
gestellt. Asymmetrische Phosphorylierung ist eine ausgezeichnete Art und Weise, um 
eine Phosphat Gruppe an einer spezifischen Position in der Struktur von myo-Inositol 
einzuführen. 
Wir werden eine neue Totalsynthese von unsymmetrischen Diphosphoinositol 
Polyphosphaten veröffentlichen, in der ein C2-symmetrisches Phosphoramidit verwendet 
wird, um verschiedene Inositol Derivate asymmetrisch zu machen. Dieses neue 
Phosphorylierungsreagenz ermöglichte uns, alle vier möglichen unsymmetrischen X-PP-
InsP5 (1-PP-InsP5, 3-PP-InsP5, 4-PP-InsP5, und 6-PP-InsP5) herzustellen. Zum ersten 
Mal wurden zusätzlich 1,5-(PP)2-InsP4, und 3,5-(PP)2-InsPy mit der selben Methode 
zubereitet. Eine neue Synthese des symmetrischen 5-PP-InsP5 und die erste 
Totalsynthese von meso 5-PPP-InsP5 werden ebenfalls veröffentlicht. Diese Resultate 
verkörpern einen neuen Ansatz in der geplanten Totalsynthese von PP-InsPy, sowie eine 
Ausgangspunkt für die Entwicklung von effizienten Reagenzien für die asymmetrische 
Phosphorylierung und Pyrophosphorylierung. Sie liefern uns zusätzlich Mittel, um die mit 
Inositol verwandte zelluläre Signalwege entschlüsseln zu können. 
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CHAPTER 1 
BIOLOGICAL IMPORTANCE OF INOSITOL 
POLYPHOSPHATES 
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1.1 MYO-INOSITOL 
Inositols are a family of cyclohexanehexols (cyclitols) that include nine 
stereoisomers prefixed: myo-, neo-, D-chiro-(+)-, L-chiro-(-)-, scyllo-, cis-, epi-, allo- and 
muco- (Figure 1.1).1,2 The first five forms are naturally occurring, while the others are 
synthetic isomers.3,4 The building block of several biologically relevant molecules is the 
isomer myo-inositol5 that has been isolated by the german scientist Johann Joseph 
Scherer in 1850 from muscle tissue and designated “Inosit”.6 Subsequently, the suffix –ol 
was added to describe all the other stereoisomers. 
 
 
 
Figure 1.1. Structures of the nine possible stereoisomers of inositol. 
 
 myo-Inositol is an optically inactive (meso) molecule due to a plane of symmetry 
that dissects the 2- and 5-position of the ring. Therefore, substitutions on the 1- or 3-
position and on the 4- or 6-position form enantiomers. The thermodynamically most 
stable conformation of myo-inositol is its chair structure7 that has been associated with 
the shape of a turtle by Bernard W. Agranoff in 1978.8 The Haworth projection of the 
molecule can cause confusion in numbering of the six hydroxyl groups,9 therefore the 
turtle is used as a mnemonic to avoid such confusion. The axial hydroxyl group in 2-
position represents the head, the four equatorial groups in 1-, 3-, 4- and 6-position the 
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limbs and the equatorial hydroxyl group in 5-position the tail of the turtle (Figure 1.2). In 
natural systems, myo-inositol is linked to a lipid backbone through one of the equatorial 
hydroxyl groups and by convention the number 1 in the myo-inositol molecule is assigned 
to this position. The numbering of the other hydroxyl groups proceeds counterclockwise 
using the D numbering convention.  
 
 
 
Figure 1.2. A) Plane of symmetry through the 2- and 5-position of myo-inositol; B) Haworth projection of 
myo-inositol; C) Structure of phosphatidylinositol 4,5-bisphosphate; D) Agranoff’s turtle7 (Adapted by 
permission from Macmillan Publishers Ltd: Nat. Rev. Mol. Cell Biol. 2001, 2, 327-338, Copyright © 
2001). 
 
 
1.1.1 BIOSYNTHESIS OF MYO-INOSITOL 
 myo-Inositol is very abundant in plants and most of the amount present in 
mammals is obtained from the diet.1 However, it can be also synthesized from D-glucose 
6-phosphate by the enzymes L-myo-inositol 1-phosphate synthase and myo-inositol 1-
phosphatase (Figure 1.3). The latter enzyme is of special importance, as it is supposed 
to be the target of lithium cations in the treatment of bipolar disorders.10 myo-Inositol that 
is taken up from food is not able to cross the blood brain barrier, therefore the levels of 
the molecule in the brain depend on its biosynthesis from D-glucose 6-phosphate. Rats 
that were treated with lithium showed a lower concentration of myo-inositol in the brain, 
which can be related to the inhibition of myo-inositol 1-phosphatase by the cation.10 In 
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absence of myo-inositol, phosphoinositides cannot be biosynthesized, therefore the 
signaling pathways that are regulated by these lipid derivatives and that are associated to 
the origin of manic depression are blocked.11 
 
 
 
Figure 1.3. a) Oxidation of D-glucose 6-phosphate to 5-keto-glucose 6-phosphate by L-myo-inositol 1-
phosphate (oxidoreductase activity); b) Conversion to L-myo-inosose-2-1-phosphate (aldolase activity); 
c) Formation of D-myo-inositol 3-phosphate by hydrogen transfer from NADH; d) Phosphate hydrolysis 
to myo-inositol by myo-inositol 1-phosphatase. (Scheme reproduced from Ref.1) 
 
  
1.1 INOSITOL POLYPHOSPHATES 
 Inositol polyphosphates are a class of second messengers that regulate several 
cellular signaling processes.7,12–14 Due to the special stereochemistry of myo-inositol, 
phosphorylation of the molecule allows the construction of 63 phosphate esters, from the 
mono- to the hexakisphosphate (6 x InsP1, 6 x InsP5, 15 x InsP2, 15 x InsP4, 20 x InsP3 
and InsP6).15 At least half of these isomers exist in biological systems, although cellular 
functions have not been attributed to all of them.7,16,17    
The best characterized inositol polyphosphate is inositol 1,4,5-trisphosphate 
(InsP3 or IP3), a second messenger discovered in 1983 that stimulates calcium release 
from intracellular reservoirs.18 Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] is 
hydrolyzed by phospholipase C (PLC) to diacylglycerol,19 which is hydrophobic and 
remains in the membrane after cleavage, and InsP3, which is soluble in the cytosol and 
able to bind the inositol trisphosphate receptor (InsP3R) present on membranes of 
cellular compartments, especially in the endoplasmic reticulum (ER) (Figure 1.4).20 After 
binding to its receptor, InsP3 stimulates the release of calcium ions from the intracellular 
stores to the cytosol. The increase of calcium concentration in the cytoplasm is important 
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in muscular contraction, secretion, cell growth and transformation, sensory perception 
and others.21 
 
 
 
Figure 1.4. Hydrolysis of PI(4,5)P2 by phospholipase C to form diacylglycerol (DAG) and InsP3 (Picture 
reproduced from Ref.22). 
 
The enzyme Ins(1,4,5)P3 3-kinase catalyzes the convertion of Ins(1,4,5)P3 to 
inositol-1,3,4,5-tetrakisphosphate [Ins(1,3,4,5)P4] that is able to activate Ca2+ channels in 
the plasma membrane of endothelial cells and neurons (Figure 1.5).23,24 Additionally, it 
interacts with InsP3 receptors on the membrane of the endoplasmic reticulum inhibiting or 
enhancing the action of Ins(1,4,5)P3, depending on the receptor isoform.7 Finally, it is 
dephosphorylated by the enzyme 5-phosphatase, the same enzyme that hydrolizes 
Ins(1,4,5)P3, but with higher affinity, thus protecting InsP3 from hydrolysis.25 The role of 
inositol-3,4,5,6-tetrakisphosphate [Ins(3,4,5,6)P4] is correlated to the secretion of Cl¯ as it 
inhibits Cl¯ channels that are stimulated by calcium ions.26 This process is especially 
important in cystic fibrosis, as this is the only Cl¯ channel that is active in patients affected 
by the disease. Therefore, generation of Ins(1,4,5)P3 in these patients can be both 
beneficial as it leads to an increased concentration of calcium cations in the cell and 
consequently to Cl¯ secretion, but also harmful as the metabolite Ins(3,4,5,6)P4 is 
produced and inhibits Cl¯ secretion.  
Inositol-1,3,4,5,6-pentakisphosphate (InsP5) is abundant in mammalian cells 
(Figure 1.5).27 Among the roles that have been attributed to it, it has been shown that it 
interacts with proteins competing for their binding to phosphoinositides. For example, it 
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 6 
binds Akt (protein kinase B), inhibiting its activation and therefore stimulating apoptosis in 
cancer cells.7  
The most abundant InsP is myo-inositol (1,2,3,4,5,6)-hexakisphosphate (InsP6 or 
phytic acid) with a concentration of 10-60 µM in mammalian cells and 0.7 mM in 
Dictyostelium discoideum (Figure 1.5).28 It is the first inositol phosphate that has been 
discovered29 and it is the main phosphate storage molecule in plants – “look at a field of 
wheat and you are gazing at tons of InsP6” (quote from Irvine and Schell, Ref.7). InsP6 is 
a highly negatively charged molecule able to interact with positively charged groups on 
proteins that are mainly involved in secretion and vesicular trafficking.7  
 
 
 
Figure 1.5. Structures of some myo-inositol polyphosphates present in organisms. 
 
 
1.3 DIPHOSPHOINOSITOL POLYPHOSPHATES 
1.3.1 INITIAL DISCOVERIES 
 The structural diversity of inositol polyphosphates can be expanded by 
introducing one or two diphosphate groups onto the fully phosphorylated InsP6, 
generating InsP7 and InsP8, that contain seven or eight phosphate groups (Figure 1.6). 
These molecules are commonly known as inositol pyrophosphates, a designation that 
has been introduced by Steven Shears and subsequently used by others. However, it is 
important to mention that this is not the correct IUPAC nomenclature since the term 
“pyrophosphate” describes an inorganic phosphoanhydride.14 Therefore the correct prefix 
for this particular moiety is diphospho- and the appropriate name for these molecules 
would be “diphosphoinositol polyphosphates”. They have been discovered in 1993 
independently by two distinct research groups: by the group of Shears that was studying 
pancreatoma cells and by the group of Mayr that was studying the amoeba Dictyostelium 
discoideum.30,31 These molecules have been identified by strong ion-exchange HPLC 
column and characterized by 31P-NMR and subsequently they have been found to be 
present in all eukaryotic cells (Figure 1.6). A higher level of phosphorylation was 
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attributed to them as they were retained in the column more than InsP6 and therefore 
they had to be more polar than the fully phosphorylated InsP6. Subsequently, in a 
chromatography analysis of the yeast Saccharomyces cerevisiae, lower inositol 
pyrophosphates have been identified and considered to be PP-InsP3, PP-InsP4, (PP)2-
InsP2 and (PP)2-InsP3.32 
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Figure 1.6. A) Two examplary structures of diphosphoinositol polyphosphates; B) HPLC separation of 
inositol polyphosphates; C) 31P-NMR spectra of PP-InsP5 (top spectrum) and bis(PP)-InsP4 (bottom 
spectrum) separated by HPLC.31 (Pictures B and C were originally published in the Journal of Biological 
Chemistry. Stephens, L.; Radenberg, T.; Thiel, U.; Vogel, G.; Khoo, K. H.; Dell, a; Jackson, T. R.; 
Hawkins, P. T.; Mayr, G. W. The detection, purification, structural characterization, and metabolism of 
diphosphoinositol pentakisphosphate(s) and bisdiphosphoinositol tetrakisphosphate(s). J. Biol. Chem. 
1993, 268, 4009–4015. © the American Society for Biochemistry and Molecular Biology) 
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1.3.2 STEREOCHEMISTRY AND PRESENCE IN BIOLOGICAL SYSTEMS  
The assignment of the correct stereochemistry of diphosphoinositol 
polyphosphate isomers that are present in the cell has been under discussion for years. 
This question is of high importance to understand which isomers mediate cellular 
signaling pathways and has recently been solved (see below). In general, a specific 
isomer is recognized by the catalytic site of an enzyme, thus the determination of the 
correct stereochemistry would provide a better understanding of the mechanism that is 
responsible for the metabolism of PP-InsPs. Similarly, receptors can distinguish between 
different isomers, thus providing information about their structure-function relationships.33   
 
1.3.2.1 INOSITOL PYROPHOSPHATES IN MAMMALIAN CELLS  
The most abundant inositol pyrophosphate in mammalian cells is 5-
diphosphoinositol pentakisphosphate (5-PP-InsP5 or 5-InsP7) as demonstrated by Shears 
and coworkers in 1997 (Figure 1.7).33 The minor inositol pyrophosphate isomer found in 
mammalian cells is 1-PP-InsP5, while the most abundant (PP)2-InsP4 contains 
pyrophosphate moieties in the 1 and 5 positions.34 As mentioned above, the 
determination of the correct stereochemistry of the naturally occurring isomers has not 
been straightforward.35 In 2007, the O’Shea and York laboratories identified an InsP7 
isomer produced by Vip1 and involved in phosphate starvation and they wrongly believed 
that it contained a diphosphate moiety in the 4 or 6 position.36,37 In 2009 Mayr and 
coworkers showed that the product of Vip1 is pyrophosphorylated in the 1 or 3 position38 
and only in 2011 the Shears laboratory obtained crystal structures of the kinase domain 
of human PPIP5K2 complexed with various substrates demonstrating that the naturally 
occurring isomers are 1-InsP7 and 1,5-InsP8.34  
 
 
 
Figure 1.7. Structures of diphosphoinositol polyphosphates present in mammalian cells. 
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1.3.2.2 INOSITOL PYROPHOSPHATES IN DICTYOSTELIUM DISCOIDEUM  
The investigation of the functions of PPx-InsPy in mammalian cells is difficult due 
to the low intracellular concentration of these molecules (less than 1 µM). Therefore, the 
slime mold Dictyostelium discoideum has been investigated, as in this organism the 
intracellular levels of PP-InsPs are about 300-fold higher (0.05-0.25 mM).31 However, the 
slime mold is not a representative model to study inositol pyrophosphate related signaling 
pathways in mammalian cells, as the isomers present in the two organisms are different. 
Vogel and coworkers determined in 1996 by two-dimensional 1H/31P NMR analysis that 
the diphosphoinositol pentakisphosphate present in Dictyostelium discoideum was the 4- 
and/or the 6-PP-InsP5 and that the bisdiphosphoinositol tetrakisphosphate was the 4,5- 
and/or 5,6-(PP)2-InsP4.39 However, using NMR spectroscopy only, it was not possible to 
differentiate the enantiomers and determine which isomers were present in the slime 
mold. The following year, the same group reported that the naturally occurring isomers in 
Dictyostelium are 6-PP-InsP5 and 5,6-(PP)2-InsP4 using a PP-InsP5 kinase isolated from 
the mold, which phosphorylates only the naturally occurring PP-InsP5. Synthetic PP-InsP5 
(1-, 3-, 4- and 6-PP-InsP5) were used as substrates for the enzyme, showing that only 
the 6-PP-InsP5 was converted, thus producing 5,6-(PP)2-InsP4 (Figure 1.8).40 However, 
low purity of the synthetic compounds might have biased these results. 
 
 
 
Figure 1.8. Structures of diphosphoinositol polyphosphates present in Dictyostelium discoideum. 
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1.3.3 BIOSYNTHESIS AND METABOLISM OF INOSITOL PYROPHOSPHATES 
 Phosphatidylinositol 4,5-bisphosphate (PIP2) anchors myo-inositol to the plasma 
membrane in biological systems and it is the precursor of the various inositol phosphate 
derivatives that are present in the cell. Phospholipase-C (PLC) is the enzyme that 
hydrolyzes the phospholipid generating the membrane-bound diacylglycerol (DAG) and 
the cytosol-soluble inositol 1,4,5-trisphosphate (InsP3). InsP3 is then converted to the 
various phosphorylated forms of inositol by a series of kinases and phosphatases 
starting the IP signaling (Figure 1.9).12,13,41 
 
 
 
Figure 1.9. Possible routes of inositol pyrophosphates synthesis in mammalian (red) and S. cerevisiae 
(blue). PLC/Plc1 = Phospholipase C; IPMK/Arg82 = Inositol phosphate multikinase; IPPK/Ipk1 = Inositol 
1,3,4,5,6-pentakisphosphate 2-kinase; IP6Ks/Kcs1 = Inositol hexakisphosphate kinase; PPIPKs/Vip1 = 
Diphosphoinositol pentakisphosphate kinase. (Picture reproduced from Ref.13) 
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1.3.3.1 KINASES  
InsP6 is the precursor of 5-PP-InsP5 and inositol hexakisphosphate kinases 
(IP6Ks) are the enzymes responsible for this transformation using ATP as a phosphate 
donor. Three different isoforms of the kinase exist in mammalian cells: IP6K1, IP6K2 and 
IP6K3. IP6K1 and IP6K3 phosphorylate InsP5 and InsP6, with a slight preference for 
InsP6, while the selectivity of IP6K2 for InsP6 is 20-fold higher than for InsP5.42,43 In a 
study of the three different isoforms, it has been suggested that IP6K2 is also able to 
synthesize a higher phosphorylated inositol derivative with a triphosphate in position 5 
known as 5-PPP-InsP5 (InsP8), although in lower concentration as compared to InsP7.43–
45 Incubation of IP6K2 with InsP6 for a longer period of time (12 h) leads to the formation 
of a more polar molecule, presumably an InsP9 isomer.45 Another precursor of inositol 
pyrophosphates is Ins(1,3,4,5,6)P5 that can be phosphorylated by IP6K at positions 1 or 
3 generating 1/3-PP-InsP4.43 This substrate that contains one unphosphorylated hydroxyl 
group can be then phosphorylated again by the same enzyme to generate (PP)2-InsP3.46 
 Besides the IP6K family, PPIP5K or PP-InsP5 kinases are another class of 
enzymes responsible for the biosynthesis of inositol pyrophosphates in mammalian 
cells.47,48 They phosphorylate both InsP6 and 5-PP-InsP5, introducing a phosphate 
specifically in position 1 and generating 1-PP-InsP5 and 1,5-(PP)2-InsP4 respectively.34,38 
However, PPIP5K contains also a phosphatase domain that might antagonize the action 
of the kinase domain by dephosphorylating 1-PP-InsP5, suggesting that the main target 
of the enzyme is InsP7.13  
The kinases found in yeast S. cerevisiae are Kcs1 (IP6K homolog) and Vip1 
(PPIP5K homolog) and phosphorylate the 5 and 1 position of InsP6 and 5-PP-InsP5, 
respectively.13,37,42 
 
 
1.3.3.2 PHOSPHATASES 
 Diphosphoinositol-polyphosphate phosphatases (DIPPs) are phosphatases that 
belong to the nudix (nucleoside diphosphate attached-moiety X) family and catalyze the 
hydrolysis of diphosphate bonds in inositol pyrophosphates, diadenosine polyphosphates 
and inorganic polyphosphate.46,49 In mammalian cells, 4 DIPP genes have been identified 
that encode for 5 proteins: (DIPP1, DIPP2α, DIPP2β, DIPP3α and DIPP3β), while in 
yeast S. cerevisiae only the protein Ddp1 has been found.50 DIPP1 is the most active in 
hydrolyzing inositol pyrophosphates, followed by the two isoforms of DIPP2 and finally 
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DIPP3, which is the least active.51 This class of enzymes dephosphorylates mainly the β-
phosphate in position 1 of inositol pyrophosphate, followed by dephosphorylation at 
position 5.51  
  Multiple inositol polyphosphate phosphatase (MIPP) is another enzyme that 
catalyzes the hydrolysis of the pyrophosphate bond in position 5 of diphosphoinositol 
polyphosphates in vitro, but not in vivo.52,53  
 
 
1.3.3.3 TURNOVER 
 The proposal that inositol pyrophosphates have significant biological functions 
was inspired by their rapid metabolic turnover caused by the action of kinases and 
phosphatases. Intracellular concentrations of InsP5 and InsP6 are high as compared to 
the concentration of inositol pyrophosphates, however every 60-90 min 20% of InsP5 and 
50% of InsP6 are converted to PP-InsP4 and PP-InsP5. Therefore the low concentration of 
inositol pyrophosphates can be associated with their rapid turnover, suggesting that 
these molecules have a role in cellular signaling.30 Shears and coworkers also 
demonstrated that in primary cultured hepatocytes inositol pyrophosphate pools turn over 
ten times every 40 minutes, while only the 10% of the InsP6 pool turns over in the same 
time.54 
 
 
1.3.4 MECHANISM OF ACTION AND FUNCTIONS 
Many functions have been attributed to inositol pyrophosphates since their 
discovery and it has been proposed that they act in the cell mainly by two mechanisms of 
action: by binding to a particular protein and by donating the β-phosphate of the 
pyrophosphate moiety to a specific protein target (Figure 1.10).14,55–57  
The intracellular concentrations of inositol pyrophosphates increase in response 
to stimuli generated inside cells, related to the maintenance of energy balance, therefore 
a description of them as “metabolic messengers” has been proposed.14,35 However, InsP8 
levels increase on extracellular stimulus in line with a functional second messenger.58–60 
An example that supports the definition as metabolic messengers comes from a recent 
study by Saiardi and coworkers that demonstrates that inositol pyrophosphates regulate 
intracellular ATP concentration.61 They showed that in yeast Saccharomices cerevisiae 
ATP concentration increased in the absence of inositol pyrophosphates, while when IP6K 
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was overexpressed, and therefore the levels of inositol pyrophosphates were presumably 
higher, the intracellular concentration of ATP dropped. The hypothesis that arises is that 
inositol pyrophosphates are “biosensors that detect variations in energy balance”.14 If 
they are not synthesized, then ATP is not consumed and the energy of the cell is 
conserved, which is especially important when the cell is in an energetically challenging 
condition. 
 
 
 
Figure 1.10. “Possible mechanisms of signal transduction by inositol pyrophosphates. The upper panel 
depicts the direct binding mechanism in which a protein target possesses a specific pocket able to 
recognise InsP7. The lower panel shows the pyrophosphorylation modification of a protein carried out by 
InsP7. A pre-phosphorylated serine (yellow circle) is the recipient of the b-phosphate (red circle) of the 
pyrophosphate moiety of InsP7.” 57 (Burton, A.; Hu, X.; Saiardi, A. Are inositol pyrophosphates signalling 
molecules? J. Cell. Physiol. 2009, 220, 8-15. Copyright © 2009 Wiley-Liss, Inc.) 
 
 
1.3.4.1 PROTEIN BINDING 
Similarly to InsPy, X-PP-InsPy can modulate cellular signaling pathways by 
binding proteins, especially those involved in vesicular trafficking.62–67 The first 
suggestion that inositol pyrophosphates might have this role emerged from a study on 
pancreatic β cells where InsP7 was produced after overexpression of IP6K stimulating 
exocytosis of insulin, while RNA silencing of IP6K1 inhibited exocytosis.68 
Pleckstrin homology (PH) domains are responsible for protein-protein and 
protein-phospholipid interactions.35 Proteins that contain PH domains are recruited to the 
plasma membrane and bind phosphoinositides in response to certain cellular stimuli, but 
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they are able to bind also soluble inositol phosphates.69 Therefore, InsPy can compete 
with the polar head groups of phosphoinositides for binding PH domains, thus inhibiting 
the migration of certain proteins to the cell membrane.70–72 The Snyder laboratory was 
the first to demonstrate that also inositol pyrophosphates can bind PH domains of 
proteins. They showed that in Dictyostelium 5-InsP7 competes with PtdIns(3,4,5)P3 by 
binding PH domain containing proteins and ultimately decreasing the chemotactic 
response that is regulated by these proteins in the mold.73 The PH domain of Akt is 
another binding site of InsP7. Akt is a kinase that is activated by binding PIP3 at the 
plasma membrane and InsP7 competes with this binding. The kinase regulates various 
cellular processes, such as growth factor signaling, glucose uptake, glycogen synthesis 
and protein synthesis.74 Therefore, an abnormal activity of the kinase can lead to 
diseases such as cancer or diabetes.74,75 It has been shown that IP6K1 knockout (KO) 
mice are characterized by a reduced fat accumulation and consequently by a reduced 
body weight in comparison to wild type (WT) mice. When IP6K1 KO mice were on high-
fat diet (HFD) they showed resistance to obesity, suggesting that inhibition of IP6K1 
could represent a strategy to treat obesity and diabetes.74 
In mammalian cells, inositol pyrophosphates seem to have a role in the regulation 
of apoptosis through inositol hexakisphosphate kinase (IP6K), the enzyme responsible 
for the conversion of InsP6 to 5-PP-InsP5. In the absence of this enzyme there is no 
increment of the intracellular levels of 5-PP-InsP5 and cell death is also decreased, 
suggesting that 5-PP-InsP5 promotes apoptosis.76  
Inositol pyrophosphate levels, and especially the levels of 1/3,5-(PP)2-InsP4, 
increases as a consequence of hyperosmotic stress, thus representing a sensor for this 
stimulus.59,60  
Another function that has been attributed to inositol pyrophosphate is the 
regulation of telomere length in yeast. Telomeres are DNA sequences situated at the end 
of chromosomes with the function of preventing their degradation. Their shortening is 
associated with cellular aging.77 When Kcs1 (yeast homologue of IP6K) was 
overexpressed and high levels of inositol pyrophosphates were produced, telomere 
shortening was observed, while longer telomeres were a consequence of reduced levels 
of inositol pyrophosphates. This function is specific for PP-InsP4, the inositol 
pyrophosphate that is produced by phosphorylation of InsP5.78,79  
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1.3.4.2 PROTEIN PYROPHOSPHORYLATION 
Diphosphoinositol polyphosphates are especially interesting for their role as 
phosphate donors. Diphosphoinositol polyphosphates phosphorylate proteins in a 
process called protein pyrophosphorylation or transphosphorylation. This new kind of 
post-translational modification has been described to take place in vitro in 2004, but it is 
not clear if it takes place also in vivo.80,81 The high amount of energy released upon 
hydrolysis of the diphosphate bond of InsP7 (6.6 kcal/mol) and InsP8 (7.3 kcal/mol) is 
comparable to the energy released upon hydrolysis of ADP and ATP.31 This is due to the 
release of electrostatic and steric constraints.39 Therefore these molecules are able to 
transfer their β-phosphate to proteins. Strikingly, these processes occur in a kinase 
independent mechanism. This transfer seems to target prephosphorylated serine 
residues surrounded by acidic aminoacids in the presence of Mg2+ cations (Figure 
1.11).82  
 
 
 
Figure 1.11. Mechanism of protein pyrophosphorylation mediated by diphosphoinositol polyphosphates. 
(Picture reproduced from Ref.83)  
 
 
Proteins that are targets of pyrophosphorylation belong to the family of nucleolar 
proteins, which are involved in the synthesis of ribosomal RNA (rRNA) and the best 
characterized are the yeast proteins Srp40p and Nsr1p and the mammalian proteins 
nucleolin, Nopp140 and TCOF1.80 This is another example that suggests that inositol 
pyrophosphates might be metabolic messengers involved in the maintenance of energy 
balance, as ribosomal synthesis consumes 80% of the energy of the proliferating cell.14 
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Pyrophosphorylation as well as regular protein phosphorylation induce changes in protein 
conformation, influencing their activity and localization. The difference between the two 
modifications is evidenced by the special properties conferred to the pyrophosphorylated 
proteins. They are more acid labile and more resistant to phosphatases and 
pyrophosphatases than proteins modified by regular phosphorylation.82 This means that 
they are able to transduce the signal over a longer period of time in the presence of a 
phosphatase.57 However, it is not known if the opposite process occurs, that is the 
dephosphorylation of pyrophosphorylated proteins, as no phosphatase able to mediate 
such activity has been identified.14 
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CHAPTER 2 
CHEMICAL SYNTHESIS OF INOSITOL 
POLYPHOSPHATES 
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2.1 “WHY NATURE CHOSE PHOSPHATES” 
In 1987 Westheimer stated that “phosphate esters and anhydrides dominate the 
living world”. Phosphates are found, for example, in DNA and RNA, coenzymes, ATP and 
many metabolic intermediates demonstrating the importance of this functional group in 
biological systems.84 Phosphates are ionized in living systems due to the pH (6.8 to 7.3) 
of the environment and the negative charges have mainly two functions: 1) to prevent 
hydrolysis of phosphodiesters, since it is not likely that a hydroxide ion attacks a 
negatively charged species such as a phosphate; 2) to retain phosphorylated molecules 
inside cells by inhibiting their diffusion across lipid membranes. However, phosphorylated 
compounds are not the only ionized species that could exist in biological systems and 
examples include citric acid, arsenic acid and silicic acid. Although all these compounds 
bear negative charges, they can be hydrolyzed much faster than phosphates. Thus, 
biomolecules (e.g. genetic material) that would contain them would not be protected from 
hydrolysis. Therefore, these negatively charged molecules are not appropriate to 
substitute phosphates in living systems, as biomolecules would not be stable enough 
over longer periods of time, which is fundamental for the life of organisms.  
Westheimer also stated that the phosphate group is rarely used by organic 
chemists due to its poor reactivity and therefore groups that can be activated more easily 
(e.g. chlorides, tosylates) are preferred in synthetic organic chemistry. However, this 
statement is not correct anymore due to the enormous advances that have been made in 
phosphorus chemistry in the past decades.  
 
 
2.1 PHOSPHORAMIDITE CHEMISTRY 
2.2.1 INTRODUCTION 
 Phosphoramidites are amides of trivalent phosphorous acid H3PO3 characterized 
by one P-N and two P-O bonds (Figure 2.1).85 Over the past decades, phosphoramidites 
have been used to introduce phosphate moieties on hydroxyl groups of a variety of 
molecules.86,87 Phosphoramidites are phosphitylating reagents involved in a nucleophilic 
substitution reaction by an alcohol on a trivalent phosphorus centre.88 Initially P(III) 
chloridite reagents have been employed in the coupling reaction with alcohols. A 
drawback of these highly reactive compounds is that they are not stable, therefore they 
have been replaced with phosphoramidites (P-amidites) by Caruthers. P-amidites are 
less reactive and therefore prior activation by an acidic promoter is required.89 The acidic 
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promoter protonates the nitrogen atom and the amino group is displaced, favoring the 
subsequent coupling to an alcohol (Figure 2.1).  
 
 
 
Figure 2.1. Phosphytilation mechanism. Phosphoramidites are activated by acidic promoters, which 
favors the coupling to an alcohol to form the phosphitylation product and a salt. (Scheme reproduced 
from Ref. 90)  
 
 
Many P(III) amidites are moisture sensitive in the presence of acid, as these 
species react with water generating hydrogen phosphonates. Therefore, dry aprotic 
solvents are employed in phosphoramidite chemistry, such as dichloromethane or, more 
commonly, acetonitrile. Pentavalent (P(V)) reagents are also employed as 
phosphorylating reagents, however their P(III) analogs are preferred by many groups due 
to their higher reactivity. Moreover, phosphitylated (P(III)) compounds can be converted 
into their P(V) analogs by oxidation, also facilitating sulfurizations and selenizations. 
 
 
2.2.2 MECHANISM OF THE PHOSPHORAMIDITE COUPLING REACTION 
 The phosphoramidite coupling reaction or phosphitylation (often confused with 
phosphorylation) can be defined as a nucleophilic substitution reaction and classified in 
three sub-categories depending on the attack of the nucleophile and the displacement of 
the amino group: 1) dissociative SN1-type reaction; 2) concerted SN2-type reaction; 3) 
associative mechanism (Figure 2.2).88,91 The dissociative SN1-type mechanism is 
characterized by the departure of the amino group after protonation and the subsequent 
formation of a phosphenium cation that reacts with a nucleophile. In the SN2-type 
mechanism the nucleophilic attack and the departure of the amino group occur 
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simultaneously, while the associative mechanism occur through the formation of a 
pentacoordinated intermediate. However, also the formation of a four-membered ring has 
been proposed to be involved in the substitution of phosphoramidites. 
 
 
 
Figure 2.2. Dissociative (D), concerted (C) and associative mechanism (A) for P(III) substitution. Four-
membered (FM) ring transition state involved in the mechanism of the phosphoramidite coupling 
reaction. Lg = leaving group. (Schemes reproduced from Ref.88) 
 
 
Protonation of the phosphorus atom shortens and strengthens the P-N bond and 
it promotes the phosphoramidite coupling via pentacoordination, while protonation of the 
nitrogen atom lengthens and weakens the P-N bond favoring a dissociative or concerted 
mechanism.88 However, nitrogen protonation is required for the phosphoramidite coupling 
reaction to occur.92  
 
 
2.2.3 ACTIVATORS 
Activators used in phosphoramidite chemistry have a pKa in the range of 12.5-
18.5 in acetonitrile, while the pKa of the same activators is different in other solvents. 
Promoters with a pKa in this range protonate the nitrogen of phosphoramidites weakening 
the P-N bond and favoring a dissociative mechanism, while weaker acids (pKa>18.5) are 
not able to activate phosphoramidites. More acidic activators (pKa<10) promote the 
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protonation of the phosphorus atom, strengthening the P-N bond and slowing down the 
alcoholysis (Figure 2.3).92 
 
 
 
Figure 2.3. ”Effect of acids on phosphoramidites as a function of the acid strength.” 88 2-CPyrH = 2-
chloropyridinium ion; DMAnH = N,N-dimethylanilinium ion; PyrH = pyridinium ion; DIAnH = 
diisopropylanilinium ion; BDMAH = N,N-dimethylbenzylammonium ion; BimiH = benzimidazolium ion; 
ImiH = imidazolium ion; Tri = triazole; TH = 1H-Tetrazole; TFA = Trifluoroacetic acid. (Nurminen, E.; 
Lönnberg, H. Mechanisms of the substitution reactions of phosphoramidites and their congeners. J. 
Phys. Org. Chem. 2004, 17, 1–17. Copyright © 2003 John Wiley & Sons, Ltd.) 
 
 
 
The first reported and most common activator of phosphoramidites is 1H-
tetrazole89 (for structure see Figure 2.1) and it can be modified with electron-withdrawing 
groups at the C-5 position to obtain more acidic and therefore more potent activators 
(e.g. 5-nitrophenyl-1H-tetrazole, 5-ethylthio-1H-tetrazole, 5-benzylthio-1H-tetrazole, 5-
methylthio-1H-tetrazole, 5-mercapto-tetrazole).93 1H-Tetrazole is usually used as a 0.45 
M solution in acetonitrile, as higher concentrations cause its precipitation (> 0.5 M). 1H-
Tetrazole has a dual role in the activation of phosphoramidites and promotion of 
phosphitylation, as it acts as a proton donor and subsequently as a nucleophile.94 The 
mechanism of phosphitylation by 1H-tetrazole can be divided into three steps: 1) 1H-
tetrazole protonates the nitrogen of the phosphoramidite; 2) it acts as a nucleophile 
displacing the amino group and forming a tetrazolide intermediate; 3) a nucleophilic 
attack by the alcohol on the tetrazolide intermediate generates the phosphite triester 
(Figure 2.1).90 However, due to its cost, hygroscopy, poor solubility, toxicity and instability 
(explosive), alternative activators are also employed, such as acidic azoles, azolium 
salts, pyridinium salts, anilinium salts, ammonium salts, carboxylic acids and phenols.88,93 
Besides increasing the acidity of activators, the phosphitylation reaction can be improved 
by accelerating the displacement of the amino group, which is the rate determining step. 
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For example, 4,5-dicyanoimidazole (DCI) is less acidic but more nucleophilic than 1H-
tetrazole and it has been shown that it can improve phosphoramidite couplings.95  
 
Activator pKa 
1H-Tetrazole 14.5 
5-(Ethylthio)-1H-tetrazole 12.9 
Benzimidazolium salts (triflate, fluoroborate) 14.3 
Imidazolium salts (triflate, fluoroborate, perchlorate, chloride) 17.1 
N-Methylimidazolium salts (triflate, chloride, trifluoroacetate) 17.1 
N-Phenylimidazolium salts (triflate, perchlorate, fluoroborate) 16.0 
Pyridinium salts (chloride, bromide, fluoroborate, tosylate, triflate) 12.6 
4-Chloropyridinium chloride 10.9 
2,4-Dinitrophenol 16.0 
 
Table 2.1. List of activators and pKa values in acetonitrile. (Ref.88) 
 
 
2.3 STEREOSELECTIVE SYNTHESIS 
“One of the most active current areas of chemical research is 
centered on how to synthesize handed (chiral) compounds in a selective 
manner, rather than as mixtures of mirror-image forms (enantiomers) with 
different three-dimensional structures (stereochemistries). Nature points the 
way in this endeavor: different enantiomers of a given biomolecule can 
exhibit dramatically different biological activities, and enzymes have 
therefore evolved to catalyze reactions with exquisite selectivity for the 
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formation of one enantiomeric form over the other. Drawing inspiration from 
these natural catalysts, chemists have developed a variety of synthetic 
small- molecule catalysts that can achieve levels of selectivity approaching, 
and in some cases matching, those observed in enzymatic reactions.”  
T. P. Yoon and E. N. Jacobsen, Science, 2003, 299, 1691. 
 
The success of stereoselective synthesis has been made possible by the design of 
chiral ligands to control regio-, diastereo-, and enantioselectivity of chemical 
transformations.85 High levels of stereocontrol have been achieved with the development 
of asymmetric catalysts that permit the preferential generation of an enantiomer starting 
from achiral compounds. The so called “privileged chiral catalysts” are applicable to a 
broad range of different reactions resulting in high enantioselectivity of the chemical 
transformation (Figure 2.4).96 They also facilitate the discovery of new enantioselective 
reactions after screening and optimization of privileged catalyst structures. Some 
examples include BINAP, BINOL, TADDOLs, bis(oxazoline) and salen complexes.   
 
 
 
Figure 2.4. Privileged ligand structures (Structures reproduced from Ref.97) 
 
 
A common characteristic of these structures is that they possess C2-symmetry. 
Dang and Kagan developed the C2-symmetric ligand DIOP in 1971.98 This symmetry was 
chosen as the ligand resulted in two equivalent P atoms, thus reducing the number of 
possible isomeric metal complexes, substrate-catalyst arrangements and reaction 
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pathways.97 It was assumed that C2-symmetry could be responsible for the high 
enantioselectivity generated by this class of catalysts and the next decades were 
characterized by an intensive development of C2-symmetric catalysts.  
Phosphoramidites are a class of privileged chiral ligands that have shown to 
enable high levels of stereocontrol (Figure 2.5).85 These ligands have been used in 
combination with metals to form complexes that are used in catalysis of a wide range of 
metal-mediated reactions such as arylations, cycloadditions, hydrosilylations, 
hydrogenations and cross-coupling reactions.85 Some examples include the application 
of monodentate phosphoramidites to the asymmetric synthesis of α- and β-amino acids, 
diacid and esters, heterocycles and amines, all prepared in excellent ee values.85 
However, phosphoramidites possessing C2-symmetry have never been employed as 
reagents in direct phosphorylations of the achiral meso-compound myo-inositol, leading 
to its desymmetrization. 
 
 
 
Figure 2.5. Examples of chiral phosphoramidites (Structures reproduced from Ref.85) 
 
 
2.4 DESYMMETRIZATION OF MYO-INOSITOL  
 The chemical synthesis of InsPy and X-PP-InsPy is challenging due to numerous 
factors, one of the most important being the requirement of a selective phosphorylation of 
a specific hydroxyl group of the inositol ring. Different strategies have been employed to 
achieve this goal and they include numerous protective group manipulations and the use 
of chiral auxiliaries, the use of precursors of inositol (e.g. glucose) and, more recently, 
O
O
chiral BINOL,
nonchiral amine
O
OO
O
Ph Ph
Ph Ph
TADDOL backbone
P N
O
O
R R
RR
P N
Ph
Ph
flexible biphenol,
chiral amine
P
O
O
N
Ph
Ph
methylenediphenol,
chiral amine
P N P N
O
O
Ar
Ar
catechol, chiral pyrrolidine
O
O
P N
R
R
8,8'-fused binaphthol
CHEMICAL SYNTHESIS OF INOSITOL POLYPHOSPHATES 
 26 
enantioselective phosphorylation to introduce a phosphate group in a specific position of 
the myo-inositol ring.22  
 Precursors of myo-inositol have been employed to achieve the synthesis of 
enantiomerically pure InsPy starting from D-glucose derivatives via a Ferrier 
rearrangement or ring closing methatesis in 14 and 17 steps, respectively (Figure 2.6).99–
101  
 
 
 
Figure 2.6. Synthesis of enantiomerically pure InsPy via a Ferrier rearrangement (A) and ring closing 
methatesis (B). Ac = acetyl; Bn = benzyl; Me = methyl; PMB = p-methoxybenzyl; RCM = ring closing 
methatesis. (Schemes reproduced from Ref.99 and Ref.101) 
 
 
Numerous protective group manipulations and chiral auxiliary approaches have 
been employed towards the same goal. The first total synthesis of Ins(1,4,5)P3 has been 
reported three years after the discovery of this second messenger and was achieved by 
appropriate protection of the OH groups of myo-inositol with acetal groups, followed by 
optical resolution and phosphorylation of specific positions.102 However, this approach 
resulted in a large number of steps to obtain enantiomerically pure InsP3. Therefore, a 
new methodology that used chiral acetals was developed, thus avoiding the additional 
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optical resolution step.103,104 This approach consisted in the use of D- and L-camphor 
acetals to obtain various enantiomerically pure inositol derivatives. Protective groups like 
orthoesters (orthoformates, orthoacetates or orthobenzoates) allow the selective 
protection of the hydroxyl groups in 1-, 3- and 5-position of myo-inositol leaving the other 
hydroxyl groups free for further functionalizations (Figure 2.7),105–108 while the 
regioselective protection of hydroxyl groups of myo-inositol with reagents like bis-
dihydropyran, disiloxane and butanedione permits to have the OH in 2-position free.3,109–
111 However, these approaches require multiple protecting group manipulations leading to 
a low synthetic efficiency. 
 
 
 
Figure 2.7. Protection of myo-inositol with acetal groups, chiral camphor acetals and orthoesters. 
 
 
The desymmetrization of myo-inositol by phosphorylation is a very attractive 
approach for the synthesis of enantiomerically pure InsPy. The group of Scott Miller made 
impressive achievements in the asymmetric phosphorylation of myo-inositol using 
peptides as catalysts that enabled the introduction of a phosphate group in a specific 
position of myo-inositol. In 2001 the group reported the asymmetric synthesis of 
enantiomerically pure Ins-(1)-P catalyzed by a small peptide112 and subsequently also the 
synthesis of other unsymmetric isomers was reported using the same catalytic 
approach.113–115 However, this approach had important limitations: only P(V) reagents 
could be employed, which are much less reactive than their P(III) analogues; exclusively 
phenyl substituents could be used as protecting groups of the phosphate moiety, which 
required harsh conditions for their cleavage in later stages of the synthesis and additional 
protective group manipulations were required; Ins(1)P and Ins(3)P could be obtained in 
high enantiomeric excess, but the enantioselectivity was low in case of the 4- and 6-InsP 
derivatives (Figure 2.8). To overcome these drawbacks, the group developed a tetrazole-
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based chiral peptide that allowed the enantioselective synthesis of Ins(6)P using P(III) 
reagents protected with benzyl groups.116  
 
 
 
Figure 2.8. Desymmetrization of myo-inositol using peptides as catalysts. Selective phosphorylation of 
(A) 1,3 and (B) 4,6 hydroxyls.116 (Jordan, P. a; Kayser-Bricker, K. J.; Miller, S. J. Asymmetric 
phosphorylation through catalytic P(III) phosphoramidite transfer: enantioselective synthesis of D-myo-
inositol-6-phosphate. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20620–20624. Copyright © 2010 
National Academy of Sciences, USA) 
 
 
2.5 SYNTHESIS OF DIPHOSPHOINOSITOL POLYPHOSPHATES 
 The first total synthesis of 1-PP-InsP5 and 3-PP-InsP5 was reported by the group 
of Falck in 1995 (Figure 2.8).117 The reported synthesis started from an enantiopure 
cyclohexylidene myo-inositol derivative or its enantiomer that had been obtained using 
the camphor acetal approach, followed by phosphorylation of the hydroxyl group in 1- or 
3-position with benzyl methyl N,N-diisopropylphosphoramidite. Demethylation with LiCN 
and coupling with dibenzyl chlorophosphate facilitated the formation of the 
pyrophosphate moiety. However, the 31P-NMR and 1H-NMR spectra were published only 
for the 1-PP-InsP5 isomer and the integrations were not reported. Poorly resolved spectra 
were obtained (see Figure 2.9 B and C). 
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Figure 2.9. A) First synthesis of 1/3-PP-InsP5; B) 1H-NMR of 1-PP-InsP5; C) 31P-NMR of 1-PP-InsP5. 
(Scheme reproduced from Ref.117; Figures B and C adapted with permission from Falck, J. R.; Reddy, 
K. K.; Ye, J.; Saady, M.; Mioskowski, C.; Shears, S. B.; Tan, Z.; Safranyg, S. Synthesis and structure of 
cellular mediators: inositol polyphosphate diphosphates. J. Am. Chem. Soc. 1995, 117, 12172–12175.  
Copyright © 1995 American Chemical Society) 
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This procedure was then adapted for the preparation of the isomers 
pyrophosphorylated in 4- and 6-position (Figure 2.10).33 The same group reported also 
the first total synthesis of the meso compounds 2- and 5-PP-InsP5.118 Their approach 
consisted in the use of symmetric bis-disiloxane derivative of myo-inositol that was 
prepared employing a procedure developed by Ozaki119 and subsequently 
phosphorylated in 2- or 5-position with benzyl methyl N,N-diisopropylphosphoramidite. 
Desilylation and phosphorylation of the remaining hydroxyl groups, followed by 
demethylation with LiCN and coupling with dibenzyl chlorophosphate yielded the 
corresponding inositol pyrophosphates (Figure 2.10). 
 
 
Figure 2.10. A) Synthesis of 6-PP-InsP5; B) Synthesis of 2-PP-InsP5 and 5-PP-InsP5. (Schemes 
reproduced from Ref.33 and Ref.118) 
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The synthesis of 5-PP-InsP5 has been reported also by the group of Prestwich in 
2009.120 After appropriate protection and deprotection of the myo-inositol ring via an 
orthoformate intermediate, the pyrophosphate moiety was introduced in position 5. To 
this aim, a β-cyanoethyl phosphoramidite was used, since the protecting group of this 
phosphoramidite can be easily cleaved under mild basic conditions, thus allowing the 
formation of a diphosphate in position 5. Final hydrogenation yielded 5-PP-InsP5 that was 
obtained after 13 steps in 5% overall yield. However, the 31P-NMR and 1H-NMR spectra 
of the final product were complex, which was justified by attributing its complexity to a 
“distribution of sodium salt and protonated species each with characteristic chemical 
shifts” (Figure 2.11).120 PAGE analysis of these compounds has now clearly shown that 
they are impure.121 After this analysis, the commercialized 5-PP-InsP5 has been 
withdrawn from the market.  
 
 
 
Figure 2.11. Synthesis, 1H-NMR and 31P-NMR of 5-PP-InsP5. (Scheme reproduced from Ref.120; NMR 
spectra adapted with pemission from Zhang, H.; Thompson, J.; Prestwich, G. A scalable synthesis of 
the IP7 isomer, 5-PP-Ins(1,2,3,4,6)P5. Org. Lett. 2009, 11, 1551–1554. Copyright © 2009 American 
Chemical Society) 
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 The synthesis of the meso compound 2,5-(PP)2-IP4 is the only literature-known 
preparation of a bis-diphosphoinositol polyphosphate. However, this is not a naturally 
occurring isomer and the only proof that it has been synthesized is shown in an HPL 
chromatogram where the compound is highly impure (Figure 2.12-C, purity < 10%).38 
Additionally, the procedure for its preparation and the NMR spectra have never been 
reported, although the authors claimed that they prepared it by chemical synthesis. 
 
 
 
Figure 2.12. HPLC analysis of eight different (PP)2-IP4 isomers. 1/3,5-(PP)2-InsP4 (A) and 5,6-(PP)2-
InsP4 are enzymatic preparations and derive from Polysphondylium and Dictyostelium, respectively. 2,5-
(PP)2-InsP4 (C) has been prepared chemically, however the purity is low. Panel D shows PP-InsP5 and 
(PP)2-InsP4 prepared enzymatically by human GST-IP6K1 and GST-ScVip1 from InsP6. The broken line 
in each panel represents the HPLC separation of a standard mixture containing PP-InsP5 (peaks 1-2) 
and (PP)2-InsP4 isomers (peaks 3-8).38 (This figure was originally published in the Journal of Biological 
Chemistry. Lin, H.; Fridy, P. C.; Ribeiro, A. a; Choi, J. H.; Barma, D. K.; Vogel, G.; Falck, J. R.; Shears, 
S. B.; York, J. D.; Mayr, G. W. Structural analysis and detection of biological inositol pyrophosphates 
reveal that the family of VIP/diphosphoinositol pentakisphosphate kinases are 1/3-kinases. J. Biol. 
Chem. 2009, 284, 1863–1872. Copyright © the American Society for Biochemistry and Molecular 
Biology)
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Second messengers are important for the maintenance of life as they carry 
information within cells. Disphosphoinositol polyphosphates (PP-InsPy, Figure 3.1 and 
Figure 3.2) are a novel class of second messengers that are involved in several cellular 
processes (Chapter 1). It has been suggested that they act in the cell with two different 
mechanisms: by binding a particular receptor and by transferring a phosphate group to 
proteins, giving rise to a new type of posttranslational modification called protein 
pyrophosphorylation. This process occurs in vitro but it is still unclear if it occurs also in 
vivo. The identification of PP-InsPy in nature is relatively recent and the elucidation of 
their roles in living systems requires further investigation. However, the detailed 
understanding of their structure and functions is complicated by the scarce amount of 
material that is available for biological studies. The concentration of PP-InsPy in 
mammalian cells is low, which complicates the isolation and purification of these 
molecules. A higher amount of PP-InsPy is present in the amoeba Dictyostelium 
discoideum and this organism is often taken into account for the study of PP-InsPy. 
However, PP-InsPy isomers differ from one species to another and therefore D. 
discoideum cannot be considered a general model. Moreover, the isolated enantiomers 
cannot be distinguished by NMR or by HPLC but only enzymatically, and this complicates 
the assignment of the correct stereochemistry of the isomers that are found in nature. 
Enzymatic preparations of PP-InsPy are possible but failed to produce an amount of 
material that is suitable for biological studies. Additionally, this technique does not give 
access to functionalized isomers that could be used as chemical probes to study the 
cellular pathways regulated by diphosphoinositol polyphosphates. 
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Figure 3.1. Structures of all X-PP-InsP5. The backbone of all isomers is myo-inositol 1. 
 
 
 
 
 
Figure 3.2. Structures of two unsymmetric X,Y-(PP)2-InsP4 and meso 5-PPP-InsP5. 
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Chemical synthesis is the only method that guarantees to obtain large amounts of 
PP-InsPy with known stereochemistry. The chemical routes could be then also adapted 
for the generation of differently modified natural and unnatural isomers, giving access to 
a set of tools that could be useful to elucidate the chemical biology of PP-InsPy. The 
synthesis of PP-InsPy has already been reported by other groups. However, the natural 
products were obtained in low purity after a large number of synthetic steps due to 
multiple protecting group manipulations. This fact underscores the interest and the 
challenges related to the total synthesis of PP-InsPy. Diphosphoinositol polyphosphates 
are highly charged molecules and the high hydrophilicity makes their synthesis and 
purification difficult. These molecules contain up to thirteen (X-PP-InsP5) or fourteen (X,Y-
(PP)2-InsP4) negative charges distributed on the rim of the myo-inositol ring (Figure 3.1 
and Figure 3.2). Another problem is represented by phosphate migration that can occur 
when adjacent hydroxyl groups are not protected. This event may lead to the formation of 
polar mixture of compounds that are phosphorylated in different positions and difficult to 
separate. Another complication is the instability of the phosphoanhydride bond and its 
potential hydrolysis, especially in the protected state during synthesis.  
A novel synthesis of the most abundant diphosphoinositol polyphosphate in 
nature (5-PP-InsP5) will be reported (Chapter 4.1.1). The choice of protecting groups 
allowed us to introduce specifically a pyrophosphate moiety in position 5. For this key 
step, we developed an efficient one-flask procedure that combined eight transformations. 
This procedure was then adapted for the generation of a triphosphate moiety that 
enabled us to achieve the first total synthesis of 5-PPP-InsP5 (Chapter 4.1.2). It has been 
shown that this isomer can be synthesized enzymatically in vitro. This finding suggested 
that it might be present also in nature and a chemical synthesis will help us to elucidate 
its biological role. 
Unsymmetric diphosphoinositol polyphosphates require a stereoselective 
synthetic approach. Different methods have been employed for the desymmetrization of 
myo-inositol. However, a desymmetrization by phosphorylation permits the direct 
introduction of a phosphate in a specific position of the myo-inositol ring, thus avoiding 
multiple protecting group manipulations and reducing the number of synthetic steps 
necessary for the synthesis.  
The development of a novel C2-symmetric phosphoramidite will be reported 
(Figure 3.3 and Chapter 4.2). This reagent allowed the desymmetrization of myo-inositol 
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giving access to all four X-PP-InsP5 (Figure 3.1 and Chapter 4.3) and two possible X,Y-
(PP)2-InsP4 (Figure 3.2 and Chapter 4.4). At the same time the chiral auxiliary served as 
an orthogonal protecting group, as it can be cleaved without affecting the other protecting 
groups in the molecule. The structure of this reagent resembles β-cyanoethyl 
phosphoramidites (Figure 3.3) used in DNA chemistry and it can be cleaved under mild 
basic conditions. This feature will be exploited in a one-flask synthesis of the 
phosphoanhydride bond characteristic of diphosphoinositol polyphosphates. This 
procedure is also useful to introduce modifications in the pyrophosphate moiety, thus 
allowing the construction of biological probes. The synthesis of a sulfurized analog of 3-
PP-InsP5 will be reported as an example (Chapter 4.3.1.2).  
 
 
 
Figure 3.3 Structures of β-cyanoethyl phosphoramidite 11 and C2-symmetric phosphoramidite 12. 12 
can be understood as a chiral version of 11. 
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4.1 SYNTHESIS OF SYMMETRIC DI- AND TRI-PHOSPHOINOSITOL 
POLYPHOSPHATES 
4.1.1 SYNTHESIS OF MESO 5-PP-INSP5 
The most abundant diphosphoinositol polyphosphate in cells is 5-PP-InsP5. This 
molecule is a meso compound and therefore its preparation does not require an 
asymmetric synthetic approach. The total synthesis of 5-PP-InsP5 has been reported by 
the group of Falck in 1997, by the group of Prestwich in 2009 and by the Fiedler group in 
2012.118,120,122 However, the syntheses reported by these groups required multiple 
protecting group manipulations resulting in low yields and the purity of the final 
compounds was questionable. Therefore, we developed a novel synthetic approach for 
the total synthesis of 5-PP-InsP5 that resulted in a lower number of steps required for the 
preparation of the compound, higher overall yield and higher purity of the final natural 
product.  
The first step of the synthesis was the regioselective protection of commercially 
available myo-inositol 1. Following a reported procedure, the hydroxyl groups in positions 
1, 3 and 5 of the molecule were protected employing trimethyl orthobenzoate as 
protecting group.3 The remaining free hydroxyl groups in positions 2, 4 and 6 were now 
protected with three p-methoxybenzyl (PMB) groups. Next, diisobutylaluminium hydride 
(DIBAL-H) was used for the selective reductive cleavage of the cyclic acetal 13 to release 
the hydroxyl group in position 5 (Scheme 4.1).  
 
 
 
Scheme 4.1. Regioselective protection of myo-inositol with trimethyl orthobenzoate and p-
methoxybenzyl (PMB) groups, followed by selective reductive cleavage with diisobutylaluminium hydride 
(DIBAL-H).  
 
 
It has already been reported on a benzyl (Bn) protected substrate (13, replace 
PMB with Bn) that reduction with DIBAL-H is highly selective and allows the release of 
the bicyclic 1,3-acetal at room temperature in DCM.123 However, using the reported 
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reaction conditions we observed also the formation of the 1,5-acetal and only when we 
performed the reaction at -78 °C we could observe high selectivity for the formation of the 
1,3-acetal 14. The two products can be distinguished by 1H-NMR analysis, since the 
pattern of signals that appear in the 1H-NMR of the two molecules is different due to the 
different substitution of the myo-inositol ring. The 1,3-acetal is a meso compound while 
the 1,5-acetal is unsymmetric, therefore the higher symmetry of the 1,3-acetal enables its 
unambiguous identification by NMR spectroscopy.  
Two equivalents of DIBAL-H are necessary for the completion of the reaction. 
One equivalent acts as a Lewis acid coordinating the oxygen in position 5 of myo-inositol 
and subsequently cleaves the bond, forming an oxocarbenium ion. The second 
equivalent of DIBAL-H reduces the oxocarbenium ion forming the 1,3-acetal. Therefore, 
the side product 1,5-acetal is formed when the oxygen in position 3 is coordinated by 
DIBAL-H. The opposite happens when the substrate is treated with trimethylaluminium. 
In this case the oxygen in position 3 of myo-inositol is coordinated by the reducing agent 
and the preferred product is the 1,5-acetal (Figure 4.1).124,125 The difference in the 
selectivity of the reduction depends on steric effects related to the two reducing reagents. 
DIBAL-H is a bulky reagent and the oxygen in position 5 of myo-inositol is the most 
accessible one of the ring. Consequently, this oxygen is coordinated preferentially and 
the related bond cleaved. Additionally, when the hydroxyl group in position 5 is released, 
the myo-inositol ring can flip into a boat conformation relieving steric crowding, which 
would not be possible in case of cleavage in position 1 or 3.124 Trimethylaluminium is less 
bulky than DIBAL-H and it has been suggested that it coordinates first to the oxygen in C-
2 and then to one of the two equivalent oxygens in C-1 or C-3, cleaving one of the two 
bonds.124  
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Figure 4.1. Proposed mechanism of the (A) DIBAL-H and (B) AlMe3 reduction. (Schemes reproduced 
from Ref.126) 
 
 
 We observed that the obtained 1,3-benzylidene acetal 14 is very sensitive 
towards acids. Therefore, it was necessary to avoid acidic conditions during the 
preparation and purification of the molecule. For example, NMR spectra were recorded 
only in DMSO-d6, as the addition of the acidic CDCl3 cleaved the acetal group. 
Purification of the final compound was achieved by column chromatography, after 
neutralizing acidic protons on the silica gel with triethylamine, which was necessary to 
avoid deprotection at the 1 and 3 position of myo-inositol. Finally, compound 14 was 
obtained in high purity on a 10 g scale with only the hydroxyl at position 5 free for further 
functionalization.  
Position 5 was subsequently phosphorylated with bis-cyanoethyl-N,N-diisopropyl 
phosphoramidite 11 (Scheme 4.2). The special feature of this molecule is that the 
protecting groups can be cleaved under mild basic conditions. This property was later 
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exploited in the formation of the pyrophosphate bond in position 5 (Scheme 4.4 and 
Scheme 4.5). The acetal group that is blocking positons 1 and 3 is very sensitive under 
acidic conditions, while the protecting groups on the phosphate are cleaved under basic 
conditions. Therefore special considerations had to be made. First, oxidation after 
phosphitylation with bis-cyanoethyl phosphoramidite 11 has been achieved using tert-
buthyl hydroperoxide (tBuOOH), as it is less acidic than meta-chloroperbenzoic acid 
(mCPBA) that is commonly used as an oxidizing reagent in phosphoramidite chemistry 
(pKa tBuOOH = 12.69; pKa mCPBA = 7.57 (water)). Again, it was not possible to record 
NMR spectra in CDCl3 but only in DMSO due to the sensitivity of the 1,3-acetal. 
Purification of the crude material was not possible by flash column chromatography, as 
the acetal group would have been cleaved by the acidity of the silica gel. In this case, it 
was not an option to neutralize the silica gel with triethylamine as previously described, 
because basic treatment would have cleaved the protecting groups on the phosphate in 
position 5. Therefore, the crude mixture was used directly without purification in the 
selective deprotection of the benzylidene acetal (Scheme 4.2). The usefulness of 
intermediate 16 will be described further in section 4.3 for the preparation of unsymmetric 
X,Y-(PP)2-InsP4 derivatives. 
 
 
Scheme 4.2. Selective phosphorylation of position 5 of myo-inositol and cleavage of the 1,3-
benzylidene acetal. tBuOOH = tert-butyl hydroperoxide; PMB = para-methoxybenzyl; pTsOH = para-
toluenesulfonic acid. 
 
  
In contrast, treatment of 15 with trifluoroacetic acid (TFA) cleaved all PMB 
protecting groups and pentaol 17 was obtained after crystallization (Scheme 4.3). 
Hexakisphosphate 19 was obtained after phosphorylation of the five free hydroxyl group 
of intermediate 17 with o-xylylene N,N-diisopropylamino phosphoramidite 18 (XEP-
amidite). Phosphoramidite 18 is widely used as a phosphitylating reagent in inositol 
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chemistry. It is characterized by “benzyl-like” protecting groups that can be cleaved by 
hydrogenation, which is orthogonal to the β-cyanoethyl protecting group. This property 
was exploited in the next step for the formation of the pyrophosphate bond in position 5.  
 
 
 
Scheme 4.3. Cleavage of PMB protecting groups and generation of hexakisphosphate 9. mCPBA = 
meta-chloroperbenzoic acid; DCI = 4,5-dicyanoimidazole; PMB = para-methoxybenzyl; TFA = 
trifluoroacetic acid. 
 
 
Next, a novel one-flask procedure was developed for the synthesis of the 
phosphoanhydride moiety. The first step toward this goal was to remove efficiently the 
two β-cyanoethyl protecting groups in order to enable the introduction of a second 
phosphate in position 5 to form a phosphoanhydride. The β-cyanoethyl protecting group 
is commonly used in nucleotide synthesis and it is known that it can be cleaved under 
basic conditions. The protecting groups at the remaining five hydroxyl groups cannot be 
cleaved using this methodology. Therefore, this property can be exploited for the 
selective release of only the 5 phosphate in the molecule. It has been previously reported 
that treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) permits the cleavage of 
only one of the two β-cyanoethyl protecting groups, but addition of chlorotrimethylsilane 
(TMS-Cl) completes the deprotection.127,128  
We exploited this knowledge to develop an appropriate methodology to cleave 
the protecting groups of the phosphate in position 5 of myo-inositol. Also in our case, we 
observed that addition of DBU cleaves only one of the two β-cyanoethyl protecting 
groups, even when an excess of the base was added. The cleavage of the first protecting 
group leads to the formation of a negative charge on the phosphate diester. Presumably 
this negative charge prevents the removal of the second β-cyanoethyl group due to 
repulsive coulombic interactions, as a second negative charge would be formed on the 
same phosphate group upon deprotection. Therefore, it was necessary to mask these 
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negative charges with groups that would be easier to cleave than the β-cyanoethyl 
protecting groups, in order to complete the deprotection. We decided to use a 
trimethylsilyl (TMS) group to transiently mask the charges on the phosphate and N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) as a silyl donor. Treatment with TMS-Cl as 
described above led to decomposition. Treatment of hexakisphosphate 9 with DBU and 
BSTFA led to complete deprotection of the β-cyanoethyl group on the phosphate in 
position 5 and their replacement with TMS groups (Scheme 4.4). 
 
 
 
Scheme 4.4. Mechanism of the generation of the phosphoanhydride bond in a one-pot procedure. Part 
A: cleavage of the β-cyanoethyl protecting groups. 
 
 
TMS groups are easier to cleave as compared to β-cyanoethyl groups and the 
removal occurs quickly in MeOH. However, when both the TMS groups are removed, 
negative charges are generated on the dibasic phosphate and the neighboring 
phosphotriesters at positions 4 and 6 are electrophilic, so that a nucleophilic attack 
occurs. This cleaves the xylylene protecting group and a cyclic diphosphate is formed 
between positions 4-5 or positions 5-6 as evidenced by phosphoanhydride resonances in 
31P-NMR. Therefore, it was necessary to protonate one of the oxygens of the phosphate 
after removal of the TMS group in order to avoid this side reaction by adding 
trifluoroacetic acid (TFA) simultaneously with MeOH (Scheme 4.5). 
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Scheme 4.5. Mechanism of the generation of the phosphoanhydride bond in a one-pot procedure. Part 
B: deprotection of the TMS groups and phosphoramidite coupling. 
 
 
Next, after mild deprotection, the phosphoanhydride was introduced in position 5: 
coupling with bis-benzyl N,N-diisopropylamino phosphoramidite 20 and oxidation with 
mCPBA afforded the pyrophosphate derivative 21 (Scheme 4.6). It is remarkable to 
mention that the compound was purified by simple crystallization and that the generated 
pyrophosphate derivative was pure enough to be used in the final step. With the 
described protocol, eight transformations were conducted in a one-flask procedure to 
form the pyrophosphate bond. This is the first example for the application of PIII-PV 
chemistry in the synthesis of inositol pyrophosphates. A feature of this one-flask 
procedure is that it allows to introduce other functionalities in the β-phosphate. This 
property will be described in detail in section 4.1.3.2 where the synthesis of a sulfurized 
analog is illustrated. This procedure has already been adapted by other groups.129 
 
 
Scheme 4.6. One-pot synthesis of protected inositol pyrophosphate 21. 
 
 
Analysis of the 31P-NMR spectrum of 21 showed characteristic signals at -10 and 
-12 ppm that correspond to the phosphoanhydride moiety. The signals that correspond to 
the other five phosphates in the myo-inositol ring are visible in the range between -1 and 
-3 ppm, in a ratio of 2:1:2 since it is a meso compound (Figure 4.2).  
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Figure 4.2. 31P-NMR (decoupled) of pyrophosphate 21. 
 
 
Final high pressure hydrogenation was applied to cleave all protecting groups in 
the molecule yielding 5-PP-InsP5 (Scheme 4.7). The final compound was purified by 
simple crystallization from water-acetone. 31P-NMR analysis and polyacrylamide gel 
electrophoresis (PAGE) showed that the synthesized material was highly pure and no 
signals were present in the aromatic region of 1H-NMR spectrum, confirming that all the 
protecting groups were successfully cleaved by hydrogenation. The assignment of each 
peak to the α or β phosphate was possible after evaluation of the proton coupled 31P-
NMR spectrum where the coupling with neighboring protons were visible (Figure 4.3). 
 
 
 
Scheme 4.7. High pressure hydrogenation of intermediate 21 to generate 5-PP-InsP5.  
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Figure 4.3. 31P-NMR (coupled) of 5-PP-InsP5 and assignment of the signals to each phosphate in the 
molecule. The coupling of the signals (doublets) in range between 3 and 1 ppm indicates that all 
protecting groups in the molecule have been removed. The signal at -9.5 ppm has been attributed to the 
α-phosphate (doublet of doublets, indicates P-P and P-H couplings). 
 
 
4.1.2 SYNTHESIS OF MESO 5-PPP-INSP5 
It has been reported that the enzyme IP6K synthesizes not only diphosphate but 
also triphosphate groups on the inositol ring, generating 5-PPP-InsP5 (for structure see 
Figure 4.4) from InsP5 or InsP6 in vitro.45 The compound has been purified by HPLC and 
characterized by 31P-NMR spectroscopy that reveled two doublets at -4.3 ppm and -10.2 
ppm, and a multiplet at -20 ppm. These signals were assigned to γP5, αP5 and βP5, 
respectively (Figure 4.4).45  
 
 
Figure 4.4. 1H-decoupled 31P-NMR spectrum of HPLC-purified IP8 synthesized by IP6K1 in vitro 
(Picture taken from Ref.45). 
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 The synthesis of 5-PPP-InsP5 (Figure 4.4) in vitro by mammalian enzymes 
indicates that this compound might be present in biological systems, although its 
importance is not known. The enzymatic preparation could provide the material in 
sufficient amount for NMR analysis, however a chemical synthesis of 5-PPP-InsP5 has 
never been reported.  
 A modified version of the synthetic procedure developed for the preparation of 5-
PP-InsP5 can in principle be applied for the synthesis of 5-PPP-InsP5. The installation of 
the diphosphate moiety in position 5 of the inositol ring previously described was 
achievable due to the possibility to cleave selectively the protecting groups of that 
particular phosphate without affecting other functional groups in the molecule. Therefore, 
we envisaged that the same strategy could be used for the introduction of a third 
phosphate in position 5. The β-phosphate of the pyrophosphate moiety of derivative 21 is 
protected with a benzyl group that can be cleaved by hydrogenation, thus cleaving also 
the remaining phosphate protecting groups. Therefore, the benzyl group had to be 
replaced with a group that could be cleaved under, for example, basic conditions. To this 
aim, instead of bis-benzyl N,N-diisopropylamino phosphoramidite 20, fluorenylmethyl 
(Fm) protected phosphoramidite 22 has been chosen to pyrophosphorylate derivative 19 
in the one-flask procedure described above. The Fm protecting group can be cleaved 
under basic condition like the β-cyanoethyl group and this property can be exploited in 
the next step for the formation of the triphosphate in position 5. A similar strategy has 
recently been described for nucleoside oligophosphate synthesis.130  
Diphosphorylation of hexakisphosphate derivative 19 with (FmO)2PN(iPr)2 22 
required a special precaution. The removal of the β-cyanoethyl group is performed with 
an excess of DBU that remains in the reaction mixture during the formation of the 
pyrophosphate moiety. This is not an issue when reagents like bis-benzyl N,N-
diisopropylamino phosphoramidite 20 are used, as the benzyl groups are stable under 
basic conditions. However, when the Fm-P-amidite 22 is added to such a mixture, the 
excess of base can cleave the Fm protecting groups. Therefore, an excess of 1H-
tetrazole has to be added before the Fm-P-amidite 22 to neutralize the DBU present in 
the flask. This creates mild acidic conditions and thus favors activation of the 
phosphoramidite. Oxidation with mCPBA and crystallization afforded pyrophosphate 
derivative 23 that was subsequently transformed into the triphosphate 24 employing a 
modified version of the one-flask procedure applied before (Scheme 4.8). 
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Scheme 4.8. One-pot syntheses of diphosphate 23 and triphosphate 24. 
 
 
 Treatment of pyrophosphate derivative 23 with DBU in DMF was sufficient to 
cleave both the Fm protecting groups on the β-phosphate without the requirement of a 
silylating reagent to complete the cleavage. Therefore, the use of the Fm-P-amidite 22 
rather than the β-cyanoethyl-P-amidite 11 permitted a faster cleavage of the protecting 
groups. Coupling with bis-benzyl N,N-diisopropylamino phosphoramidite 20 afforded the 
protected triphosphate derivative 24 (Scheme 4.8). The compound was purified by simple 
crystallization and obtained in a purity that was sufficient to use the material in the next 
step without further purification. 31P-NMR analysis showed the characteristic signals of 
the triphosphate moiety at -10.9 ppm, -11.2 ppm and -21.2 ppm that can be attributed to 
the γP5, αP5 and βP5, respectively (Figure 4.5). 
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Figure 4.5. 31P-NMR (proton decoupled) of crude triphosphate 24.  
 
 
Cleavage of all protecting groups in the molecule was achieved by final high 
pressure hydrogenation (Scheme 4.9). However, the standard hydrogenation procedure 
that employs NaHCO3 lead to partial decomposition of the triphosphate moiety. When the 
hydrogenation was performed without the addition of base, 5-PPP-InsP5 was obtained in 
good quality, although partial decomposition to 5-PP-InsP5 could not be avoided (Figure 
4.6). 
 
 
 
Scheme 4.9. Hydrogenation of protected triphosphate 24 to form 5-PPP-InsP5. 
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Figure 4.6. 31P-NMR (decoupled) of 5-PPP-InsP5. 
 
 
4.2 DEVELOPMENT OF A C2-SYMMETRIC PHOSPHORAMIDITE AND ITS 
APPLICATION TO DESYMMETRIZE MYO-INOSITOL 
The synthesis of meso diphospho- and triphospho- derivatives of myo-inositol was 
complicated due to several factors previously described in Chapter 3 and in Chapter 4.1. 
The preparation of unsymmetric diphosphorylated derivatives such as 1-PP-InsP5, 3-PP-
InsP5, 4-PP-InsP5 and 6-PP-InsP5 adds one more challenge to the synthesis of these 
molecules, as the introduction of a diphosphate moiety in a position different from 2 or 5 
of the myo-inositol ring requires the development of a stereoselective synthetic approach.     
Many methods have been described for the desymmetrization of myo-inositol 
(Chapter 2.4). However, a desymmetrization by phosphorylation represents a more 
efficient and elegant approach, as many protecting group manipulations can be avoided. 
Scott Miller’s strategy made use of peptides as catalysts to phosphorylate or 
phosphitylate a specific position of the myo-inositol ring. This method allowed the 
preparation of unsymmetric inositol phosphates with high enantioselectivity (>98% ee).116 
However, only phenol and benzyl protecting groups can be introduced in the molecule 
using this approach, which have to be cleaved using harsh conditions or conditions that 
require hydrogenation.   
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Although all these techniques proved to be efficient in the desymmetrization of 
myo-inositol, we did not find them appropriate for our aims. We wanted to develop a 
method to desymmetrize efficiently myo-inositol that would allow the synthesis of all four 
unsymmetric X-PP-InsP5. We wanted to obtain our target molecules in few synthetic 
steps using mild conditions in order to avoid the decomposition of the delicate 
phosphoanhydride bond and other protecting groups in the molecule. Therefore, we 
envisaged that a desymmetrization by phosphorylation would represent the most 
advantageous strategy toward this goal.  
C2-symmetric phosphoramidites have never been applied in the desymmetrization 
of myo-inositol. Given the ability of C2-symmetric ligands to achieve high stereocontrol in 
chemical transformations, we envisaged the possibility to exploit this property for the 
desymmetrization of myo-inositol. Additionally, C2-symmetry would avoid chirality at the 
phosphorus atom, thus facilitating the interpretation of 31P-NMR spectra. One advantage 
compared to enantioselective phosphorylation is that using a C2-symmetric 
phosphoramidite reagent one obtains diastereomers that can be separated. 
Consequently, no high selectivity is required for this approach to be synthetically useful. 
The first phosphitylating reagent that we designed for our studies was a cyclic C2-
symmetric phosphoramidite that contained benzyl like protecting groups (Scheme 4.10). 
Hydroxyalkene 25 was subjected to Sharpless epoxidation conditions to obtain a mixture 
of the enantiomerically enriched hydroxyalkene 26 and the epoxyalcohol 27 using a 
previously reported procedure.131 After separation, the enantiomerically pure epoxide was 
treated with Red-Al to generate the C2-symmetric 1,3-diol 28 that was subsequently 
converted into the phosphoramidite 30 by treatment with dichloro N,N-
diisopropylphosphoramidite 29. However, the resulting phosphoramidite was not stable 
and a considerable amount of material was converted into a P(V) side product, probably 
derived from an Arbuzov ring contraction rearrangement to phosphonate 31.  
 
RESULTS AND DISCUSSION 
 53 
 
 
Scheme 4.10. Synthesis of phosphoramidite 30 and proposed mechanism for its decomposition through 
an Arbuzov ring contraction rearrangement. tBuOOH = tert-butyl hydroperoxide; L-(+)-DIPT = L-(+)-
diisopropyl tartrate; Red-Al = sodium bis(2-methoxyethoxy)aluminum dihydride; Ti(OiPr)4 = titanium 
isopropoxide. 
 
 
Treatment of the 1,3-diol 28 with PCl3 lead to the formation of the 
phosphochloridite analog 32. Due to the high reactivity of P(III) chloridites, isolation of 
this compound was not possible. Therefore, to test the phosphitylating properties of the 
reagent, it was generated in situ and used directly to phosphitylate cyclohexanol or 
phenol. After oxidation with mCPBA it was possible to isolate the phosphorylated alcohol 
33 (Scheme 4.11).  
 
 
 
Scheme 4.11. Phosphitylation of cyclohexanol with phosphochloridite 32. 
 
 
Next, we investigated the ability of the phosphochloridite derivative to 
desymmetrize benzyl protected meso diol 34 with free hydroxyls at positions 1 and 3. In 
situ generation of 32 followed by addition of the diol 34 (1 eq.) to the reaction mixture at -
78 °C resulted in the formation of the two diastereomers 35 and 36 and the double 
phosphorylated side product 37. 31P-NMR analysis showed three signals in ratio 1:1.6:0.7. 
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With further experiments we noticed that we could decrease the amount of side product 
37 by using an excess of the meso diol 34 (1.5 eq.) (Scheme 4.12). The ratio of signals 
from 31P-NMR analysis was 1.0:1.4:0.3 (Figure 4.7).  
 
 
 
Scheme 4.12. Desymmetrization of benzyl protected myo-inositol 34. 
 
 
 
Figure 4.7. 31P-NMR of the reaction mixture containing 35, 36 and 37 using 1.5 eq. of diol 34. Signals at 
-6.0 ppm and -6.5 ppm correspond to compounds 35 and 36. The double phosphorylated side product 
37 appears in the spectrum at -6.8 ppm and -6.5 ppm, overlapping with the signal of one of the two 
diastereomers.  
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molecule. Additionally, due to the high reactivity of the phosphochloridite, we could not 
isolate or store the reagent. Therefore, it had to be prepared every time and used 
immediately in a phosphorylation reaction.  
The next goal was the development of a phosphorylating reagent that could be 
easily prepared on scale and that would be stable enough to be stored and used over a 
long period of time. Another important feature was the orthogonality with other protecting 
groups that would allow in a successive step its selective cleavage without affecting other 
protecting groups in the molecule.  
 Analyzing the structure of phosphoramidite 11, we realized that it was possible to 
create a C2-symmetric reagent by introducing a phenyl group in position C-α of the 
cyanoethyl protecting group. The synthesis of the compound that we wanted to use as a 
protecting group has been already reported. We employed a chiral pool synthesis starting 
from mandelic acid.132,133 Briefly, S-(+)-mandelic acid 38 was converted to the methyl 
ester 39 by treatment with HCl in MeOH and subsequently reduced to the diol 40 using 
NaBH4. Selective tosylation of the primary alcohol, followed by treatment with NaCN 
yielded nitrile 42. Finally, coupling of nitrile 42 with dichloro N,N-
diisopropylphosphoramidite 29 afforded C2-symmetric phosphoramidite 12 as a white 
solid on a 10 gram scale (Scheme 4.13). The phosphoramidite was highly pure (> 95%) 
after column chromatography and stable for over one year when stored at -18 °C without 
additional special handling. 
 
 
 
Scheme 4.13. Synthesis of C2-symmetric phosphoramidite 12. 
 
  
 The C2-symmetric reagent 12 was used in the desymmetrization of silylated myo-
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as activator. After complete activation, a cooled solution of meso diol 43 was added to 
the mixture at -78 °C and the desymmetrization was analyzed by 31P-NMR. The two 
diastereomers were now formed in 2.3:1 ratio when using 1H-tetrazole as activator due to 
the lower temperature. This finding set the foundation for further studies on the 
asymmetric phosphorylation of myo-inositol using C2-symmetric phosphoramidite 12. 
 
 
Scheme 4.14. Desymmetrization of diol 43 with the C2-symmetric phosphoramidite 12. 
 
 
 
Figure 4.8. 31P-NMR (coupled) of the mixture derived from desymmetrization of diol 43 with 
phosphoramidite 12. The stereochemistry of diastereomers 44 and 45 was not assigned. However, in 
section 4.3.2 the crystal structure of a similar derivative is reported. This enables us to suggest 
tentatively that diastereomer 45 is formed preferentially after desymmetrization. 
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 We assumed that a higher selectivity in the desymmetrization would be 
achievable by decreasing the rate of phosphorylation at low temperatures. The first step 
in the activation of phosphoramidites by acidic promoters is the protonation of the amino 
group. Subsequently, the promoter acts as a nucleophile displacing the protonated amino 
group (Figure 2.1, page 20). The phosphoramidite in this form is active and can 
phosphitylate hydroxyl groups. The reaction rate of phosphitylation depends on the ability 
of the hydroxyl group to displace the acidic promoter, in other words it depends on how 
good the promoter is as a leaving group. Phosphoramidite chemistry has been well 
developed in the field of oligonucleotide synthesis, where a fast phosphorylation is 
preferred. Therefore, all known activators are easily displaced by the hydroxyl group and 
theoretically are thus not ideal for a selective phosphitylation. Our goal was to find an 
acidic promoter that would activate quickly the C2-symmetric phosphoramidite, without 
being displaced easily by the OH group at the same time. A screening of possible 
activators led to the identification of pentafluorophenol as a good candidate for our 
aims.134 The activation of C2-symmetric phosphoramidite with this phenol derivative at rt 
was fast (30 - 40 min) and led to the formation of a more stable phosphite triester that 
could be tracked by 31P-NMR. This is usually not possible with conventional activators. 
As expected, a slower phosphitylation reaction resulted at low temperatures. 
Consequently, also a higher selectivity in the phosphitylation of derivative 46 with free 
hydroxyls at positions 4- and 6- was observed, leading to the formation of the two 
diastereomers in 1:2.7 ratio at -40 °C (Scheme 4.15).134 However, at lower temperatures 
the reaction became very slow and was not synthetically useful anymore.134 
 
 
 
Scheme 4.15. Desymmetrization of TBS protected myo-inositol 46 with phosphoramidite 12 in the 
presence of pentafluorophenol.  
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A similar result was obtained when using pentafluorophenol as activator for the 
desymmetrization of TES derivative 49 with C2-symmetric phosphoramidite 12 (Scheme 
4.16). According to 31P-NMR diastereomers 50 and 51 were obtained in 2.7:1 ratio 
(Figure 4.9). Diastereomer 50 phosphorylated in position 6 was formed preferentially as 
confirmed by crystal structure reported in section 4.3.2.  
 
 
 
Scheme 4.16. Desymmetrization of TES protected myo-inositol 49 with phosphoramidite 12 in the 
presence of pentafluorophenol. Diastereomers 50 and 51 were obtained in 2.7:1 ratio as confirmed by 
31P-NMR.  
 
 
 
 
Figure 4.9. 31P-NMR (coupled) of the mixture derived from reaction illustrated in Scheme 4.16. The 
diastereomer that is formed preferentially is phosphorylated in position 6 as confirmed by crystal 
structure reported in section 4.3.2.  
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 Meso diol 52 with free hxdroxyls at position 1- and 3- was also desymmetrized 
with C2-symmetric phosphoramidite 12 using different activators (Scheme 4.17). However, 
the degree of selectivity was much lower as compared to phosphitylation of 4,6-diols, 
presumably due to lower steric hindrance of the molecule. The desymmetrization was 
performed using 1H-tetrazole as activator in acetonitrile at room temperature. A ratio of 
1.2:1 was observed in the formation of the two diastereomers 53 and 54 and it was 
important to use an excess of the meso substrate (3.5 eq.) to avoid the formation of the 
double phosphitylated side product. The absolute configuration was assigned by 
comparison of optical rotations after cleavage of all protecting groups (Chapter 4.3.1.1). 
When pentafluorophenol was used as activator at room temperature, the two 
diastereomers phosphitylated at positions 1- or 3- were obtained in 1:1.8 ratio and using 
only 2 eq. of the achiral substrate 52.134 
 
 
 
Scheme 4.17. Desymmetrization of meso diol 52 with phosphoramidite 34. 
  
 
 In summary, we developed a novel phosphoramidite that is easy to prepare, 
stable and additionally equipped with protecting groups that are easily cleaved under mild 
basic conditions. This property will be described in the next section, where the generation 
of a pyrophosphate moiety was possible exploiting this feature. This feature facilitated the 
application of the phosphoanhydride synthesis reported for symmetric 5-PP-InsP5 
(Chapter 4.1.1). Additionally, the C2-symmetry avoided chirality at phosphorus and 
offered a starting point for the investigation of a method to phosphorylate selectively any 
non-symmetric position of the myo-inositol ring.  
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4.3 SYNTHESIS OF UNSYMMETRIC X-PP-INSP5 DERIVATIVES 
 The features of the novel phosphoramidite 12 were exploited for the installation of 
a pyrophosphate moiety in a specific position of myo-inositol, thus providing access to all 
four unsymmetric X-PP-InsP5.   
 
 
 
Figure 4.10. Structures of the four unsymmetric X-PP-InsP5. 
 
 
4.3.1 SYNTHESIS OF 1- AND 3-PP-INSP5 
The preparation of 1- and 3-PP-InsP5 was achieved by modifying the procedure 
developed for the preparation of meso derivative 5-PP-InsP5. A different pattern of 
protecting groups was required, as we now wanted to introduce selectively a 
pyrophosphate moiety in 1- or 3- position. Achiral 1,3-benzylidene acetal 14 obtained by 
selective DIBAL-H reduction was protected at position 5 with a PMB group. Selective 
acid-catalyzed cleavage of the acetal yielded PMB-protected diol 52 with positions 1- and 
3- free for desymmetrization (Scheme 4.18). 
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Scheme 4.18. Preparation of meso derivative 52. 
 
 
Phosphitylated diastereomers 53 and 54 were obtained in 1.2:1 ratio as shown by 
31P-NMR analysis (Scheme 4.17 and Figure 4.11). 1H-tetrazole was used as an activator 
and the resulting P(III) intermediate was oxidized with mCPBA. Both of the diastereomers 
were required in successive steps of the synthesis and it was possible to separate them 
efficiently by flash chromatography or crystallization on gram scale. However, it was 
necessary to use an excess of the meso substrate 52 (3.5 eq.) to avoid the formation of a 
side product phosphorylated in both 1- and 3-position that was difficult to separate from 
the reaction mixture. After separation of the excess of starting material by flash column 
chromatography, diastereomer 54 was isolated by simple crystallization and obtained as 
a white solid in a diastereomeric ratio of >99:1. The other diastereomer 53 was purified 
by column chromatography and obtained as a colorless oil in a diastereomeric ratio of 
98:2. The excess of starting material was then subjected to additional desymmetrizations 
using the same conditions. 
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Figure 4.11. 31P-NMR (decoupled) of reaction illustrated in Scheme 4.16. A) 31P-NMR of diastereomeric 
mixture containing diastereomers 53 and 54 (ratio 1.2:1) and double substituted side product before 
separation; B) 31P-NMR of diastereomer 53 after flash column chromatography; C) 31P-NMR of 
diastereomer 54 after crystallization. The assignment of the absolute configuration of 53 and 54 will be 
explained in section 4.3.1.1. 
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were purified by crystallization from diethyl ether. The compounds were obtained in good 
quality and no further purification was necessary. 55 and 56 were then phosphitylated 
with XEP-amidite 18 and oxidized in situ with mCPBA. The excess of non reacted XEP-
amidite 18 was removed by crystallization and filtration over a plug of silica gel. This 
procedure yielded hexakisphosphates 57 or 58 in high purity. Purification of these 
compounds by longer flash column chromatography led to a significant loss of material 
and crystallization should thus be preferred (Scheme 4.19). 
 
 
 
Scheme 4.19. Acidic removal of PMB protecting groups and phosphorylation to hexakisphosphates 57 
and 58. 
 
 
With these protected derivatives in hand, the generation of the pyrophosphate 
moiety in position 1- or 3- was possible under the same one-pot reaction conditions 
described previously for the formation of 5-PP-InsP5. Addition of DBU and BSTFA 
cleaved the two chiral auxiliaries on the phosphate eliminating cinnamonitrile. Therefore, 
the chiral auxiliary that we developed proved to be equivalent to the β-cyanoethyl 
protecting group when the method of cleavage is considered, but additionally enabled 
desymmetrization of a myo-inositol derivative. The bis-TMS protected phosphate was 
then subjected to methanolysis. TFA was added simultaneously with MeOH to reduce the 
risk of nucleophilic attack of the negatively charged phosphate to the neighboring XEP-
protected phosphates. Coupling with dibenzyl-N,N-diisopropyl phosphoramidite in the 
presence of 1H-tetrazole, followed by oxidation and crystallization yielded protected 
pyrophosphates 59 and 60 in high yield. The purity was good enough to use the 
compounds in the next step without further purification, although better results are 
achieved also after purification by reversed column chromatography (Scheme 4.20 and 
Figure 4.12). 
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Scheme 4.20. A) One-pot synthesis of diphosphates 59 and 60; B) Mechanism: 1. DBU permits the 
cleavage of one of the chiral phenyl modified beta-cyanoethyl protecting groups; 2. BTFSA transfers a 
TMS group facilitating the cleavage of the second protecting group by DBU, followed by a second 
silylation; 3. MeOH removes the TMS groups and TFA protonates one of the two negatively charged  
oxygens; 4. Tetrazole promotes the phosphitylation, followed by oxidation with mCPBA. 
 
 
 
Figure 4.12. 31P-NMR (decoupled) of inositol diphosphate 59 after reversed phase column 
chromatography.  
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High pressure hydrogenation of pyrophosphates 59 and 60 led to global cleavage 
of all protecting groups giving natural products 1-PP-InsP5 and 3-PP-InsP5. The catalyst 
was removed by centrifugation and compounds were purified by simple crystallization 
from water/acetone and no further purification was needed. According to 31P-NMR and 
1H-NMR analysis, compounds were completely deprotected and obtained in high purity. 
These molecules tend to show broad signals in the recorded NMR spectra. However, the 
quality can often be improved with ion exchange resin (Dowex Na+) in order to obtain 
well-resolved peaks, thus identifying impurities that would go otherwise unnoticed 
(Scheme 4.21 and Figure 4.13). 
 
 
 
Scheme 4.21. Hydrogenation of inositol pyrophosphates 59 and 60 and generation of 1-PP-InsP5 (2) 
and 3-PP-InsP5 (4).  
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Figure 4.13. A) 31P-NMR (decoupled), B) 1H-NMR (water suppression) and C) 13C-NMR in D2O of 3-PP-
InsP5. 
 
 
4.3.1.1 ASSIGNMENT OF THE ABSOLUTE CONFIGURATION OF 1-PP-INSP5 AND 3-PP-
INSP5 
After synthesizing the two natural products 1-PP-InsP5 and 3-PP-InsP5, we needed 
to find a method to assign their absolute configuration since optical rotations are very low 
and have not been reported reliably. As they are enantiomers, 31P-NMR and 1H-NMR 
spectra showed the same pattern of signals. Therefore, NMR spectroscopy was not a 
suitable method to distinguish one isomer from the other. The best solution would have 
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been the examination of a crystal structure. However, it was not possible to obtain 
crystals of the two molecules, nor crystals of the intermediates produced in the different 
steps of the synthesis after several attempts.  
The synthesis of inositol-1-phosphate (Ins(1)P, 61) and inositol-3-phosphate 
(Ins(3)P, 62) has been reported and these compounds have been already fully 
characterized.135 This paper also reported the [α]D20 values in a pH dependent manner 
and was thus more reliable. As 61 and 62 are enantiomers, they are characterized by 
opposite optical rotation values and we exploited this property to assign the absolute 
configuration of 1-PP-InsP5 and 3-PP-InsP5. We envisaged that cleavage of all protecting 
groups of the precursors 55 and 56 would give us access to 1-InsP and 3-InsP. 
Therefore, we tried to cleave the chiral auxiliaries of pentaols 55 and 56 thinking that this 
would be the most straightforward way to obtain Ins(1)P and Ins(3)P (Scheme 4.22). 
However, treatment with bases or hydrogenation of 55 and 56 did not lead to the 
expected result. 31P-NMR analysis showed several signals, indicating that not only 
Ins(1)P or Ins(3)P was formed. We attributed those peaks to phosphorylated side 
products that were formed probably due to phosphate migration generating a mixture of 
polar compounds.  
 
 
Scheme 4.22. Attempted preparation of Ins(1)P (61) and Ins(3)P (62). 
 
 
The hydroxy groups of diastereomers 53 and 54 are protected with PMB groups 
and we envisaged that this protection could prevent phosphate migration. When the 
chiral auxiliaries of 53 and 54 were cleaved in the presence of DBU followed by 
hydrogenation of the PMB protecting groups Ins(1)P 61 and Ins(3)P 62 were obtained in 
good quality for analytical studies (Scheme 4.23). We measured the optical rotations of 
the two molecules in water at different pH values and observed the same [α]D20 values 
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for the two enantiomers, except for opposite signs as expected. Finally, we compared the 
values that we obtained from these measurements with the data that are already 
reported in literature to assign the correct stereochemistry of compounds 61 and 62 and 
indeed also observed an inversion of [α]D20 in a pH dependent manner (See 
Experimental Part, page 96 for data).135  
 
 
Scheme 4.23. Synthesis of Ins(1)P (61) and Ins(3)P (62). 
 
 
4.3.1.2 SYNTHESIS OF A SULFURIZED ANALOG 
The one-pot procedure that we developed allowed not only the efficient generation 
of a pyrophosphate moiety in the myo-inositol structure, but it also enabled us to 
introduce non-natural modifications on the β-phosphate of the phosphoanhydride. For 
example, with this strategy we were able to form a thiopyrophosphate in position 3 of 
myo-inositol (63) (Scheme 4.24). The synthesis of this moiety was possible following a 
modified version of the one-flask procedure described above. Briefly, the chiral auxiliaries 
were removed with DBU and BSTFA, followed by methanolysis in the presence of TFA. 
Coupling with dibenzyl-N,N-diisopropyl phosphoramidite 20 led to the formation of a P(V)-
P(III) intermediate. Sulfurization of phosphorus (III) atom in position β was achieved by 
addition of elemental sulfur, instead of mCPBA.  
 
 
 
Scheme 4.24. Synthesis of thiopyrophosphate 63.  
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31P-NMR analysis revealed a characteristic peak at 60 ppm typical of the 
thiophosphate moiety (Figure 4.14). This technique enabled us to introduce a different 
modification in the molecule and it is promising for the development of chemical probes to 
study inositol metabolism. It furthermore highlights the flexibility provided by P(III) 
chemistry as opposed to P(V) chemistry. 
 
 
Figure 4.14. 31P-NMR of thiopyrophosphate 63. 
 
 
4.3.2 SYNTHESIS OF 4- AND 6-PP-INSP5 
The synthesis of 4- and 6-PP-InsP5 was achieved by applying the same chemistry 
developed for the synthesis of 1- and 3-PP-InsP5. The main difference was the choice of 
protecting group strategy to have hydroxy groups in positions 4 and 6 available for 
desymmetrization. This would allow the generation of the pyrophosphate moiety in 
position 4 or 6 in the following steps. Protection of positions 1, 3 and 5 of myo-inositol 
with an ortho-formate protecting group and selective silylation of the equatorial position 2 
enabled the generation of the desired substrate 49 (Scheme 4.25). Desymmetrization of 
compound 49 with C2-symmetric phosphoramidite 12 yielded diastereomers 50 and 51 in 
a 0.8:1.0 ratio (Scheme 4.25). After separation by flash column chromatography, 
diastereomeric ratios of >99:1 were obtained for both the compounds on gram scale. The 
absolute configuration was determined by analysis of the crystal structure of compound 
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51 revealing its phosphorylation in position 4 (Scheme 4.25). With this result, the other 
diastereomer 50 was necessarily phosphorylated at position 6. 
 
 
 
Scheme 4.25. Selective protection of myo-inositol, desymmetrization of meso compound 49 and crystal 
structure of 51. Diastereomers 51 and 50 were obtained in a 1.0:0.8 ratio. 
 
 
Treatment with catalytic amount of pTsOH cleaved first the TES group at position 2 
and it is known that this hydroxyl group enables the acid-catalyzed cleavage of ortho-
esters of myo-inositol.106,136,137 Consequently, after cleavage of the TES group, the ortho-
ester was cleaved through a 2-formyl intermediate releasing pentaols 64 and 65 that 
were purified by crystallization. The same chemistry described above for the synthesis of 
1-PP-InsP5 and 3-PP-InsP5 was applied in the following steps to yield 4-PP-InsP5 and 6-
PP-InsP5. Briefly, phosphitylation of pentaols 64 and 65 with XEP-amidite 18 followed by 
oxidation with mCPBA produced hexakisphosphates 66 and 67 that were converted into 
derivatives 68 and 69 with a pyrophosphate moiety in 4 or 6 position using the one-flask 
procedure for phosphoanhydride formation described previously (Scheme 4.20, page 64). 
Global deprotection by high pressure hydrogenation finally yielded natural products 4-PP-
InsP5 and 6-PP-InsP5 (Scheme 4.26). 
 
O
O
O
O
HO
OH
Si
HO
OH
OH
OH
HO OH
P N
O
O
Ph
CN
Ph
NC
DCI
mCPBA
O
O
O
O
O
OH
Si
P OO
O
Ph
NC
Ph
CN
O
O
O
O
HO
O
Si
P OO
O
Ph
NC
Ph
CN
+
myo-inositol 1 49
51   45% 50    36%
1. Trimethylorthoformate
2. TESCl, lutidine
51
12
RESULTS AND DISCUSSION 
 71 
 
 
Scheme 4.26. Synthesis of 4-PP-InsP5 and 6-PP-InsP5. 
 
 
4.4 SYNTHESIS OF UNSYMMETRIC X,Y-(PP)2-INSP4 DERIVATIVES 
Unsymmetric X,Y-(PP)2-IP4 derivatives harbor eight phosphate groups and up to 
fourteen negative charges, thus representing the most densely phosphorylated natural 
products. The high polarity that characterizes these compounds makes their synthesis 
and purification difficult. Only symmetric 2,5-(PP)2-InsP4 has been prepared chemically.38 
However, analysis by HPLC showed that the compound was not pure (Figure 2.12, page 
32). We were able to achieve the first preparation of both 1,5-(PP)2-InsP4 and 3,5-(PP)2-
InsP4 in high quality by adapting the synthetic procedures developed for the synthesis of 
unsymmetric X-PP-InsP5 further showcasing their broad applicability.138 The two key 
steps that enabled us to synthesize these compounds are: 1) desymmetrization and 
phosphorylation of myo-inositol with C2-symmetric phosphoramidite 12 and 2) 
simultaneous generation of two pyrophosphate moiety in a one-flask procedure where 
sixteen transformations were combined. 
Our goal was the introduction of a pyrophosphate moiety in position 5 and another 
pyrophosphate moiety in position 1 or 3 of myo-inositol. We already demonstrated that it 
is possible to introduce such a group in all these positions, when they are protected with 
groups that can be cleaved under mild basic conditions. Therefore we selected a 
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protecting group strategy that would potentially allow us to form two pyrophosphate 
moieties simultaneously using the one-pot procedure that we developed for the 
preparation of X-PP-InsP5. We envisaged that meso PMB protected derivative 16 bearing 
β-cyanoethyl protecting groups on phosphate in position 5 could have been a good 
starting material for the preparation of 1,5-(PP)2-InsP4 and 3,5-(PP)2-InsP4. We 
envisaged that desymmetrization with C2-symmetric phosphoramidite 12 would enable us 
to generate the substrates with the characteristics that we needed to form the two 
pyrophosphate moieties in later stages of the synthesis. However, desymmetrization of 
16 with C2-symmetric phosphoramidite 12 led to a mixture of diastereomers 70 and 71 
that we could not separate by flash column chromatography or crystallization (Scheme 
4.27).  
 
 
 
Scheme 4.27. Desymmetrization of 16 with phosphoramidite 12 led to a diastereomeric mixture that we 
could not separate. 
 
 
Therefore, we decided to introduce a different base-labile protecting group in 
position 5 that might facilitate separation of the diastereomers after desymmetrization. 
The fluorenyl protecting group seemed to be a good candidate as it can be cleaved under 
the same conditions as the β-cyanoethyl protecting group, thus representing another 
orthogonal group that could potentially allow the generation of the pyrophosphate moiety. 
Position 5 of 1,3-acetal 14 was phosphorylated with phosphoramidite 22 and acidic 
treatment led to diol 72 with positions 1 and 3 free for desymmetrization (Scheme 4.28). 
Phosphorylation of 1,3-diol 72 with C2-symmetric phosphoramidite 12 produced a mixture 
of diastereomers in a 1.0:1.0 ratio (Figure 4.15). After separation of the excess starting 
material, repeated flash column chromatography enabled us to obtain diastereomers 73 
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and 74 in 90% to 95% purity. More than 1 g of each diastereomer was obtained in this 
purity starting from 2.7 g of diastereomeric mixture (Scheme 4.28).  
 
 
 
Scheme 4.28. Desymmetrization of meso diol 72 with phosphoramidite 12. Diastereomers 73 and 74 
were separated by column chromatography.  
 
 
 
Figure 4.15. 31P-NMR of diastereomers 73 and 74 before separation. 
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Cleavage of the PMB protecting groups under acidic conditions and crystallization 
led to tetraols 75 and 76 (Scheme 4.29). In this step, essentially diasteropure material 
was obtained due to enrichment by crystallization. Mixing experiments monitored by 31P-
NMR analysis confirmed that the two molecules were obtained in diastereomerically pure 
form (d.r. >98:2) (Figure 4.16). Phosphitylation of tetraols 75 and 76 with XEP-amidite 18 
followed by oxidation with mCPBA, generated hexakisphosphates 77 and 78 (Scheme 
4.29). Crystallization and filtration over a short plug of silica were necessary for their 
purification. A >98:2 diastereomeric ratio was confirmed by mixing the two compounds 
and the diastereomeric purity was again analyzed by 31P-NMR (Figure 4.17). 
 
 
 
Scheme 4.29. Cleavage of PMB groups of diastereomers 73 and 74 and generation of 
hexakisphosphates 77 and 78.  
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Figure 4.16. Mixing experiments to check the diastereopurity of tetraols 75 and 76. 
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Figure 4.17. Mixing experiments to check the diastereopurity of hexakisphosphates 77 and 78. 
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At this point, hexakisphosphates 77 and 78 were used as substrates for the 
generation of protected 1,5-(PP)2-InsP4 (79) or 3,5-(PP)2-InsP4 (80) (Scheme 4.30). The 
base labile protecting groups at 1 or 3 and 5 positions allowed the simultaneous 
formation of two pyrophosphate moieties in a one-flask procedure. The reaction 
conditions developed for the formation of a single phosphoanhydride as for 1/3-PP-InsP5 
(see Scheme 4.20, page 64) were adapted for this step, now combining sixteen 
transformations. Therefore, the number of equivalents of each reagent was doubled. 
Briefly, the Fm protecting groups in position 5 and the chiral auxiliaries in position 1 or 3 
were cleaved with DBU and silylated with BSTFA. Methanolysis removed the four TMS 
groups and simultaneous addition of TFA stabilized the molecule by monoprotonation of 
the two phosphates. Twofold phosphitylation with bis-benzyl P-amidite 20 followed by 
oxidation with mCPBA generated finally two pyrophosphate moieties in the 1 or 3 and 5 
position (Scheme 4.30). The protected (PP)2-InsP4 derivatives were purified by 
crystallization and obtained in good quality. Additional purifications by column 
chromatography led to decomposition of the material. The compounds were not stable 
enough to be stored for a longer period, therefore it was necessary to use them in the 
next step as soon as they were available. 
 
 
 
Scheme 4.30. One-flask synthesis of two diphosphate moieties simultaneously to form 79 and 80. 
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Figure 4.18. 31P-NMR (proton decoupled) of compounds 79 and 80. This is the result of 16 steps in 
one-flask after crystallization without additional purification. 
 
 
Global deprotection was achieved by high pressure hydrogenation (150-180 bar) to 
obtain 1,5-(PP)2-InsP4 and 3,5-(PP)2-InsP4 in high quality after crystallization from 
water/acetone (Scheme 4.31). The quality of the 31P-NMR spectra was highly dependent 
on the pH value of the D2O solution in which the spectra were recorded. Acidic pH led to 
very broad 31P-NMR signals. However, a strong improvement was observed after 
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addition of NH4OH to the same NMR tube until pH values of 9 or 10 were obtained 
(Figure 4.19). The deprotected compounds were much more stable as compared to their 
protected precursors 79 and 80. The resulting quality of the material is suitable for 
biological assays as shown in Chapter 4.5. 
 
 
 
Scheme 4.31. High pressure hydrogenation of 79 and 80 to form 1,5-(PP)2-InsP4 and 3,5-(PP)2-InsP4. 
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Figure 4.19. 31P-NMR (decoupled) of 1,5-(PP)2-InsP4 and 3,5-(PP)2-InsP4 in D2O at pH 9 after addition 
of NH4OH. The compounds were obtained after crystallization from water-acetone without additional 
purification. 
 
 
4.4.1 ASSIGNMENT OF THE ABSOLUTE CONFIGURATION OF 1,5-(PP)2-INSP4 AND 3,5-
(PP)2-INSP4 
The determination of the absolute configuration was a challenge since we could 
not obtain crystals of the final compounds or their precursors after several attempts. We 
excluded to possibility to assign the absolute configuration of the synthesized compounds 
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based exclusively on the evaluation of optical rotations, as they tend to be small and 
change considerably depending on pH values at which the measurement is done.116 In 
this case, no reliable data were available that facilitated the analysis of the synthesis of 
1/3,5-(PP)2-InsP4. In collaboration with the group of Steven Shears (National Institutes of 
Health, NIH, USA) we found a solution to this problem. Both synthetic enantiomers 1,5-
(PP)2-IP4 and 3,5-(PP)2-IP4 were soaked separately into crystals of the kinase domain of 
human PPIP5K2, the enzyme responsible for the biosynthesis of inositol pyrophosphates 
in mammalian cells.47,48 As the naturally occurring isomer has been recently identified in 
such complex (PPIP5K2KD),34 the obtained electron-density maps allowed the 
assignment of the absolute configuration of each isomer. The naturally occurring 1,5-
(PP)2-InsP4 was accommodated in the catalytic site of the enzyme as expected but 
surprisingly also the unnatural isomer 3,5-(PP)2-InsP4 was found in separate crystals, 
although in a different orientation. 
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Figure 4.20. Assignment of the absolute configuration of 1,5-(PP)2-InsP4 and 3,5-(PP)2-InsP4. Refined 
2Fo-Fc maps contoured at 2.0 or 1.0 σ are shown in blue mesh. InsP8 molecules are shown in a stick 
model. The catalytic domain of PPIP5K2 is shown in a transparent cartoon. The phosphate groups 
around the inositol ring are numbered. Panels A and B are PPIP5K2KD/ADP in complex with 1,5-(PP)2-
InsP4, showing two orientations. Panels C and D are PPIP5K2KD/AMP-PNP in complex with 3,5-(PP)2-
InsP4.138 (Capolicchio, S.; Wang, H.; Thakor, D. T.; Shears, S. B.; Jessen, H. J. Synthesis of densely 
phosphorylated bis-1,5-diphospho-myo-inositol tetrakisphosphate and its enantiomer by bidirectional P-
anhydride formation. Angew. Chem. Int. Ed. Engl. 2014, 53, 9508–9511. Copyright © 2014 Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim) 
 
 
 
4.5 BIOLOGICAL APPLICATIONS OF DIPHOSPHOINOSITOL 
POLYPHOSPHATES 
 We were able to synthesize several diphosphoinositol polyphosphate derivatives 
in high purity suitable for biological studies. With all natural and unnatural isomers in 
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hand, we started to perform evaluations of their biological properties. Moreover, we 
started to support groups worldwide that are studying the metabolism of 
diphosphoinositol polyphosphates in biological systems. 
The first biological application of our synthetic X-PP-IP5 derivatives involved the 
assignment of the regioisomeric preference of diphosphoinositol polyphosphates 
phosphatase 1 (Ddp1) from yeast. Ddp1 is an enzyme that belongs to a particular class 
of phosphatases able to cleave the β-phosphate of the pyrophosphate moiety of X-PP-IP5. 
1-PP-InsP5, 2-PP-InsP5, 3-PP-InsP5, 4-PP-InsP5, 5-PP-InsP5 and 6-PP-IP5 were 
incubated with Ddp1 and the ability of the enzyme to cleave the pyrophosphate of one 
specific isomer was tested employing a malachite green assay (Figure 4.21).139 Analysis 
of the obtained data showed that Ddp1 dephosphorylates specifically 1-PP-InsP5 and this 
outcome is in accordance with documented results.51 Additionally, this is a further proof 
of the absolute configuration of synthetic 1-PP-InsP5. (For more information about 
enzymes involved in diphosphoinositol polyphosphate metabolism see Chapter 1.3.3). 
 
 
 
Figure 4.21. Phosphate release from X-PP-InsP5 upon phosphatase treatment was quantified with a 
modified malachite green assay. The values on the left of the graph represent the percentage of 
hydrolysis catalyzed by Ddp1. The obtained data shows that Ddp1 is a selective 1-PP-InsP5 
phosphatase. 
 
  
In the group of Steven Shears, the activity of the phosphatase DIPP1 against the 
natural 1,5-(PP)2-IP4 and unnatural 3,5-(PP)2-IP4 enantiomers was tested. The release of 
the inorganic phosphate was measured using a malachite green assay as previously 
described by the group,140 and the obtained data showed that both isomers are 
substrates for the enzyme.138 
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In the Fiedler group (Princeton University) our synthetic 1-PP-InsP5 was used as a 
control in the evaluation of PP-InsPy ability to inhibit protein kinase Akt.141 It has been 
shown that binding of X-PP-InsP5 to the PH domain of Akt inhibits its phosphorylation by 
3-phosphoinositide-dependent protein kinase (PDK1), thus preventing the activation of 
Akt.74,141 The group developed a non-hydrolyzable analog of 1-PP-InsP5 (1-PCP-InsP5) 
and its ability to inhibit Akt was evaluated. Our synthetic 1-PP-InsP5 was used in this 
study as a reference to compare the activity of the non-hydrolyzable analog toward Akt. 
Both compounds resulted to be good inhibitors of protein Akt and the activities were 
comparable (Figure 4.22). 
 
 
 
Figure 4.22. A) Binding of X-PP-InsP5 inhibits Akt phosphorylation by PDK1 (PH = pleckstrin homology 
domain; KD = kinase domain; T308 = threonine 308; PDK1 = 3-phosphoinositide-dependent protein 
kinase; B) Inhibition of Akt phosphorylation by 1-PP-InsP5 and 1-PCP-IP5 in vitro.141 (Wu, M.; Chong, L. 
S.; Capolicchio, S.; Jessen, H. J.; Resnick, A. C.; Fiedler, D. Elucidating diphosphoinositol 
polyphosphate function with nonhydrolyzable analogues. Angew. Chem. Int. Ed. Engl. 2014, 53, 7192–
7197. Copyright © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim) 
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CHAPTER 5 
CONCLUSION AND OUTLOOK 
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In summary, we developed a novel synthetic strategy for the synthesis of several 
natural and unnatural diphosphoinositol polyphosphates. The key step in the 
preparations of both symmetric and unsymmetric isomers was a one-flak generation of 
the diphosphate moiety characteristic of these natural products. This transformation was 
possible due to the use of orthogonal phosphate protecting groups that were cleaved 
under mild basic conditions enabling the introduction of an additional phosphate. This 
feature facilitated the installation of a diphosphate group in specific positions of the myo-
inositol ring.  
The synthesis of meso 5-PP-InsP5 has been reported previously by other groups. 
However, multiple protecting group manipulations were required in all the preparations 
and the final compound was never obtained in good quality. With our approach, we could 
reduce the number of steps required for its synthesis and the material was pure enough 
for biological assays. The one-flask procedure has been subsequently adapted for the 
generation of a triphosphate moiety in position 5 of myo-inositol, completing the first total 
synthesis of 5-PPP-InsP5, We could therefore gain access to the first chemical tool that 
can help the elucidation of the biological function of 5-PPP-InsP5.  
We developed a novel C2-symmetric phosphoramidite that was stable, easy to 
prepare, and the chiral auxiliary served also as an orthogonal protecting group. The 
double function of the new reagent enabled us to desymmetrize myo-inositol and to 
generate a diphosphate moiety in a one-flask procedure, as the chiral auxiliary could be 
cleaved under mild basic conditions. These features enabled us to prepare all four 
possible unsymmetric X-PP-InsP5 in unprecedented purity and high enantiomeric excess. 
Moreover, we were able to introduce chemical modifications generating 
thiopyrophosphates. The desymmetrization of myo-inositol by phosphorylation allowed us 
to introduce directly a phosphate group in a specific position of the molecule, thus 
reducing the number of steps necessary for the syntheses of unsymmetric X-PP-InsP5. 
As all the isomers were required, no high regioselectivity was required in the 
desymmetrization step. However, we observed the preferential formation of a specific 
isomer when using different reaction conditions. This finding set the basis for the further 
development of a methodology based on phosphoramidite chemistry that allows the 
selective phosphorylation of a specific position in the myo-inositol ring. 
The same chemistry was then adapted to achieve the first total synthesis of the 
natural 1,5-(PP)2-InsP4 and the unnatural 3,5-(PP)2-InsP4. In the key step of their 
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preparation, sixteen transformations occurred in a one-flask procedure to generate two 
phosphoanhydride bonds simultaneously.  
With all these isomers in hand, we gained access to a set of natural and 
unnatural chemical tools that will help to elucidate the structure and functions of 
diphosphoinositol polyphosphates in nature. Moreover, the synthesis can be adapted for 
the generation of functionalized chemical probes to study the inositol related cellular 
signalling pathways. 
  88 
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6.1 EXPERIMENTAL PROCEDURES 
Reactions were carried out using oven-dried glassware under an atmosphere of dry Ar 
or N2 and magnetically stirred, unless noted otherwise. Air- and moisture-sensitive 
liquids and solutions were transferred via syringe or stainless steel canula.  
Reagents were purchased from commercial suppliers (Acros, Aldrich, Fluka, Lancaster) 
and used without further purification, unless noted otherwise. 
Solvents (methylene chloride, diethyl ether, tetrahydrofuran, acetonitrile, toluene) for 
reactions were purified by filtration and dried by passage over activated anhydrous 
neutral A-2 alumina (MBraun solvent purification system) under an atmosphere of dry 
nitrogen. Chloroform (analytical grade) was filtered over Alox-N. Methanol (analytical 
grade) was used as received. Ethyl acetate (Fluka, 99.5%), n-hexane (Fluka, 99.5%), 
N,N-dimethylformamide (Fluka, 99.5%) and 1,4-dioxane (Acros, 99.5%) were stored over 
molecular sieves. Analytical grade solvents were used as received for extractions and 
chromatographic purifications. Deuterated solvents were obtained from Armar Chemicals, 
Switzerland, in the indicated purity grade. 
Methods. Triethylamine, N,N-diisopropylamine and pyridine were distilled from calcium 
hydride under an atmosphere of dry nitrogen.  
Thin Layer Chromatography were used for monitoring reactions and carried out using 
Merck silica gel 60 F254 plates, visualized with UV light or developed either with aqueous 
cerium ammonium molybdate (CAM) stain followed by heating or with potassium 
permanganate solution. 
Flash Chromatography was performed using Fluka silica gel 60 (230-400 Mesh) at a 
pressure of ca. 0.3 bar. Eluents and Rf are indicated.  
Lyophilizations were performed on a Christ Freeze Dryer Alpha 1-2 LD+.  
Optical rotations were measured at 589 nm (Na-D line) on a Jasco P-2000 polarimeter 
(1 dm cylindrical cell). 
1H-NMR spectra were recorded on Bruker 400 MHz spectrometers or Bruker 500 MHz 
spectrometers (equipped with a cryo platform) at 298K in the indicated deuterated 
solvent. Data are reported as follow: chemical shift (δ, ppm), multiplicity (s, singulet; d, 
doublet; t, triplet; q, quartet; m, multiplet or not resolved signal; br, broad signal), coupling 
constant(s) (J, Hz), integration. All signals were referenced to the internal solvent signal 
as standard (CDCl3, δ 7.26; D2O, δ 4.79; CD3OD, δ 3.31; DMSO-d6, δ 2.50).  
13C-NMR spectra were recorded with 1H-decoupling on Bruker 101 MHz or Bruker 125 
MHz spectrometers (equipped with a cryo platform) at 298K in the indicated deuterated 
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solvent. All signals were referenced to the internal solvent signal as standard (CDCl3, 
δ 77.0; CD3OD, δ 49.0; DMSO-d6, δ 39.5). 
31P-NMR spectra were recorded with proton coupling and 1H-decoupling on Bruker 162 
MHz or Bruker 202 MHz spectrometers (equipped with a cryo platform) at 298K in the 
indicated deuterated solvent. All signals were referenced to an internal standard (PPP)  
IR spectra were recorded on a JASCO FT-IR-4100 spectrometer and data are reported 
in terms of frequency of absorption (cm-1). 
Mass spectra were recorded by the Mass spectroscopy Service of UZH on Finnigan 
MAT95 MS, Bruker EsquireLC MS , Bruker maXis QTof HR MS and Finnigan TSQ700 
MS machines. 
 
 
6.2 SYNTHESIS OF 1-PP-INSP5 AND 3-PP-INSP5 
 
Synthesis of (R)-3-Hydroxy-3-phenylpropanenitrile 42 
 
   
 
Nitrile 42 was synthesized as described before on a 10 g scale starting from (S)-(+)-
mandelic acid. Analytical data were identical with the values reported in the literature.142 
 
 
Synthesis of bis((R)-2-cyano-1-phenylethyl) diisopropylphosphoramidite 12  
 
 
 
6.25 g (42.5 mmol, 2.0 eq.) nitrile 42, 4.30 g (21.3 mmol, 1.0 eq.) 
(dichlorophosphanyl)bis(propan-2- yl)amine and 4.96 g (49.0 mmol, 2.3 eq.) triethylamine 
were stirred for 3 days at room temperature under an inert atmosphere in dry THF (50 
CN
OH
P
N
OO
NC CN
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mL). The precipitate was filtered off, rinsed with Et2O and the solution concentrated in 
vacuo. The product was purified by gradient chromatography (hexane/EtOAc 9:1-1:1). 
Yield: 7.01 g 11 as colorless crystals (16.6 mmol, 78%) 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): = 7.47 - 7.35 (m, 5H), 7.31 - 7.24 (m, 3H), 
7.19 - 7.13 (m, 2H), 5.13 (dt, J=9.0, 5.9, 1H), 4.78 (dt, J=10.2, 6.0, 1H), 3.61 (dhept, 
J=10.5, 6.8, 2H), 2.88 - 2.77 (m, 2H), 2.58 - 2.47 (m, 2H), 1.24 (d, J=6.8, 6H), 0.97 (d, 
J=6.8, 6H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 140.5 (d, J=1.6), 140.0 (d, J=2.0), 
128.9, 128.8, 128.7, 128.7, 126.4, 126.1, 117.0, 116.9, 72.2 (d, J=19.5), 71.2 (d, J=18.8), 
43.7 (d, J = 12.6 Hz), 28.5 (d, J=5.4), 28.2 (d, J=4.0), 24.8 (d, J=7.8), 24.3 (d, J=7.0); 
31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): 150.76; 31P-NMR (162 MHz, 298 K, 
CDCl3, δ/ppm): 150.76 (dddd, J=10.2, J=10.2, J=10.2, J=10.2); m.p. 66 - 69 °C; IR (neat, 
cm-1) 2967.0, 1455.0, 1180.2, 1027.9, 978.7, 760.8, 700.0, 423.3; Rf (SiO2, 
hexane/ethylacetate 8:2) 0.38; HRMS (ESI) calcd for 446.1973 (M+Na), found 446.1970; 
[α]D20 = - 15.8 (C 1.2, CHCl3). 
 
 
Synthesis of (1R,3s,5r,6R,7S,8s,9S)-3-phenyl-2,4,10-trioxaadamantane-6,8,9-triol 1a 
 
 
 
The compound was synthesized as described before on a 50 g scale starting from myo-
inositol. Analytical data were identical with the values reported in the literature.107 
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Synthesis of (1R,3s,5r,6R,7S,8s,9S)-6,8,9-tris((4-methoxybenzyl)oxy)-3-phenyl-2,4,10-
trioxaadamantane 13 
 
 
 
26.6 g (0.100 mol, 1.0 eq.) 1a were dissolved in dry DMF (150 mL). 14.0 g (0.350 mol, 
3.5 eq.) NaH (60% dispersion in oil) were added at 0 °C, followed by careful addition of 
51.7 g (0.330 mol, 44.9 mL, 3.3 eq.) PMB-Chloride. The reaction was stirred overnight at 
room temperature with a catalytic amount of TBAI. The reaction was stopped by addition 
of water (250 mL), the precipitate was filtered off, rinsed with water and the crystals dried 
in vacuo overnight. Yield: 60.5 g 13 as colorless crystals (0.097 mol, 97%). 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.69 - 7.64 (m, 2H), 7.36 - 7.27 (m, 5H), 7.17 - 
7.11 (m, 4H), 6.87 - 6.80 (m, 6H), 4.64 - 4.61 (m, 2H), 4.59 - 4.57 (m, 1H), 4.57 - 4.54 (m, 
1H), 4.53 - 4.50 (m, 1H), 4.48 - 4.40 (m, 6H), 4.08 (t, J=1.6, 1H), 3.81 (s, 6H), 3.78 (s, 
3H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 159.9, 159.9, 137.9, 130.8, 130.4, 130.2, 
129.9, 129.9, 128.5, 126.0, 114.4, 114.4, 108.5, 74.4, 72.6, 71.9, 71.3, 69.8, 66.3, 55.9, 
55.8; m.p. 145-147 °C; IR (neat, cm-1) 1611.2, 1511.9, 1453.1, 1336.4, 1245.8, 1106.0, 
978.7, 761.7, 991.1, 514.9; Rf (SiO2, solvent hexane/ethylacetate 7:3) 0.36; HRMS (ESI) 
calcd for 649.2414 (M+Na), found 649.2405. 
 
 
Synthesis of (1R,3r,5S,6R,7s,8S,9s)-6,8,9-tris((4-methoxybenzyl)oxy)-3-phenyl-2,4- 
dioxabicyclo[3.3.1]nonan-7-ol 14 
 
 
 
To a cooled solution (-78 °C) of 12 g (19.2 mmol, 1.0 eq.) ortho-benzoate 13 in dry DCM 
(50 mL) were slowly added 51.8 mL (51.8 mmol, 2.7 eq.) DIBAL-H (1.0 M in DCM). The 
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solution was stirred 1h at -78 °C and then warmed to -20 °C. After another 20 minutes, 
the reaction was stopped by careful addition of methanol. The solution was diluted with 
diethylether and and saturated aqueous Rochelle’s salt. The biphasic mixture was stirred 
vigorously for 45 min. The layers were separated and the organic phase washed twice 
with water and once with brine. The organic layer was dried over magnesium sulfate, 
filtered and evaporated in vacuo. Purification was achieved by column chromatography 
(pentane/Et2O/EtOAc 1:1:0.5). Yield: 10.3 g 14 as a colorless oil (16.5 mmol, 86%). 
1H-NMR (400 MHz, 298 K, MeOD, δ/ppm): 7.55 - 7.44 (m, 2H), 7.41 - 7.24 (m, 9H), 6.93 - 
6.85 (m, 6H), 5.79 (s, 1H), 4.82 (s, 4H), 4.67 - 4.54 (m, 6H), 4.24 (d, J=2.4, 2H), 3.91 (d, 
J=7.6, 2H), 3.82 - 3.71 (m, 9H), 3.67 (t, J=7.6, 1H), 3.56 (t, J=2.4, 1H); 13C-NMR (126 
MHz, 298 K, DMSO-d6, δ/ppm): 158.7, 138.8, 130.2, 130.2, 129.3, 129.2, 128.8, 127.9, 
126.4, 113.5, 91.8, 82.5, 73.0, 72.9, 70.5, 69.1, 67.5, 55.0, 55.0; IR (neat, cm-1) 3500, 
1612.2, 1512.9, 1245.8, 819.6; Rf (SiO2, solvent hexanes/ethylacetate 6:4) 0.33; HRMS 
(ESI) calcd for 651.2570 (M+Na), found 651.2561. 
 
 
Synthesis of (1R,2r,3S,4R,5r,6S)-2,4,5,6-tetrakis((4-methoxybenzyl)oxy) cyclohexane-
1,3-diol 52  
 
 
 
A) 4.40 g (7.00 mmol, 1.0 eq.) 14 were dissolved in dry DMF (15 mL). 336 mg (8.40 
mmol, 1.2 eq.) NaH (60% dispersion in oil) were added at 0°C, followed by careful 
addition of 1.32 g (8.40 mmol, 1.14 mL, 1.2 eq.) PMB-Chloride. The reaction was stirred 
overnight at room temperature with a catalytic amount of TBAI. The reaction was stopped 
by addition of saturated ammonium chloride solution (3 mL). The resulting mixture was 
diluted with Et2O and washed twice with water and once with brine. The organic layer 
was dried over magnesium sulfate, filtered and evaporated in vacuo. The obtained oil 
was directly used in the next step. 
B) The intermediate was dissolved in 20 mL MeOH and 8 mL DCM. 560 mg (2.94 mmol, 
0.42 eq.) pTsOH were added and the solution heated to reflux for 5 minutes. After mixing 
OPMB
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with saturated aqueous NaHCO3 (30 mL) and Et2O (150 mL) and separation, the organic 
layer was washed once with water and once with brine. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Purification was achieved by gradient column 
chromatography (hexanes/TBME, 0.1% TEA 1:3 until pure TBME, 0.1% TEA). Yield: 3.61 
g 52 as a colorless solid (5.44 mmol, 78%, over 2 steps). 
1H-NMR (400 MHz, 298 K, CDCl3, δ/ppm): 7.34 - 7.15 (m, 8H), 6.91 - 6.85 (m, 8H), 4.84 
(d, J=10.9, 2H), 4.81 (s, 2H), 4.71 (s, 2H), 4.70 (d, J=11.3, 2H), 3.96 (t, J=2.8, 1H), 3.82 
(s, 3H), 3.80 (s, 9H), 3.84 - 3.83 (m, 1H), 3.74 (t, J=9.5, 2H), 3.55 - 3.47 (m, 2H), 3.43 (t, 
J=9.2, 1H); 13C-NMR (101 MHz, 298 K, DMSO-d6, δ/ppm): 158.4, 158.4, 158.4, 131.6, 
131.3, 131.0, 129.1, 128.9, 128.8, 113.4, 113.3, 113.3, 82.7, 82.2, 81.8, 74.1, 73.9, 73.7, 
71.7, 55.0, 55.0, 55.0; m.p. 92-93 °C; IR (neat, cm-1) 3542.6, 3034.4, 2999.7, 1611.2, 
1511.9, 1243.9, 1060.7, 1029.8, 817.7, 733.8, 517.8; Rf (SiO2, solvent Et2O) 0.3; HRMS 
(ESI) calcd for 683.2832 (M+Na), found 683.2831. 
 
 
Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1R,2R,3R,4R,5S,6R)-3-hydroxy-
2,4,5,6-tetrakis((4- methoxybenzyl)oxy)cyclohexyl) phosphate 53 and 54 
 
 
 
1.84 g (2.78 mmol, 3.5 eq.) PMB-protected diol 52 and 335 mg (0.79 mmol, 1.0 eq.) 
phosphoramidite 12 were evaporated twice with dry MeCN (2 mL) and then dissolved in 
dry MeCN (5 mL). After addition of 195 mg (1.19 mmol ,1.5 eq.) 5-(para-F-phenyl)1H-
tetrazole (dried by twofold evaporation with MeCN) the reaction mixture was stirred at 
room temperature for 4.5 h. The mixture was cooled down (0 °C) and 164 mg (0.95 mmol, 
1.2 eq.) mCPBA (70% with water) were added. The mixture was stirred at this 
temperature for 20 min. The solution was diluted with ethyl acetate, washed with brine 
(2x), dried over Na2SO4 and the solvents were removed in vacuo. The excess of starting 
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material was recovered by flash column chromatography (diethyl ether/isopropanol 40:1). 
Crystallization of the mixture at 0 °C from diethyl ether/isopropanol with seeding crystals 
yielded diastereoisomer 54 (316 mg, 0.32 mmol, 40 %, based on 12) as a white solid. 
Diastereoisomer 53 was purified by flash chromatography (dichloromethane/ethyl acetate 
1.5:1 v/v) and isolated as a colorless oil (318 mg, 0.32 mmol, 40 %, based on 12). 
Analytical data for 53: 1H-NMR (400 MHz, 298 K, CDCl3, δ/ppm): 7.43 - 7.14 (m, 16H), 
7.12 - 7.04 (m, 2H), 6.91 - 6.79 (m, 8H), 5.55 (ddd, J=6.1, J=6.1, J=6.1, 1H), 5.33 (ddd, 
J=8.0, J=8.0, J=8.0, 1H), 4.83 - 4.70 (m, 4H), 4.68 - 4.49 (m, 4H), 4.29 - 4.99 (m, 1H), 
4.02 - 3.98 (m, 1H), 3.88 (dd, J=9.6, J=9.6, 1H), 3.83 - 3.77 (m, 12H), 3.67 (dd, J=9.6, 
J=9.6, 1H), 3.38 - 3.25 (m, 2H), 2.75 (d, J=6.0, 2H), 2.59 - 2.46 (m, 2H); 13C-NMR (126 
MHz, 298 K, CDCl3, δ/ppm): 159.5, 159.4, 136.9 (d, J=3.1), 136.7 (d, J=4.5), 130.8, 
130.8, 130.7, 129.9, 129.8, 129.7, 129.6, 129.4, 129.2, 129.0, 126.4, 126.0, 115.9, 115.5, 
114.1, 114.0, 113.9, 113.9, 82.8, 81.3, 80.0 (d, J=6.1), 79.4 (d, J=6.7), 78.2, 75.6, 75.5, 
75.2, 75.2, 75.1 (d, J = 4.7 Hz), 75.0, 55.4, 55.4, 27.1 (d, J=7.9), 26.8 (d, J=6.2); 31P{1H}-
NMR (162 MHz, 298 K, CDCl3, δ/ppm): -4.12; 31P-NMR (162 MHz, 298 K, CDCl3, δ/ppm): 
-4.12 (ddd, J=8.0, J=8.0, J=8.0); IR (neat, cm-1): 2933.2, 2835.8, 1612.2, 1512.9, 1246.8, 
1028.8, 820.6, 700.0; Rf (SiO2, dichloromethane/ethyl acetate 1:1) 0.45; HRMS (ESI) 
calcd for C56H59N2O13P [(M+Na)+] 1021.3647, found 1021.3651; [α]D20 = + 23.3 (C 0.5, 
CHCl3). 
 
Analytical data for 54: 1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.42 - 7.25 (m, 5H), 
7.25 - 7.13 (m, 11H), 7.09 - 7.02 (m, 2H), 6.91 - 6.75 (m, 8H), 5.42 (ddd, J=7.3, J=7.3, 
J=5.7, 1H), 5.26 (ddd, J=8.2, J=8.2, J=5.8, 1H), 4.81 - 4.73 (m, 3H), 4.69 (d, J=10.5, 1H), 
4.62 (s, 2H), 4.60 (d, J=10.9, 1H), 4.46 (d, J=10.5, 1H), 4.19 - 4.11 (m, 2H), 3.86 (dd, 
J=9.4, J=9.4 , 1H), 3.81 - 3.72 (m, 12H), 3.68 (dd, J=9.5, J=9.5, 1H), 3.44 - 3.32 (m, 2H), 
2.84 (ddd, J=16.9, J=5.5, J=1.2, 1H), 2.58 (dd, J=16.9, J=5.9, 1H), 2.45 (ddd, J=16.7, 
J=5.7, J=0.9, 1H), 2.37 (dd, J=16.8, J=5.9, 1H), 2.05 (d, J=5.2, 1H); 13C-NMR (126 MHz, 
298 K, CDCl3, δ/ppm): 159.4, 159.2, 136.8 - 136.66 (m), 130.7, 130.7, 130.6, 130.5, 
129.7, 129.6, 129.5, 129.4, 129.3, 129.2, 129.0, 128.8, 115.7, 115.6, 114.0, 113.9, 113.8, 
113.8, 82.8 (d, J=1.9), 81.1, 80.0 (d, J=6.4), 78.7 (d, J=6.5), 78.0, 75.4, 75.2 (d, J=6.0), 
75.2, 75.1, 75.1, 75.1, 74.9, 71.8, 55.4 - 55.24 (m), 27.0 (d, J=7.7), 27.0 (d, J=8.0); 
31P{1H}-NMR (202 MHz, 298 K, CDCl3, δ/ppm): -4.53; 31P-NMR (202 MHz, 298 K, CDCl3, 
δ/ppm): -4.53 (ddd, J=7.9, J=7.9, J=7.9); m.p. 141 - 142 °C; IR (neat, cm-1): 2933.2, 
2836.8, 1612.2, 1513.9, 1247.7, 1029.8, 821.5, 700.0; Rf (SiO2, dichloromethane/ethyl 
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acetate 1:1) 0.52; HRMS (ESI) calcd for C56H59N2O13P [(M+Na)+] 1021.3647, found 
1021.3641; [α]D20 = +18.8 (C 1, CHCl3). 
 
 
Synthesis of inositol-3-phosphate 61, 62 for assignment of the absolute configuration of 
53, 54  
 
 
 
70 mg (70 μmol, 1 eq.) P-triester 54 were dissolved in dry dichloromethane (4 mL) under 
an inert atmosphere and the solution was cooled to 0 °C. 90 mg (0.35 mmol, 94 μL, 5 
eq.) BSTFA was added and the mixture was stirred for 2 min. 53 mg (5 eq.) DBU were 
added to the mixture at the same temperature. After stirring for 20 min at 0 °C, MeOH 
(1.5 mL) was added and the mixture was stirred for another 15 min. The solvents were 
removed in vacuo. The excess of DBU was removed on a dowex column using 
water/methanol as eluent. The product was collected directly in a flask containing 
ammonia to form the ammonium salt. Lyophilization yielded 80 mg of product that was 
dissolved in a mixture of methanol/water (2:1, 10 mL). To this mixture 220 mg Pd/C 
(10%) were added and the slurry hydrogenated 4 days at 4 bar (Parr apparatus, addition 
of 10 mL water after 1 day). The catalyst was removed on a celite pad and washed with 
water. The aqueous phase was extracted twice with DCM and freeze-dried. 
Crystallization from water/dioxane and passing over a dowex column (H+ form) yielded 
compound 62 (15 mg, 58 μmol, 83%). Half of the product was transferred into a flask 
containing cyclohexylamine. Lyophilization yielded compound 62 as the bis-
cyclohexylammonium salt in quantitative yield. Analytical data were identical with those 
published before.113,135 The optical rotation at pH = 9 revealed compound 62 as the 3-
phosphate. Thus, compound 54 is modified in the 3-position and an analogous analysis 
with compound 53 as starting material revealed modification of 61 in the 1-position. This 
assignment was further verified by converting the compounds into the free phosphoric 
acids. Optical rotation was measured at pH = 2 and then the solution was adjusted to pH 
HO OH
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= 9 with NH4OH. A typical inversion in the sign of optical rotation occurred as described 
previously at pH = 6.3 This behavior was observed for both enantiomers with inverted 
values. The NMR spectra obtained for compound 62 showed broad resonances in both 
the ammonium and acidic form. A titration with 0.5 eq. of cyclohexylamine greatly 
increased the quality of the obtained spectra. 
 
61 as bis-cyclohexylammonium salt: 1H-NMR (400 MHz, 298 K, D2O, δ/ppm): 4.12 - 4.02 
(m, 1H), 3.76 (ddd, J=11.4, J=6.2, J=2.7, 1H), 3.61 (dd, J=10.5, J=8.4, 1H), 3.55 - 3.38 
(m, 2H), 3.24 - 3.14 (m, 1H), 3.07 - 2.92 (m, 2H), 1.90 - 1.75 (m, 4H), 1.70 - 1.60 (m, 4H), 
1.55-1.45 (m, 2H), 1.34 - 1.11 (m, 8H), 1.09 - 0.91 (m, 2H); 13C NMR (101 MHz, D2O, 
δ/ppm): 74.9 , 74.8 (d, J=5.1), 72.8 , 72.8 (d, J=3.9), 72.2, 71.4, 50.9, 30.9, 24.8, 24.3; 
31P{1H}-NMR (202 MHz, 298 K, D2O, δ/ppm): 5.05; HRMS (ESI) calcd for C6H12O9P- [M-] 
259.0222, found 259.0222; as bis-cyclohexylammonium salt: [α]D20 = +3.6 (C 0.5, H2O, 
pH = 9), Lit.: [α]D20 = +3.4; as free acid: [α]D20 = -10.7 (C 0.5, H2O, pH = 2), Lit.: [α]D20 = 
-9.8; as ammonium salt (free acid solution adjusted to pH = 9 with NH4OH): [α]D20 = +3.9 
(C 0.5, H2O, pH = 9), Lit.: [α]D20 = +4.4. 
 
62 all NMR/MS data obtained were identical with its enantiomer 61 despite the amount of 
counterions for obtaining well-resolved spectra. Optical rotation measurements were 
conducted as described above. 
As bis-cyclohexylammonium salt: [α]D20 = -3.7 (C 0.5, H2O, pH = 9), Lit.: [α]D20 = -4.5; as 
free acid: [α]D20 = +9.3 (C 0.5, H2O, pH = 2), Lit.: [α]D20 = not available; Lit.: [α]D20 = +3.4 
(pH = 6); as ammonium salt (free acid solution adjusted to pH = 9 with NH4OH): [α]D20 = -
4.0 (C 0.5, H2O, pH = 9), Lit.: [α]D20 = -4.5. 
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Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-
pentahydroxycyclohexyl) phosphate 55 
 
 
 
600 mg (0.60 mmol) P-triester 53 were dissolved in chloroform (37 mL) and trifluoroacetic 
acid (0.9 mL, 2.5%) was added to the solution. After stirring for 2.5 h at room temperature, 
hexane (10 mL) was added and the solvents were removed in vacuo. Crystallization from 
TBME yielded compound 55 as a colorless solid (264 mg, 0.51 mmol, 85 %). 
1H-NMR (500 MHz, 298 K, CD3OD, δ/ppm): 7.44 - 7.27 (m, 10H), 5.75 (ddd, J=8.1, J=8.1, 
J=5.7, 1H), 5.64 (ddd, J=8.1, J=8.1, J=5.7, 1H), 4.24 (ddd, J=10.3, J=7.9, J=2.8, 1H), 
4.14 (dd, J=2.7, J=2.7 1H), 3.86 (dd, J=9.6, J=9.6, 1H), 3.63 (dd, J=9.5, J=9.5, 1H), 3.35 
- 3.32 (m, 1H), 3.22 - 3.05 (m, 5H); 13C-NMR (126 MHz, 298 K, MeOD, δ/ppm): 138.7 (d, 
J=2.5), 138.6 (d, J=2.2), 130.3, 130.3, 129.8, 129.8, 127.3, 117.7, 117.4, 81.7 (d, J=6.7), 
77.0 (d, J=6.0), 76.8 (d, J=4.9), 76.2 (d, J=1.7), 73.9, 72.7, 72.7, 72.7, 72.6 (d, J=5.8), 
27.4 (d, J=3.7), 27.3 (d, J=4.0); 31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -5.54; 
31P- NMR (162 MHz, 298 K, CDCl3, δ/ppm): -5.54 (ddd, J=8.0, J=8.0, J=8.0); m.p. 148.7 - 
151.2 °C; IR (methanol, cm-1) 3387.4, 1261.2, 1008.6, 700.0, 423.3; Rf (SiO2, 
DCM/MeOH 14:3) 0.38; HRMS (ESI) calcd for C24H27N2O9P [(M+Na)+] 541.1352, found 
541.1357; [α]D20 = +29.0 (C 1, methanol). 
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Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1R,2S,3R,4R,5S,6S)-2,3,4,5,6-
pentahydroxycyclohexyl) phosphate 56 
 
 
 
Compound 54 (488 mg, 0.49 mmol) was dissolved in chloroform (30 mL) and 
trifluoroacetic acid (0.8 mL, 2.5%) was added to the solution. After stirring for 3 h at room 
temperature, hexane was added and the solvents were removed in vacuo. Crystallization 
from diethyl ether yielded compound 56 (252 mg, 0.49 mmol, 100%). 
1H-NMR (400 MHz, 298 K, DMSO-d6, δ/ppm): 7.46 - 7.20 (m, 10H), 5.72 - 5.59 (m, 2H), 
5.26 (d, J=5.2, 1H), 5.06 (d, J=4.2, 1H), 4.87 (d, J=4.6, 1H), 4.69 - 4.59 (m, 2H), 4.12 - 
3.94 (m, 2H), 3.63 (ddd, J=9.4, J=9.4, J=5.2, 1H), 3.40 (d, J=7.0, 1H), 3.30 - 3.11 (m, 5H), 
3.00 (ddd, J=9.1, J=9.1, J=4.7, 1H); 13C-NMR (126 MHz, 298 K, DMSO-d6, δ/ppm): 137.8 
- 137.5 (m), 128.7, 128.6, 128.4, 128.3, 126.2, 125.9, 117.0, 116.9, 79.9 (d, J=6.2), 74.7, 
74.3 (d, J=6.0), 73.6 (d, J=4.3), 72.2, 71.0, 70.9, 70.8 (d, J=6.1), 26.2 (d, J=5.4), 26.0 (d, 
J=6.0); 31P{1H}-NMR (162 MHz, 298 K, DMSO-d6, δ/ppm): -3.57; m.p. 146 - 154 °C; IR 
(methanol, cm-1): 3377.7, 1250.6, 1008.6, 700.0, 417.5; Rf (SiO2, DCM/MeOH 14:3) 0.34; 
HRMS (ESI) calcd for C24H27N2O9P [(M+Na)+] 541.1352, found 541.1348; [α]D20 = +50.6 
(C 0.5, methanol). 
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Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis((3-
oxido-1,5- dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)cyclohexyl) phosphate 57 
 
 
 
50.0 mg (0.096 mmol, 1.0 eq.) P-triester 55 and 231 mg (0.86 mmol, 9 eq.) o-xylylene 
N,N- diisopropylamino phosphoramidite were evaporated twice with dry acetonitrile (2 
mL). The residue was dissolved in dry MeCN (3 mL) and cooled down (0 °C). To this 
solution 3.84 mL (1.73 mmol, 18 eq.) tetrazole (0.45 M in MeCN) were added. Progress 
of the reaction was monitored by 31P-NMR. After completion of the reaction (2.5 h), 
oxidation was achieved by slow (!) addition of 133 mg (0.77 mmol, 8 eq.) mCPBA (70% 
moistened with water). The reaction mixture was diluted with EtOAc (40 mL) and washed 
twice with brine. The organic layer was dried over sodium sulfate, filtered and 
concentrated in vacuo. The product was purified by FC (ethyl acetate/methanol 200:1) 
yielding 90.0 mg 57 as a colorless solid (0.063 mmol, 65%). The yield of this procedure 
can be optimized according to the preparation of 58 procedure B. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.40 - 7.05 (m, 30H), 5.95 - 4.75 (m, 28H), 
3.29 (dd, J = 17.1, 6.4 Hz, 1H), 3.07 - 2.89 (m, 3H); 13C-NMR (126 MHz, 298 K, CDCl3, 
δ/ppm): 150.6, 148.8, 137.0 (d, J=3.4), 136.9 (d, J=3.8), 135.7, 135.6, 135.5, 135.4, 
135.4 - 135.31 (m), 131.3, 130.1 - 128.7 (m), 127.4, 126.5 - 126.0 (m), 116.5, 116.2, 77.8 
- 77.5 (m), 76.6 (d, J=4.8), 76.4 (d, J=4.9), 76.2 (d, J=5.7), 76.0 (d, J=5.1), 74.0 - 73.8 
(m), 73.8 - 73.6 (m), 69.8 (d, J=7.5), 69.7 - 68.9 (m), 27.1 (d, J=4.6), 27.0 (d, J=3.5); 
31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -1.20, -2.20, -2.59, -3.11, -3.63, -4.51; 
m.p. decomposition at 190 °C; IR (neat, cm-1): 1292.1, 1050.1, 1022.1, 860.1, 733.8; Rf 
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(SiO2, ethyl acetate) 0.45; HRMS (ESI) calcd for C64H62N2O24P6 [(M+Na)+] 1451.2016, 
found 1451.2007; [α]D20 = +25.2 (C 1, CHCl3). 
 
 
Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1R,2S,3R,4R,5S,6S)-2,3,4,5,6-
pentakis((3-oxido-1,5- dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)cyclohexyl) 
phosphate 58 
 
 
 
Procedure A: high purity 58 but low yield 
145 mg (0.28 mmol, 1.0 eq.) P-triester 56 and 674 mg (2.52 mmol, 9.0 eq.) o-xylylene 
N,N- diisopropylamino phosphoramidite were evaporated twice with dry acetonitrile (2 
mL). The residue was dissolved in dry MeCN (9 mL) and cooled down (0 °C). To this 
solution 11.2 mL (5.04 mmol, 18 eq.) tetrazole (0.45 M in MeCN) were added. Progress 
of the reaction was monitored by 31P-NMR. After completion of the reaction (2.5 h), 
oxidation was achieved by slow (!) addition of 387 mg (2.24 mmol, 8.0 eq.) mCPBA (70% 
moistened with water). The reaction mixture was diluted with EtOAc (100 mL) and 
washed twice with brine. The organic layer was dried over sodium sulfate, filtered and 
concentrated in vacuo. The product was purified by FC (ethyl acetate/methanol 200:1) 
yielding 100 mg 58 as a colorless solid (0.07 mmol, 25%). 
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Procedure B: slightly impure 58 with quantitative yield 
100 mg (0.19 mmol, 1.0 eq.) P-triester 56 and 470 mg (1.74 mmol, 9.0 eq.) o-xylylene 
N,N- diisopropylamino phosphoramidite were evaporated twice with dry acetonitrile (2 
mL). The residue was dissolved in dry MeCN (15 mL) and cooled down (-5 °C to -10 °C). 
To this solution 410 mg (3.47 mmol, 18 eq.) 4,5-dicyanoimidazole (DCI) were added. 
Progress of the reaction was monitored by 31P-NMR. After completion of the reaction (1 
h), oxidation was achieved by slow (!) addition of 300 mg (1.74 mmol, 9.0 eq.) mCPBA 
(70% moistened with water). The reaction mixture was diluted with DCM (150 mL) and 
washed twice with brine, dried over MgSO4 and the solvents were removed in vacuo. 
Crystallization from dichloromethane/diethyl ether yielded compound 58 (300 mg, 0.21 
mmol, quant.). 31P-NMR showed that the hydrolyzed P-amidite was not completely 
removed (20% from 31P-NMR). This impurity was unproblematic in the next step. 
1H-NMR (400 MHz, 298 K, CDCl3, δ/ppm): 7.33 - 7.02 (m, 30H), 5.98 - 5.90 (m, 1H), 5.81 
- 5.72 (m, 1H), 5.70 - 5.29 (m, 11H), 5.25 - 4.89 (m, 15H), 3.25 (dd, J=16.9, J=8.6, 1H), 
3.08 (dd, J=16.7, J=3.9, 1H), 2.98 (dd, J=16.7, J=8.0, 1H), 2.85 (ddd, J=16.9, J=4.7, 
J=1.6, 1H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 136.7 - 136.5 (m), 136.1 (d, J = 
2.6 Hz), 135.8, 135.9 - 135.6 (m), 135.6, 135.6, 135.5, 134.9, 134.7, 130.1 - 128.4 (m), 
126.3, 126.1, 117.4, 116.0, 77.4 - 77.3 (m), 76.2 (d, J = 5.3 Hz), 76.0 (d, J = 7.4 Hz), 73.8 
- 73.5 (m), 70.0 (d), 69.9 - 69.1 (m), 27.6 (d, J = 7.6 Hz), 27.2 (d, J = 4.4 Hz); 31P{1H}-
NMR (162 MHz, 298 K, CDCl3, δ/ppm): -1.69, -1.74, -2.42, -2.87, -3.33, -3.99; m.p. 159 - 
163 °C; IR (neat, cm-1): 1292.1, 1050.1, 1021.1, 860.1, 733.8, 463.8; Rf (SiO2, ethyl 
acetate) 0.48; HRMS (ESI) calcd for C64H62N2O24P6 [(M+Na)+] 1451.2016, found 
1451.2019; [α]D20 = +2.4 (C 0.5, CHCl3). 
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Synthesis of 3,4,5,6,7,8,9,10-octahydro-2H-pyrimido[1,2-a]azepin-5-ium dibenzyl 
((1S,2R,3R,4S,5S,6R)- 2,3,4,5,6-pentakis((3-oxido-1,5-
dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)cyclohexyl)diphosphate 59 and its 
enantiomer 3,4,5,6,7,8,9,10-octahydro-2H-pyrimido[1,2-a]azepin-5-ium dibenzyl 
((1R,2S,3R,4R,5S,6S)-2,3,4,5,6-pentakis((3-oxido-1,5-
dihydrobenzo[e][1,3,2]dioxaphosphepin-3- yl)oxy)cyclohexyl) diphosphate 60 
 
 
 
80 mg (56 μmol, 1.0 eq.) hexaphosphate 57 were dissolved in dry MeCN (2 mL). 33 μL 
(84 mg, 0.22 mmol, 4.0 eq.) DBU were added followed by addition of 60 μL (58 mg, 0.22 
mmol, 4.0 eq.) BSTFA. The solution was stirred 10 minutes at room temperature. After 
completion of the deprotection (check by 31P-NMR), a mixture of 60 μL MeOH and 18 μL 
(0.22 mmol, 26 mg, 4.0 eq.) TFA were added to the solution. The mixture was sirred for 
10 min and then evaporated to dryness. The residue was taken up in dry MeCN (2 mL) 
and 39 mg (0.11 mmol, 2.0 eq.) bis-benzyl N,N-diisopropylamino phosphoramidite and 
250 μL (0.11 mmol, 2.0 eq) 1H-tetrazole (0.45 M in MeCN) were added. The solution was 
stirred for 15 minutes at room temperature and then cooled down (0 °C). Progress of the 
reaction was monitored by 31P-NMR. After completion of the reaction, oxidation was 
achieved by slow (!) addition of 19.0 mg (0.11 mmol, 2.0 eq.) mCPBA (70% moistened 
with water). The reaction mixture was diluted with Et2O (20 mL) and cooled to 0 °C. The 
precipitate was filtered and washed with cold Et2O and then dried in vacuo. The 
precipitate was purified by RP-18 chromatography (water/MeOH 3:1 – 1:2 v/v) and 
isolated by lyophilization. Yield: 58 mg 59 as a colorless solid (37 μmol, 65%). The same 
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procedure yielded the corresponding enantiomer 60 starting from 58 in comparable yield 
(73%) and purity. Both compounds contained variable amounts of DBUH+ as counterion. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 11.10 (s, DBU), 7.60-6.50 (m, 30H), 6.00 - 
4.40 (m, 30H), 3.42 – 3.30 (m, DBU), 3.30 - 3.15 (m, DBU), 2.80 - 2.72 (m, DBU), 1.90 - 
1.75 (m, DBU), 1.65 - 1.45 (m, DBU); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 166.5, 
137.3 - 134.6 (m), 130.2 - 127.3 (m), 74.6 - 73.8 (m), 72.0 - 71.2 (m), 70.6 - 70.2 (m), 
70.2 - 67.9 (m), 54.3, 48.7, 38.3, 32.6, 29.8, 29.2, 27.0, 24.1, 19.6; 31P{1H}-NMR (162 
MHz, 298 K, MeOD, δ/ppm): -1.74 , -1.90 , -2.10 , -2.63 , -2.79 , -10.09 (d, J=15.0), -
11.95 (d, J=15.2); m.p. decomposition at 170 °C; IR (neat, cm-1): 1291.1, 1051.0, 1020.2, 
861.1, 733.8, 478.3, 416.6; Rf (SiO2, dichloromethane/methanol 8:1) 0.5; HRMS (ESI) 
calcd for C60H60O27P7 1429.1491, found 1429.1497; [α]D20 = +10.9 (59, C 1, CHCl3). 
[α]D20 = -9.9 (60, C 0.5, CHCl3). The analytical data obtained for 59, 60 were identical in 
all respects (besides minor concentration dependent shifts in the NMR spectra), except 
for the inverted optical rotations. 
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Synthesis of 3,4,5,6,7,8,9,10-octahydro-2H-pyrimido[1,2-a]azepin-5-ium dibenzyl 
((1R,2S,3R,4R,5S,6S)-2,3,4,5,6-pentakis((3-oxido-1,5-
dihydrobenzo[e][1,3,2]dioxaphosphepin-3- yl)oxy)cyclohexyl) diphosphothioate 63, a 
sulfurized analog 
 
 
 
15 mg (11 μmol, 1.0 eq.) hexaphosphate 58 were subjected to the same procedure as 
described above (for 60). The only difference was that the 2 equivalents of mCPBA in the 
oxidation step were replaced with 2 equivalents of elemental, powdered sulfur. The 
product was isolated by crystallization yielding 13 mg 63 as a sticky off-white solid (8 
μmol, 77%). Thus, it was proven, that the sequence is amenable to introduce non-natural 
modifications in the anhydride part of the molecule. 
1H-NMR (400 MHz, 298 K, CDCl3, δ/ppm): 11.07 (s, DBU), 7.52-7.00 (m, 30H), 6.05 - 
4.50 (m, 30H), 3.42 – 3.25 (m, DBU), 3.30 - 3.15 (m, DBU), 2.80 - 2.71 (m, DBU), 1.92 - 
1.76 (m, DBU), 1.65 - 1.46 (m, DBU); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 166.4, 
136.3 - 135.0 (m), 129.6 - 128.1 (m), 77.8- 77.6 (m), 74.5 - 73.8 (m), 72.0 - 71.2 (m), 70.5 
- 70.2 (m), 70.0 - 69.1 (m), 54.3, 48.6, 38.2, 32.5, 29.0, 28.8, 23.9, 19.5; 31P{1H}-NMR 
(162 MHz, 298 K, CDCl3, δ/ppm): 57.58 (d, J=17.3), -2.45 , -2.68, -2.74, - 3.45, -3.49, -
12.65 (d, J=17.4); Rf (SiO2, dichloromethane/methanol 8:1) 0.5; HRMS (ESI) calcd for 
C60H60O26P7S 1445.126, found 1445.125. 
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Synthesis of 1-PP-InsP5 and 3-PP-InsP5 
 
 
 
The reactions were either conducted in a stainless steel autoclave with a Teflon inlet at 
80 bar H2 (2-3 hours) or in a Parr apparatus at 4 bar H2 (6 hours). The reaction is given 
as an example for compound 59 but was conducted the same way for compound 60. 15 
mg (9.5 μmol, 1.0 eq.) P-anhydride 59 were dissolved in a mixture of tBuOH and water 
(4:1, 1 mL) and 10.4 mg (124 μmol, 13 eq.) NaHCO3 and PtO2 (15 eq., 32.5 mg, 143 
μmol) were added to the solution. The reaction mixture was then stirred for 2 h under H2 
(80 bar) and then water (1mL) was added. The hydrogenation was continued for 1 more 
hour. The catalyst was removed by centrifugation, washed with water and the combined 
aqueous layers were freeze dried. Crystallization of the residue from water/acetone 
yielded 1-PP-InsP5 as a colorless solid in the sodium form (6.0 mg, 8.1 μmol, < 85%, 
sodium salt with unknown amount of counter ions. Maximal yield was calculated for 
completely protonated species M = 740.01; Minimal yield > 61% (5.8 μmol) for 13 Na+; M 
= 1025.78). 
Analytical data for 1-PP-InsP5: 1H-NMR (500 MHz, 298 K, deuterium oxide, δ/ppm): 5.07 
- 4.97 (m, 1H), 4.48 (ddd, J = 9.9, J = 9.9, J = 9.9, 1H), 4.56 (ddd, J = 9.8, J = 9.8, J = 9.8, 
1H), 4.32 - 4.21 (m, 1H), 4.21 - 4.12 (m, 2H); 13C-NMR (126 MHz, 298 K, deuterium 
oxide, δ/ppm): 77.5 - 77.0 (m), 76.5 - 75.8 (m), 75.2 - 74.7 (m, 2C), 73.7 - 73.4 (m), 73.4 - 
73.1 (m); 31P{1H}-NMR (202 MHz, 298 K, deuterium oxide, δ/ppm): 2.30 , 1.25 , 1.06 , 
0.90 , 0.45 , -6.61 - (-)8.40 (m), -9.90 (d, J=20.1); 31P-NMR (202 MHz, 298 K, deuterium 
oxide, δ/ppm): 2.29 (d, J=9.6), 1.25 (d, J=9.7), 1.06 (d, J=7.9), 0.90 (d, J=9.6), 0.44 (d, 
J=7.9), -6.42 - (-)8.36 (m), -9.90 (dd, J=21.5, J=10.2); HRMS (ESI) calcd for 245.6019 
(M3-, C6H16O27P73-), found 245.6022. [α]D20 = -1.2 (C 0.1, H2O, adjusted to pH = 9 with 
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NH4OH) 
Analytical data for 3-PP-InsP5: 1H-NMR (500 MHz, 298 K, deuterium oxide, δ/ppm): 5.06 
- 4.95 (m, 1H), 4.55 (ddd, J = 9.8, J = 9.8, J = 9.8, 1H), 4.54 (ddd, J = 9.8, J = 9.8, J = 9.8, 
1H), 4.41 - 4.33 (m, 1H), 4.31 - 4.22 (m, 2H); 13C-NMR (126 MHz, 298 K, deuterium 
oxide, δ/ppm): 77.6 - 77.0 (m), 76.2 - 75.8 (m), 75.7 - 75.1 (m, 2C), 73.9 - 73.4 (m), 73.4 - 
73.0 (m); 31P{1H}-NMR (202 MHz, 298 K, deuterium oxide, δ/ppm): 1.83 , 1.01 , 0.62 , 
0.35 , -0.47 , -8.84 – -10.28 (m), -10.83 (d, J=20.4); 31P-NMR (202 MHz, 298 K, 
deuterium oxide, δ/ppm): 1.83 (d, J=9.9), 1.02 (d, J=9.2), 0.63 (d, J=9.7), 0.36 (d, J=9.3), 
-0.48 (d, J=10.9), -9.21 – (-)9.97 (m), -10.51 – (-)11.28 (m); HRMS (ESI) calcd for 
245.6019 (M3-, C6H16O27P73-), found 245.6024; [α]D20 = +0.5 (C 0.1, H2O, adjusted to pH 
= 9 with NH4OH) 
 
 
 
6.3 SYNTHESIS OF 4-PP-INSP5 AND 6-PP-INSP5 
 
Synthesis of (1R,3s,5S,6R,7s,8S,9s)-9-((triethylsilyl)oxy)-2,4,10-trioxaadamantane-6,8-
diol 49 
 
 
 
To a cooled solution (0 °C) of 3.65 g (19.2 mmol, 1.0 eq.) D-myo-inositol ortho-formate in 
dry DMF (20 mL) were added 3.20 mL (2.87 g, 19.1 mmol, 1.0 eq.) TES-chloride. 3.46 
mL (38.4 mmol, 2.0 eq.) Lutidine were added. The solution was stirred 3h at 0 °C. The 
precipitate was removed by filtration and washed with Et2O (150 mL). The organic phase 
was washed three times with water, dried over magnesium sulfate, filtered and 
evaporated in vacuo. Purification was achieved by recrystallization from Et2O/pentane. 
Yield: 4.72 g 49 as colorless crystals (15.5 mmol, 81%). 
1H-NMR (500 MHz, 298 K, DMSO-d6, δ/ppm): 5.53 (s, 2H), 5.47 (s, 1H), 4.28 (dd, J=3.9, 
3.9, 2H), 4.23 - 4.20 (m, 1H), 4.10 - 4.04 (m, 1H), 3.94 - 3.88 (m, 2H), 0.94 (t, J=7.9, 9H), 
0.60 (q, J=8.0, 6H); 13C-NMR (126 MHz, 298 K, DMSO-d6, δ/ppm): 101.8, 74.6, 69.4, 
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67.5, 60.4, 6.7, 4.3; m.p. 102-103 °C; IR (neat, cm-1) 3445.2, 2956.3, 1427.1, 1162.9, 
1060.7, 1017.3, 982.6, 965.2, 745.4, 518.6; HRMS (ESI) calcd for 327.1240 (M+Na), 
found 327.1237. 
 
 
Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1S,3R,5S,6S,7R,8S,9S)-8-hydroxy-9-
((triethylsilyl)oxy)- 2,4,10-trioxaadamantan-6-yl) phosphate 51 and bis((R)-2-cyano-1-
phenylethyl) ((1R,3S,5R,6R,7S,8R,9R)- 8-hydroxy-9-((triethylsilyl)oxy)-2,4,10-
trioxaadamantan-6-yl) phosphate 50 
 
 
 
2.30 g (7.56 mmol, 2.8 eq.) ortho-formate 49 and 1.14 g (2.69 mmol, 1.0 eq.) P-amidite 7 
were evaporated twice with dry MeCN (3 mL), dissolved in 10 mL dry MeCN and cooled 
down with an ice bath (0 °C). Molecular sieves (3Å) were added. 351 mg (2.97 mmol, 1.1 
eq.) 4,5-dicyanoimidazole (previously dried by twofold evaporation with MeCN) were 
added. The solution was stirred 45 min at 0 °C. After completion of the phosphitylation 
(checked by 31P-NMR), 1.00 mL (5.50 mmol, 2.0 eq.) tert- butylhydroperoxide (5.50 M in 
nonane) were added. The reaction was allowed to warm to room temperature and was 
stirred for 20 more minutes. Half of the acetonitrile was removed in vacuo, and then ethyl 
acetate was added (50 mL). The organic phase was washed once with water and twice 
with brine, dried over magnesium sulfate, filtered and evaporated in vacuo. Purification 
was achieved by flash column chromatography (TBME/hexanes 9:1 v/v to 100% TBME). 
Yield: 1.31 g 49 (recovered starting material) as colorless crystals (4.31 mmol). 778 mg 
51 as colorless crystals (1.21 mmol, 45%). 622 mg 50 as a colorless oil (0.97 mmol, 
36%). 
Analytical data for 51: 1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.49 - 7.37 (m, 8H), 
7.32 - 7.27 (m, 2H), 5.67 (ddd, J=6.6, J=6.6, J=6.6, 1H), 5.44 (s, 1H), 5.45 - 5.39 (m, 2H), 
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4.93 - 4.84 (m, 1H), 4.54 - 4.41 (m, 1H), 4.20 - 4.11 (m, 1H), 4.10 - 4.02 (m, 2H), 4.01 - 
3.96 (m, 1H), 3.00 (d, J=5.8, 2H), 2.79 - 2.56 (m, 3H), 0.98 (t, J=7.8, 9H), 0.64 (q, J=7.8, 
6H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 136.3 (2xd, J=2.6), 130.3, 130.2, 129.5, 
129.4, 126.3, 126.0, 116.0, 115.6, 102.7, 76.2 (d, J=4.8), 76.1 (d, J=4.9), 74.3, 72.9 (d, 
J=5.5), 72.6 (d, J=7.5), 68.8 (d, J=3.4), 67.5, 60.1, 27.4 (d, J=7.6), 26.9 (d, J=8.0), 6.9, 
4.8; 31P{1H}-NMR (202 MHz, 298 K, CDCl3, δ/ppm): -4.84; m.p. 127-129 °C; IR (neat, cm-
1) 2957.3, 2876.3, 1720.2, 1457.0, 1274.7, 1164.8, 1082.8, 999.0, 836.0, 746.3, 700.0; Rf 
(SiO2, solvent DCM/EtOAc 1:1) 0.6; HRMS (ESI) calcd for 665.2060 (M+Na), found 
665.2050; [α]D20 = + 35.5 (C 2.0, CHCl3). 
Analytical data for 50: 1H-NMR (400 MHz, 298 K, CDCl3, δ/ppm): 7.44 - 7.31 (m, 8H), 
7.29 – 7.22 (m, 2H), 5.59 (ddd, J=6.6, J=6.6, J=6.6, 1H), 5.50 (ddd, J= 6.1, J= 6.1, J= 6.1, 
1H), 5.45 (s, 1H), 4.98 - 4.81 (m, 1H), 4.50 – 4.45 (m, 1H), 4.45-4.41 (m, 1H), 4.05 – 3.92 
(m, 2H), 3.79 – 3.64 (m, 1H), 3.38 (d, J=5.1, 1H), 2.98 (d, J=6.1, 2H), 2.82 - 2.60 (m, 2H), 
0.92 (t, J=8.0, 9H), 0.57 (q, J=7.9, 6H); 13C-NMR (101 MHz, 298 K, CDCl3, δ/ppm): 136.3 
(2xd, J=4.3), 130.0, 129.7, 129.2, 129.0, 126.1, 125.8, 115.9, 115.7, 102.5, 76.1 (d, 
J=5.4), 75.5 (d, J=5.0), 74.3, 72.6 (d, J=6.0), 72.5 (d, J=7.6), 68.9 (d, J=2.4), 67.1, 60.0, 
27.2 (d, J=8.0), 26.8 (d, J=6.5), 6.7, 4.6; 31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -
5.45; IR (neat, cm-1) 2958.3, 2877.3, 1720.2, 1457.0, 1274.7, 1164.8, 1082.8, 999.9, 
835.0, 748.3, 700.0; Rf (SiO2, solvent DCM/EtOAc 1:1) 0.5; HRMS (ESI) calcd for 
665.2060 (M+Na), found 665.2057; [α]D20 = + 25.0 (C 1.0, CHCl3). 
 
 
X-ray crystal Structure of 51: 
CCDC-915304 contains the supplementary crystallographic data for compound 51. 
These data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1S,2R,3S,4S,5S,6S)-2,3,4,5,6-
pentahydroxycyclohexyl) phosphate 65 
 
 
 
400 mg (0.62 mmol, 1.0 eq.) P-triester 51 and 47 mg (0.25 mmol, 0.4 eq.) para-toluene 
sulfonic acid were dissolved in MeOH (10 mL) and stirred for 6 h. Progress of the 
reaction was monitored by 31P-NMR. After completion of the reaction, the product was 
precipitated by addition Et2O (180 mL) and hexanes (20 mL) at 0 °C. This provoked 
organogel formation. The gel was filtered and washed with Et2O/hexanes (9:1) and dried 
for several hours in vacuo. Yield: 305 mg 65 as a colorless solid (0.59 mmol, 95%). 
1H-NMR (400 MHz, 298 K, MeOD, δ/ppm): 7.46 - 7.35 (m, 5H), 7.35 - 7.30 (m, 3H), 7.30 - 
7.25 (m, 2H), 5.87 - 5.70 (m, 2H), 4.55 (ddd, J=9.6, J=9.6, J=9.6, 1H), 3.99 (dd, J=2.9, 
J=2.9, 1H), 3.67 (dd, J=9.5, J=9.5, 1H), 3.61 (dd, J=9.8, 2.9, 1H), 3.46 - 3.37 (m, 2H), 
3.25 - 2.99 (m, 4H); 13C-NMR (126 MHz, 298 K, DMSO-d6, δ/ppm): 138.3 (d, J=3.8), 
137.9 (d, J=5.7), 128.6, 128.4, 128.4, 128.3, 126.3, 125.9, 117.1, 117.0, 82.9 (d, J=6.9), 
73.6 (d, J=5.4), 73.4 (d, J=4.6), 73.4 (d, J=2.7), 72.9, 72.8, 7.3, 70.25 (d, J=2.9), 26.12 (d, 
J=6.3), 25.97 (d, J=5.1); 31P{1H}-NMR (202 MHz, 298 K, MeOD, δ/ppm): -4.57; m.p. 117-
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120 °C; IR (neat, cm-1) 3365.2, 1258.3, 1119.5, 1045.2, 1008.6, 936.3, 754.0, 700.0, 
512.0; Rf (SiO2, solvent DCM:MeOH 8:1) 0.4; HRMS (ESI) calcd for 541.1352 (M+Na), 
found 541.1355; [α]D20 = + 40.9 (C 1.0, MeOH). 
 
 
Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1R,2R,3R,4R,5R,6S)-2,3,4,5,6-
pentahydroxycyclohexyl) phosphate 64 
 
 
 
200 mg (0.31 mmol, 1.0 eq.) P-triester 50 and 23 mg (0.13 mmol, 0.4 eq.) para-toluene 
sulfonic acid were dissolved in MeOH (5 mL) and stirred for 8 h. Progress of the reaction 
was monitored by 31P-NMR. After completion of the reaction, the product was 
precipitated by addition Et2O (50 mL) and hexanes (5 mL) at 0 °C. The precipitate was 
filtered and washed with Et2O/hexanes (9:1) and dried for several hours in vacuo. Yield: 
146 mg 64 as a colorless solid (0.28 mmol, 91%). 
1H-NMR (500 MHz, 298 K, MeOD, δ/ppm: 7.53 - 7.39 (m, 5H), 7.39 - 7.31 (m, 3H), 7.31-
7.23 (m, 2H), 5.88 - 5.73 (m, 2H), 4.57 (ddd, J=9.1, J=9.1, J=9.1, 1H), 4.01 (dd, J=2.8, 
J=2.8, 1H), 3.72 - 3.63 (m, 2H), 3.45 - 3.39 (m, 2H), 3.27 - 3.00 (m, 4H); 13C-NMR (126 
MHz, 298 K, MeOD, δ/ppm): 139.0 (2xd, J=3.8), 130.1, 130.1, 129.7, 129.7, 127.5, 127.2, 
117.5, 117.4, 84.6 (d, J=7.2), 76.6 (d, J=6.1), 76.3 (d, J=4.8), 74.8 (d, J=3.2), 74.3, 74.2, 
73.1, 72.2 (d, J=3.4), 27.5 (d, J=6.6), 27.4 (d, J=6.9); 31P{1H}-NMR (202 MHz, 298 K, 
MeOD, δ/ppm): -4.47; m.p. 112-115 °C; IR (neat, cm-1) 3395.1, 1257.4, 1110.8, 1044.3, 
1009.6, 700.0, 517.8; Rf (SiO2, solvent DCM:MeOH 8:1) 0.4; HRMS (ESI) calcd for 
541.1352 (M+Na), found 541.1352; [α]D20 = + 35.5 (C 0.5, MeOH). 
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Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1S,2R,3S,4S,5S,6S)-2,3,4,5,6-pentakis((3-
oxido-1,5-dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)cyclohexyl) phosphate 67 
 
 
 
130 mg (0.25 mmol, 1.0 eq.) P-triester 65 and 738 mg (2.75 mmol, 11 eq.) o-xylylene 
N,N- diisopropylamino phosphoramidite were evaporated twice with dry acetonitrile (2 
mL). The residue was dissolved in 10 mL dry MeCN and cooled down (-10 °C to -15 °C). 
To this solution 531 mg (4.5 mmol, 18 eg.) 4,5-dicyanoimidazole (DCI) were added. 
Progress of the reaction was monitored by 31P-NMR. After completion of the reaction (20 
min), the mixture was warmed to 0 °C. Oxidation was achieved by slow (!) addition of 
66.0 mg (2.50 mmol, 10 eq.) mCPBA (70% moistened with water). The reaction mixture 
was diluted with EtOAc (60 mL) and washed twice with brine. The organic layer was 
dried over sodium sulfate, filtered and concentrated in vacuo. The mixture was not 
evaporated to dryness! After concentration to around 10 mL, TBME (70 mL) were added 
and the solution was stored at 4 °C for 1 hour. The precipitate was filtered and washed 
with cold TBME and then dried in vacuo. This procedure yielded material of reasonable 
purity for the next synthetic transformation with the major impurity being excess DCI. 
Further purification of the product by FC led to massive losses of product, although the 
material was obtained in slightly improved quality. Yield: 350 mg 67 as a colorless solid 
(0.25 mmol, 98%). 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.48 - 7.10 (m, 30H), 5.91 - 4.83 (m, 28H), 
3.08 (dd, J=16.9, J=8.5, 1H), 2.96 (d, J=5.8, 2H), 2.77 (dd, J=16.9, J=1.9, 1H); 13C-NMR 
(126 MHz, 298 K, CDCl3, δ/ppm): 137.1 (d, J=4.6), 136.8 (d, J=2.7), 129.8 - 128.5 (m), 
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126.2, 126.0, 117.2 , 116.1, 76.6 - 75.9 (m), 75.4 (d, J=5.7), 74.9 (d, J=4.8), 73.8-73.6 
(m), 73.1 (d, J=4.9), 70.0 - 68.2 (m), 27.1 (d, J=5.7), 26.8 (d, J=7.5); 31P{1H}-NMR (202 
MHz, 298 K, CDCl3, δ/ppm): -0.21, -2.93, -3.37, -3.57, -3.81, -4.38; m.p. 139-142 °C; IR 
(neat, cm-1) 3395.1, 1289.2, 1049.1, 1021.1, 871.7, 858.2, 848.5, 761.7, 748.3, 735.7; Rf 
(SiO2, solvent EtOAc/MeOH 20:1) 0.3; HRMS (ESI) calcd for 1451.2016 (M+Na), 
1474.1914 (M+2Na), found 1451.1991 (1+), 1474.1911 (2+); [α]D20 = + 8.7 (C 0.5, 
CHCl3). 
 
 
Synthesis of bis((R)-2-cyano-1-phenylethyl) ((1R,2R,3R,4R,5R,6S)-2,3,4,5,6-pentakis((3-
oxido-1,5- dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)cyclohexyl) phosphate 66 
 
 
 
130 mg (0.25 mmol, 1.0 eq.) P-triester 64 and 738 mg (2.75 mmol, 11 eq.) o-xylylene 
N,N- diisopropylamino phosphoramidite were evaporated twice with dry acetonitrile (2 
mL). The residue was dissolved in 10 mL dry MeCN and cooled down (-10 °C to -15 °C). 
To this solution 531 mg (4.5 mmol, 18 eq.) 4,5-dicyanoimidazole (DCI) were added. 
Progress of the reaction was monitored by 31P-NMR. After completion of the reaction (20 
min), the mixture was warmed to 0 °C. Oxidation was achieved by slow (!) addition of 
66.0 mg (2.50 mmol, 10 eq.) mCPBA (70% moistened with water). The reaction mixture 
was diluted with EtOAc (60 mL) and washed twice with brine. The organic layer was 
dried over sodium sulfate, filtered and concentrated in vacuo. The mixture was not 
evaporated to dryness! After concentration to around 10 mL, TBME (70 mL) were added 
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and the solution was stored at 4 °C for 1 hour. The precipitate was filtered and washed 
with cold TBME and then dried in vacuo. This procedure yielded material of reasonable 
purity for the next synthetic transformation with the major impurity being excess DCI. 
Further purification of the product by FC led to massive losses of product, although the 
material was obtained in slightly improved quality. Yield: 342 mg 66 as a colorless solid 
(0.24 mmol, 96%). 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.51 - 7.35 (m, 28H), 7.29 - 7.24 (m, 2H), 5.87 
- 5.58 (m, 11H), 5.45 - 4.86 (m, 17H), 3.34 - 3.17 (m, 2H), 3.10 (dd, J=16.9, 6.3, 1H), 
2.89 (dd, J=16.9, 4.7, 1H); 13C-NMR (101 MHz, 298 K, CDCl3, δ/ppm): 137.0 (d, J=4.6), 
136.8 (d, J=4.1), 135.8 - 135.13 (m), 134.7, 134.7, 130.0 - 128.8 (m), 128.7, 126.3, 126.0, 
116.3, 116.02, 76.4 (m), 76.1 (d, J=4.5), 75.7 (d, J=6.5), 75.3 (m), 73.9 (m), 73.0 (m), 
70.0 - 68.7 (m), 27.3 (d, J=5.8), 27.1 (d, J=6.7); 31P{1H}-NMR (202 MHz, 298 K, CDCl3, 
δ/ppm): -0.44, -0.78, -0.84, -1.26, -1.61, -2.73; m.p. 138-142 °C; IR (neat, cm-1) 3395.1, 
1291.1, 1049.1, 1016.3, 862.0, 755.0, 734.8, 458.0; Rf (SiO2, solvent EtOAc/MeOH 30:1) 
0.5; HRMS (ESI) calcd for 1474.1914 (M+2Na), found 1474.1898 (2+); [α]D20 = + 10.8 (C 
0.4, CHCl3). 
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Synthesis of 3,4,5,6,7,8,9,10-octahydro-2H-pyrimido[1,2-a]azepin-5-ium dibenzyl 
((1S,2R,3S,4S,5S,6S)- 2,3,4,5,6-pentakis((3-oxido-1,5-
dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)cyclohexyl)diphosphate 69 and its 
enantiomer 3,4,5,6,7,8,9,10-octahydro-2H-pyrimido[1,2-a]azepin-5-ium dibenzyl 
((1R,2R,3R,4R,5R,6S)-2,3,4,5,6-pentakis((3-oxido-1,5-
dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy) cyclohexyl) diphosphate 68 
 
 
 
200 mg (0.14 mmol, 1.0 eq.) hexaphosphate 66 were dissolved in dry MeCN (4 mL). 84 
μL (85 mg, 0.56 mmol, 4.0 eq.) DBU were added followed by addition of 148 μL (142 mg, 
0.56 mmol, 4.0 eq.) BSTFA. The solution was stirred 10 minutes at room temperature. 
After completion of the deprotection (check by 31P-NMR), a mixture of 140 μL MeOH and 
44 μL (0.56 mmol, 4.0 eq.) TFA were added to the solution. The mixture was sirred for 5 
min and then evaporated to dryness. The residue was taken up in 4 mL dry MeCN and 
92 mg (0.28 mmol, 2.0 eq.) bis-benzyl N,N-diisopropylamino phosphoramidite and 600 
μL (0.27 mmol, 2.0 eq) 1H-tetrazole (0.45 M in MeCN) were added. The solution was 
stirred for 15 minutes at room temperature and then cooled down (0 °C). Progress of the 
reaction was monitored by 31P-NMR. After completion of the reaction, oxidation was 
achieved by slow (!) addition of 68.0 mg (0.28 mmol, 2.0 eq.) mCPBA (70% moistened 
with water). The reaction mixture was diluted with TBME (20 mL) and cooled to 0 °C. The 
precipitate was filtered and washed with cold TBME and then dried in vacuo. The 
precipitate was purified by RP-18 chromatography (water/MeOH 3:1 – 1:2 v/v) and 
isolated by lyophilization. Yield: 152 mg 68 as a colorless solid (96.0 μmol, 68%). The 
same procedure yielded the corresponding compound 69 starting from 67 in comparable 
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yield and purity. 
1H-NMR (400 MHz, 298 K, CDCl3, δ/ppm): 10.95 (s, 1H), 7.50 - 7.01 (m, 30H), 5.97 - 
4.72 (m, 30H), 3.42 – 3.34 (m, 2H), 3.33 - 3.19 (m, 4H), 2.85 - 2.66 (m, 2H), 1.90 - 1.80 
(m, 2H), 1.69 - 1.43 (m, 6H); 13C-NMR (126 MHz, 298 K, MeOD, δ/ppm): 138.1 - 136.7 
(m), 135.7, 131.5 - 129.8 (m), 129.5, 129.5, 129.4, 129.1, 129.0, 115.7, 114.7, 78.8 - 
18.4 (m), 75.4 - 75.2 (m), 75.0 - 74.8 (m), 74.8 - 74.6 (m), 71.7 - 70.4 (m), 70.2 - 70.0 (m), 
55.9, 55.7, 55.4, 39.3, 33.7, 30.0, 27.5, 24.9, 20.4; 31P{1H}-NMR (162 MHz, 298 K, CDCl3, 
δ/ppm): -1.87 , -1.95 , -2.29 , -2.59 , -3.11 , -9.53 (d, J=12.9), -11.01 (d, J=12.9); m.p. 
134- 137 °C; IR (neat, cm-1) 2365.3, 2340.2, 2330.6, 1740.4, 1513.9, 1457.0, 1290.1, 
1107.9, 1013.4, 735.7, 476.3; Rf (SiO2, solvent DCM/MeOH 7:1) 0.4; HRMS (ESI) calcd 
for 1429.1491 (M-), found 1429.1492; [α]D20 = + 8.2 (69, C 0.4, CHCl3); - 8.8 (68, C 0.4, 
CHCl3). The analytical data obtained for 69, 68 were identical in all respects (besides 
minor concentration dependent shifts in the NMR spectra), except for the inverted optical 
rotations. 
 
 
Synthesis of 4-diphosphoinositol-1,2,3,5,6-pentaphosphate and 6-diphosphoinositol-
1,2,3,4,5- pentaphosphate 
 
 
 
The reactions were either conducted in a stainless steel autoclave with a Teflon inlet at 
80 bar H2 (2 hours) or in a Parr apparatus at 4 bar H2 (6 hours). The reaction is given as 
an example for compound 69 but was conducted the same way for compound 68. 60.0 
mg (37.9 μmol, 1.0 eq) P-anhydride 69 were dissolved in 4 mL tBuOH/H2O 3:1 and 
mixed with 38.0 mg (0.45 mmol, 12 eq.) NaHCO3 and 60 mg (0.56 mmol, 15 eq.) Pd 
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black. After 2 hours of hydrogenation (4 bar) with vigorous stirring, water was added (4 
mL) and the reaction continued for another 4 hours. The catalyst was removed by 
centrifugation and rinsed with water (10 mL) twice. The combined aqueous fractions were 
extracted twice with EtOAc (10 mL) and the aqueous layer was freeze-dried. The residue 
was taken up in water (0.3 mL) and the product precipitated by addition of acetone (4 mL). 
After centrifugation, the product was purified by strong anion exchange (SAX, Q-
Sepharose fast flow, Aldrich), eluting with ammonium formate from 0.5 M to 2 M. The 
product fractions were identified by 31P-NMR, pooled and isolated by lyophilization. Yield: 
22.0 mg 4-PP-InsP5 as a colorless solid (29.7 μmol, < 78%, ammonium salt with 
unknown amount of counter ions. Maximal yield was calculated for completely protonated 
species M = 740.01; Minimal yield > 61% for 13 NH4+; M = 961.41). The same procedure 
yielded the corresponding 6-PP-InsP5 starting from 68 in comparable yield and purity. 
Analytical data for 4-PP-InsP5: 1H-NMR (500 MHz, 298 K, D2O, δ/ppm): 4.97 - 4.90 (m, 
1H), 4.56 (ddd, J=9.5, J=9.5, J=9.5, 1H), 4.47 (ddd, J=9.4, J=9.4, J=9.4, 1H), 4.27 (ddd, 
J=9.6, J=9.6, J=9.6, 1H), 4.23 (ddd, J=9.9, J=9.9, J=9.9, 2H); 13C-NMR (126 MHz, 298 K, 
D2O, δ/ppm): 77.1 - 76.8 (m), 76.4 - 76.2 (m), 76.0 - 75.8 (m), 75.3 - 75.0 (m), 73.2 - 72.9 
(m), 72.9 - 72.6 (m); 31P{1H}-NMR (202 MHz, 298 K, D2O, δ/ppm): 1.33, 0.84, 0.75, 0.62, 
0.52, -9.06 (d, J=20.0), -10.61 (d, J=20.0); 31P-NMR (202 MHz, 298 K, D2O, δ/ppm): 1.33 
(d, J=9.9), 0.83 (d, J=8.9), 0.74 (d, J=10.6), 0.61 (d, J=9.5), 0.52 (d, J=8.5), -9.06 (d, 
J=19.0), -10.30 - (-)10.90 (m); HRMS (ESI) calcd for 379.8975 (M2-, C6H16NaO27P72-), 
found 379.8978; calcd for 390.8885 (M2-, C6H15Na2O27P72-), found 390.8887; calcd for 
412.8705 (M2-, C6H13Na4O27P72-), found 412.8709; [α]D20 = +2.5 (C 0.1, H2O, adjusted to 
pH = 9 with NH4OH), 33Lit.: [α]D20 = +2.4. 
Analytical data for 6-PP-InsP5: 1H-NMR (500 MHz, 298 K, D2O, δ/ppm): 4.94 - 4.85 (m, 
1H), 4.52 (ddd, J=9.6, J=9.6, J=9.6, 1H), 4.43 (ddd, J=9.1, J=9.1, J=9.1, 1H), 4.22 (ddd, 
J=9.2, J=9.2, J=9.2, 1H), 4.17 (ddd, J=10.6, J=10.6, J=10.6, 2H); 13C-NMR (126 MHz, 
298 K, D2O, δ/ppm): 77.2 - 76.7 (m), 76.6 - 76.1 (m), 76.0 - 75.7 (m), 75.2 - 74.7 (m), 
73.5 -73.1 (m), 73.1 - 72.7 (m); 31P{1H}-NMR (202 MHz, 298 K, D2O, δ/ppm): 1.47 , 1.04 , 
0.98 , 0.73 , 0.54 , -8.73 (d, J=19.4), -10.56 (d, J=18.9); 31P-NMR (202 MHz, 298 K, D2O, 
δ/ppm): 1.46 (d, J=9.8), 1.03 (d, J=8.8), 0.98 (d, J=8.8), 0.72 (d, J=8.4), 0.53 (d, J=8.3), -
8.74 (d, J=17.4), -10.56 (dd, J=17.7, 10.9); HRMS (ESI) calcd for 245.6019 (M3-, 
C6H16O27P73-), found 245.6016; [α]D20 = -1.6 (C 0.1, H2O, adjusted to pH = 9 with 
NH4OH), 4Lit.: [α]D20 = -2.4. 
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6.4 SYNTHESIS OF 1,5-(PP)2-INSP4 AND 3,5-(PP)2-INSP4 
 
Synthesis of meso diol 72 
 
 
 
A) 5.1 g (8.2 mmol, 1.0 eq.) 14 and 5.1 g (9.8 mmol, 1.2 eq.) phosphoramidite 22 were 
evaporated twice with dry MeCN (5 mL) and then dissolved in dry MeCN (40 mL). After 
addition of 1.55 g (10.6 mmol, 1.3 eq) 5-phenyl-1H-tetrazole, the reaction mixture was 
stirred at room temperature for 2 h. The mixture was cooled down (0 °C) and 2.20 mL 
(12.2 mmol, 1.5 eq.) tert-butyl hydroperoxide solution (5.5 M in decane) were added. The 
mixture was stirred at this temperature for 20 min and half of the solvents were 
evaporated under high vacuum. The solution was diluted with ethyl acetate, washed with 
brine (3x), dried over MgSO4 and the solvents were removed in vacuo. The crude 
material was directly used in the next step B). 
B) The crude material (9.80 g, 9.20 mmol) was dissolved in MeOH (285 mL) and DCM 
(95 mL). 700 mg (3.68 mmol, 0.4 eq.) pTsOH were added and the solution was refluxed 
for 5 minutes and then again for another 5 min. The reaction was quenched by adding 
saturated aqueous NaHCO3 and and the mixture was extracted with Et2O. After 
separation, the organic layer was washed with brine, dried over MgSO4 and the solvents 
were removed in vacuo. Purification was achieved by gradient column chromatography 
(dichloromethane/ethyl acetate 8:2 until 4:6) yielding 5.23 g 72 as a sticky solid (5.35 
mmol, 66%, over 2 steps). 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.70 – 7.64 (m, 4H), 7.45 - 7.15 (m, 18H), 
6.95 - 6.92 (m, 2H), 6.83 - 6.80 (m, 4H), 4.73 - 4.70 (m, 4H), 4.59 – 4.56 (m, 2H), 4.28 - 
4.18 (m, 5H), 3.96 - 3.93 (m, 3H), 3.86 - 3.85 (m, 3H), 3.77 - 3.72 (m, 8H), 3.52 - 3.49 (m, 
2H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 159.4, 159.2, 143.2 (d, J = 8.5 Hz), 
141.3, 130.6, 130.4, 129.6, 129.6, 127.7, 127.0, 125.2 (d, J = 5.1 Hz), 119.9 (d, J = 8.3 
Hz), 113.9, 113.8, 80.70 (d, J = 7.5 Hz), 79.91 (d, J = 2.8 Hz), 78.4, 74.9, 73.9, 71.9, 69.2 
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(d, J = 5.6 Hz), 55.3, 55.2, 47.8 (d, J = 8.4 Hz); 31P{1H}-NMR (203 MHz, 298 K, CDCl3, 
δ/ppm): -2.12; IR (neat, cm-1): 3384.5, 2946.7, 2906.2, 1612.2, 1513.9, 1450.2, 1247.7, 
1015.3, 822.5, 741.5; Rf (SiO2, dichloromethane/ethyl acetate 4:6) 0.35; HRMS (ESI) 
calcd for C58H57NaO12P [(M+Na)+] 999.3485, found 999.3483. 
 
 
Synthesis of bis-phosphate triesters 73 and 74 
 
 
 
3.24 g (3.32 mmol, 3.5 eq.) PMB-protected diol 72 and 402 mg (0.95 mmol, 1.0 eq.) 
phosphoramidite 12 were evaporated twice with dry MeCN (3 mL) and then dissolved in 
dry MeCN (20 mL). After addition of 3.2 mL (1.43 mmol, 1.5 eq) 1H-tetrazole (0.45 M in 
MeCN) the reaction mixture was stirred at room temperature for 5 h. The mixture was 
cooled down (0 °C) and 197 mg (1.14 mmol, 1.2 eq.) mCPBA were added. The mixture 
was stirred for 10 min at this temperature and 10 min at room temperature. The solution 
was diluted with ethyl acetate, washed with brine (3x), dried over MgSO4 and the 
solvents were removed in vacuo. The excess of starting material was recovered* by flash 
column chromatography (diethyl ether/isopropanol 100:1 until 9:1) yielding 874 mg of a 
mixture of both diastereomers (0.66 mmol, 69%, based on phosphoramidite 12). The two 
diastereomers 73 and 74 were separated and purified by repeated flash column 
chromatographies (dichloromethane/ethyl acetate/methanol 50:50:1) and both were 
isolated as white solids. 
*The recovered starting material 72 was again desymmetrized with phosphoramidite 12 
several times, producing up to 2.7 g diastereomers 73 and 74 as a mixture, which, upon 
separation enabled the isolation of >1 g of each diastereomer in a purity of >90%. 
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Analytical data for 73: 1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.70 - 7.63 (m, 4H), 
7.41 - 7.09 (m, 28H), 6.92 (d, J=8.5, 2H), 6.82 – 6.68 (m, 4H), 5.53 (ddd, J=6.5, J=6.5, 
J=6.5, 1H), 5.30 (m, 1H), 4.80 (d, J=10.5, 1H), 4.66 (d, J=11.0, 1H), 4.59 - 4.53 (m, 4H), 
4.34 - 4.29 (m, 2H), 4.20 - 4.10 (m, 5H), 3.97 - 3.86 (m, 6H), 3.76 - 3.72 (m, 7H), 3.49 - 
3.45 (m, 1H), 2.69 – 2.68 (m, 2H), 2.49 - 2.47 (m, 2H), 2.18 (d, J=5.8, 1H); 13C-NMR (126 
MHz, 298 K, CDCl3, δ/ppm): 159.3, 159.2, 159.1, 143.2 (d, J = 4.9 Hz), 143.1 (d, J = 4.0 
Hz), 141.3 - 141.2 (m), 136.6 (d, J = 3.1 Hz), 136.5 (d, J = 3.9 Hz), 130.5, 130.4, 130.3, 
129.7, 129.7, 129.6, 129.5, 129.0, 128.9, 127.7, 127.0, 127.0, 126.2, 125.9, 125.2 - 
125.1 (m), 119.9, 119.8, 116.0, 115.4, 113.8, 113.8, 113.7, 80.1 (d, J = 5.9 Hz), 79.3 (d, J 
= 2.8 Hz), 78.7 (d, J = 5.8 Hz), 78.1 - 78.0 (m), 75.5 (d, J = 4.7 Hz), 75.1, 75.1, 74.0, 73.6, 
71.0, 69.4 (d, J = 5.6 Hz), 55.3, 55.2 (d, J = 3.8 Hz), 47.8 – 47.7 (m), 26.9 (d, J = 8.1 Hz), 
26.7 (d, J = 6.6 Hz); 31P{1H}-NMR (203 MHz, 298 K, CDCl3, δ/ppm): -2.08, -4.22; m.p. 
81 °C; IR (neat, cm-1): 2935.1, 1613.2, 1513.9, 1451.2, 1248.7, 1011.5, 823.5, 757.9, 
741.5, 701.0, 419.4; Rf (SiO2, dichloromethane/ethyl acetate/meoh 5:5:0.1) 0.38; HRMS 
(ESI) calcd for C76H72N2NaO15P2 [(M+Na)+] 1337.4306, found 1337.4288; [α]D20 = +11.2 
(C 0.6, CHCl3). 
Analytical data for 74: 1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.74 - 7.62 (m, 4H), 
7.42 - 7.24 (m, 21H), 7.20 - 7.14 (m, 5H), 7.10 - 7.08 (m, 2H), 6.97 - 6.96 (m, 2H), 6.84 – 
6.80 (m, 4H), 5.52 (ddd, J=6.2, J=6.2, J=6.2, 1H), 5.27 (m, 1H), 4.76 – 4.67 (m, 4H), 4.56 
– 4.48 (m, 2H), 4.22 - 4.10 (m, 6H), 3.95 - 3.90 (m, 2H), 3.87 - 3.83 (m, 5H), 3.79 - 3.75 
(m, 7H), 3.46 – 3.42 (m, 1H), 2.89 (dd, J=16.9, 5.5, 1H), 2.66 (dd, J=16.8, 6.2, 1H), 2.48 
(dd, J=16.9, 5.7, 1H), 2.35 (dd, J=16.8, 5.9, 1H), 2.16 (d, J=5.5, 1H); 13C-NMR (126 MHz, 
298 K, CDCl3, δ/ppm): 159.4, 159.2, 159.1, 143.2 - 143.0 (m), 141.3, 141.2, 136.6 (d, 
J=3.5), 136.5 (d, J=2.9), 130.6, 130.3 (d, J=3.9), 129.7 - 129.4 (m), 129.0 - 128.9 (m), 
127.7, 127.7, 127.0 - 126.9 (m), 126.0, 126.0, 125.2 - 125.1 (m), 119.9, 119.8, 115.8, 
115.6, 113.9, 113.8, 113.7, 80.2 (d, J=6.6), 79.2 (d, J=2.9), 78.1 (d, J=6.5), 77.8, 75.4 - 
75.3 (m), 75.1, 74.2, 73.6, 71.1, 69.4 - 69.3 (m), 55.3 - 55.2 (m), 47.8 – 47.7 (m), 27.1 (d, 
J=7.7), 26.8 (d, J=7.8), 14.2; 31P{1H}-NMR (203 MHz, 298 K, CDCl3, δ/ppm): -2.08, -4.50; 
m.p. 70 °C; IR (neat, cm-1): 3405.7, 2935.1, 2359.5, 1613.2, 1513.9, 1451.2, 1248.7, 
1009.6, 821.5, 756.9, 701.0, 513.0; Rf (SiO2, dichloromethane/ethyl acetate/meoh 
5:5:0.1) 0.45; HRMS (ESI) calcd for C76H72N2NaO15P2 [(M+Na)+] 1337.4306, found 
1337.4291; [α]D20 = +18.5 (C 0.6, CHCl3). 
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Synthesis of tetraol 75 
 
 
 
Diastereomer 73 (410 mg, 0.31 mmol) was dissolved in chloroform (20 mL) and 
trifluoroacetic acid (1.0 mL, 5% v/v) was added to the solution. After stirring for 4 h at 
room temperature, hexane (5 mL) was added and the solvents were removed in vacuo. 
The residue was dissolved in dichloromethane and methanol (5 mL) and crystallization 
by addition of diethyl ether and TBME (ca. 5 mL, until the solution becomes turbid, 0 °C, 
overnight) yielded compound 75 as a white solid (210 mg, 0.22 mmol, 71%). 
1H-NMR (500 MHz, 298 K, DMSO, δ/ppm): 7.87 - 7.85 (m, 4H), 7.62 - 7.56 (m, 4H), 7.41 
- 7.26 (m, 18H), 5.75 – 5.71 (m, 1H), 5.67 – 5.63 (m, 1H), 4.34 - 4.18 (m, 8H), 4.06 - 4.01 
(m, 2H), 3.90 – 3.86 (m, 2H), 3.77 - 3.65 (m, 3H), 3.29 - 3.18 (m, 5H); 13C-NMR (126 
MHz, 298 K, DMSO, δ/ppm): 143.9 - 143.8 (m), 141.3 - 141.2 (m), 138.1 (d, J=4.3), 138.0 
(d, J=4.8), 129.2 (d, J=7.8), 128.9 (d, J=8.1), 128.1, 127.4, 126.7, 126.5, 125.7 - 125.6 
(m), 120.5, 117.4, 82.7 (d, J=6.5), 79.8 (d, J=6.0), 74.8 (d, J=5.7), 74.4 (d, J=4.6), 71.3 - 
71.1 (m), 70.0 - 69.9 (m), 68.8 – 68.7 (m), 49.2, 47.9 – 47.8 (m), 27.3, 26.6-26.4 (m); 
31P{1H}-NMR (203 MHz, 298 K, DMSO, δ/ppm): -1.93, -4.46; m.p. 165 – 167 °C; IR (neat, 
cm-1): 2361.4, 2174.4, 2163.7, 2010.4, 1974.8, 1025.0; Rf (SiO2, ethyl acetate/methanol 
10:1) 0.24; HRMS (ESI) calcd for C52H48N2NaO12P2 [(M+Na)+] 977.2580, found 977.2568; 
[α]D20 = +1.3 (C 0.45, DMSO). 
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Synthesis of tetraol 76 
 
 
 
Diastereomer 74 (490 mg, 0.37 mmol) were dissolved in chloroform (24 mL) and 
trifluoroacetic acid (1.2 mL, 5% v/v) was added to the solution. After stirring for 3.5 h at 
room temperature, hexane (5 mL) was added and the solvents were removed in vacuo. 
The residue was dissolved in dichloromethane and methanol (5 mL) and crystallization 
by addition of TBME (ca. 5 mL, until the solution becomes turbid, 0 °C, overnight) yielded 
compound 76 as a white solid (248 mg, 0.26 mmol, 70%). 
1H-NMR (500 MHz, 298 K, DMSO, δ/ppm): 7.88 - 7.85 (m, 4H), 7.61 - 7.57 (m, 4H), 7.42 
- 7.26 (m, 18H), 5.74 (d, J=6.7, 1H), 5.71 – 5.65 (m, 2H), 5.32 (s, 1H), 5.20 (s, 1H), 5.00 
(s, 1H), 4.35 - 4.15 (m, 7H), 4.10 - 4.04 (m, 2H), 3.92 - 3.86 (m, 1H), 3.69 - 3.65 (m, 1H), 
3.40 - 3.25 (m, 3H), 3.22 - 3.16 (m, 2H); 13C-NMR (126 MHz, 298 K, DMSO, δ/ppm): 
143.9 - 143.8 (m), 141.3, 141.2, 138.1 (2xd, J=4.7), 129.2 (d, J=6.3), 128.9, 128.8, 128.1, 
127.5, 127.5, 126.7, 126.4, 125.7, 125.7, 125.7, 120.5, 117.4, 82.6 - 82.5 (m), 79.7 (d, 
J=6.3), 74.9 (d, J=6.0), 74.3 (d, J=4.5), 71.3 (d, J=3.0), 71.0 (d, J=4.2), 70.0 - 69.9 (m), 
68.8 – 68.7 (m), 47.9 – 47.8 (m), 26.7 – 26.5 (m); 31P{1H}-NMR (203 MHz, 298 K, DMSO, 
δ/ppm): -1.96, -4.57; m.p. 180 °C; IR (neat, cm-1): 2358.5, 2341.2, 1698.0, 1558.2, 
1507.1, 1260.3, 1014.4; Rf (SiO2, ethyl acetate/methanol 10:1) 0.30; HRMS (ESI) calcd 
for C52H48N2NaO12P2 [(M+Na)+] 977.2580, found 977.2562; [α]D20 = +21.1 (C 0.46, 
DMSO). 
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Synthesis of hexakisphosphate 77 
 
 
 
75 (200 mg, 0.21 mmol, 1.0 eq.) and o-xylylene N,N-diisopropylamino phosphoramidite 
18 (390 mg, 1.46 mmol, 7.0 eq.) were evaporated twice with dry acetonitrile (2 mL). The 
residue was dissolved in dry MeCN (20 mL) and cooled down (0 °C). To this solution 371 
mg (3.14 mmol, 15.0 eq.) 4,5- dicyanoimidazole (DCI) were added. Progress of the 
reaction was monitored by 31P-NMR. After completion of the reaction (2.5 h), oxidation 
was achieved by addition of 252 mg (1.46 mmol, 7.0 eq.) mCPBA at 0 °C. The mixture 
was stirred for 10 min at this temperature and 10 min at room temperature. The reaction 
mixture was diluted with DCM (150 mL) and washed twice with brine, dried over MgSO4 
and the solvents were removed in vacuo. Crystallization from dichloromethane/diethyl 
ether (4 mL/8 mL, 0 °C, overnight) and purification over a short* plug of silica using ethyl 
acetate as eluent yielded 225 mg 77 as a white solid (0.13 mmol, 64%). 
* long FC leads to decomposition 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.69 - 7.65 (m, 5H), 7.56 – 7.53 (m, 2H), 7.48 
- 7.17 (m, 30H), 7.12 - 7.01 (m, 5H), 5.88 - 5.84 (m, 1H), 5.72 - 5.56 (m, 4H), 5.35 - 4.76 
(m, 16H), 4.69 – 4.66 (m, 1H), 4.53 – 4.50 (m, 1H), 4.45 - 4.39 (m, 4H), 4.15 - 4.11 (m, 
2H), 4.05 – 3.99 (m, 1H), 3.21 (dd, J=16.9, J=6.2, 1H), 3.08 - 2.90 (m, 3H); 13C-NMR 
(126 MHz, 298 K, CDCl3, δ/ppm): 143.1 (d, J=2.6), 142.9, 142.8, 141.4 (d, J=6.0), 141.3 
(d, J=1.9), 140.4, 136.9 (d, J=3.7), 136.6 (d, J=3.8), 135.3, 135.2, 135.0 - 134.9 (m), 
134.7, 134.4, 129.8 - 128.8 (m), 128.0 (d, J=3.7), 127.9, 127.3 (d, J=4.2), 127.1, 126.3, 
126.1, 125.3 (d, J=6.4), 125.1, 125.0, 120.1 (d, J=9.7), 116.3, 115.9, 76.2 (d, J=5.4), 75.9 
- 75.6 (m), 73.4, 69.8 - 68.8 (m), 47.8 (d, J=8.0), 27.1 (d, J=6.7), 26.9 (d, J=6.8); 31P{1H}-
NMR (203 MHz, 298 K, CDCl3, δ/ppm): -1.54, -1.93, -2.90 (2P), -3.43, -5.49; m.p. 131 °C; 
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IR (neat, cm-1): 1451.2, 1286.3, 1225.5, 1050.1, 1023.1, 859.1, 755.0, 738.6, 460.9; Rf 
(SiO2, ethyl acetate) 0.43; HRMS (ESI) calcd for C84H76N2NaO24P6 [(M+Na)+] 1705.3111, 
found 1706.3116; [α]D20 = +18.7 (C 1.3, CHCl3). 
 
 
Synthesis of hexakisphosphate 78 
 
 
 
76 (150 mg, 0.16 mmol, 1.0 eq.) and o-xylylene N,N-diisopropylamino phosphoramidite 
18 (294 mg, 1.10 mmol, 7.0 eq.) were evaporated twice with dry acetonitrile (2 mL). The 
residue was dissolved in dry MeCN (15 mL) and cooled down (0 °C). To this solution 279 
mg (2.36 mmol, 15.0 eq.) 4,5- dicyanoimidazole (DCI) were added. Progress of the 
reaction was monitored by 31P-NMR. After completion of the reaction (3 h), oxidation was 
achieved by addition of 190 mg (1.10 mmol, 7.0 eq.) mCPBA at 0 °C. The mixture was 
stirred for 10 min at this temperature and 10 min at room temperature. The reaction 
mixture was diluted with DCM (150 mL), washed with brine, dried over MgSO4 and the 
solvents were removed in vacuo. Crystallization from dichloromethane/diethyl ether (3 
mL/6 mL, 0 °C, overnight) and purification on a short* plug of silica using ethyl acetate as 
eluent yielded 183 mg 78 as a white solid (0.11 mmol, 69%). 
* long FC leads to decomposition 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.76 – 7.71 (m, 4H), 7.65 (s, 1H), 7.59 - 7.56 
(m, 2H), 7.51 – 7.47 (m, 2H), 7.42 - 7.01 (m, 33H), 6.01 - 5.99 (m, 1H), 5.84 - 5.80 (m, 
1H), 5.69 - 5.64 (m, 2H), 5.59 – 5.54 (m, 1H), 5.50 - 5.39 (m, 3H), 5.29 - 5.15 (m, 6H), 
5.09 - 4.72 (m, 9H), 4.47 - 4.36 (m, 4H), 4.17 - 4.12 (m, 3H), 3.19 (dd, J=17.0, J=8.8, 1H), 
3.09 - 3.07 (m, 2H), 2.91 - 2.86 (m, 1H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 
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143.2 (d, J=8.2), 142.8 (d, J=3.1), 141.4, 141.3, 140.4, 136.3 (d, J=5.6), 135.8 (d, J=2.8), 
135.2 - 135.1 (m), 134.9 - 134.8 (m), 134.7, 134.5, 129.7 (d, J=4.9), 129.6, 129.5, 129.4 
(d, J=4.2), 129.2 - 129.0 (m), 128.8 - 128.6 (m), 128.1 (d, J=5.1), 127.9 (d, J=2.6), 127.3 
(d, J=4.3), 127.2 (d, J=2.6), 125.8 (d, J=2.9), 125.4 (d, J=2.7), 125.2, 125.1, 120.1, 120.1, 
117.4, 115.9, 76.6, 76.5, 75.9 (d, J=7.1), 75.7, 75.6, 73.5 - 73.2 (m), 69.9 - 68.8 (m), 47.9 
- 47.8 (m), 27.6 (d, J=7.1), 27.2 (d, J=4.2); 31P{1H}-NMR (203 MHz, 298 K, CDCl3, 
δ/ppm): -1.10, -1.42, -2.85, -3.20, -3.25, - 4.81; m.p. 123 °C; IR (neat, cm-1): 1292.1, 
1049.1, 1022.1, 850.5, 757.9, 735.7, 456.1; Rf (SiO2, ethyl acetate) 0.53; HRMS (ESI) 
calcd for C84H76N2NaO24P6 [(M+Na)+] 1705.3111, found 1706.3150; [α]D20 = +4.6 (C 2.7, 
CHCl3). 
 
 
Synthesis of protected 1,5-IP8 79 
 
 
 
Hexakisphosphate derivative 77 (50 mg, 0.03 mmol, 1.0 eq.) was evaporated twice with 
dry MeCN (0.2 mL) and then dissolved in dry MeCN (1.5 mL). 36.0 μL (37.0 mg, 0.24 
mmol, 8.0 eq.) DBU and 65 μL (62 mg, 0.24 mmol, 8.0 eq.) BSTFA were added. The 
solution was stirred 20 min at room temperature. After completion of the deprotection 
(checked by 31P-NMR), 65 μL MeOH and 18.0 μL (27.0 mg, 0.24 mmol, 8.0 eq.) TFA 
were added simultaneously to the solution. The mixture was stirred for 30 min and then 
evaporated to dryness. The residue was dissolved again in dry MeCN (1.5 mL) and 40 
μL (41 mg, 0.12 mmol, 4.0 eq.) bis-benzyl N,N-diisopropylamino phosphoramidite 20 and 
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0.27 mL (0.12 mmol, 4.0 eq.) 1H-tetrazole (0.45 M in MeCN) were added. The solution 
was stirred for 20 minutes at room temperature. Progress of the reaction was monitored 
by 31P-NMR. After completion of the reaction, oxidation was achieved by addition of 21 
mg (0.12 mmol, 4.0 eq.) mCPBA at 0 °C. The mixture was stirred 10 min at this 
temperature and 10 min at room temperature. Solvents were removed in vacuo and the 
residue was dissolved in dichloromethane (1 mL). Crystallization by addition of diethyl 
ether (ca. 0.5 mL, added until the precipitate starts to form, 0 °C, overnight) yielded 
compound 79 (50 mg, 0.026 mmol, 87%) as a colorless hygroscopic solid. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 10.77 (DBU), 8.93 (DBU), 7.37 - 6.98 (m, 
36H), 5.86 - 4.73 (m, 30H), 3.36 - 3.29 (m, 16H, DBU), 2.71 - 2.69 (m, 5H, DBU), 1.87 - 
1.85 (m, 5H, DBU), 1.60 - 1.57 (m, 16H, DBU), 1.29 - 1.25 (m, 5H, DBU); 13C-NMR (126 
MHz, 298 K, CDCl3, δ/ppm): 166.4, 143.3, 136.2 - 135.6 (m), 135.0, 134.3, 132.7, 132.5, 
129.9, 129.6, 129.3 - 128.7 (m), 128.5 - 128.1 (m), 127.9, 127.5, 74.3 – 74.2 (m), 72.5 – 
72.4 (m), 69.7 - 69.0 (m), 54.4 (DBU), 48.6 (DBU), 38.2 (DBU), 32.5 (DBU), 28.9 (DBU), 
26.7 (DBU), 23.8 (DBU), 19.4 (DBU);* 31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -
0.68, -1.25, -1.95, -2.53, -9.77 (d, J=12.6), -9.83 (d, J=13.9), -11.65 (d, J=12.5), -12.01 (d, 
J=14.0); IR (neat, cm-1): 3040.2, 2936.1, 1646.9, 1456.0, 1288.2, 1051.0, 1021.1, 848.5, 
736.7; Rf (SiO2, dichloromethane/metanol 8:1.5) 0.46; HRMS (ESI) calcd for 
C66H66NaO30P8- [(M+Na)-] 1609.1430, found 1609.1429; [α]D20 = +3.6 (C 2.0, CHCl3). 
* 1H NMR and 13C NMR indicate the presence of TFA-DBU salt. 
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Synthesis of protected 3,5-IP8 80 
 
 
 
Hexakisphosphate derivative 78 (100 mg, 0.059 mmol, 1.0 eq.) was evaporated twice 
with dry MeCN (0.3 mL) and then dissolved in dry MeCN (2.5 mL). 71.0 μL (72.0 mg, 
0.47 mmol, 8.0 eq.) DBU and 126 μL (121 mg, 0.47 mmol, 8.0 eq.) BSTFA were added. 
The solution was stirred 20 min at room temperature. After completion of the deprotection 
(checked by 31P-NMR), 125 μL MeOH and 36.0 μL (54.0 mg, 0.47 mmol, 8.0 eq.) TFA 
were added simultaneously to the solution. The mixture was stirred for 30 min and then 
evaporated to dryness. The residue was dissolved again in dry MeCN (2.5 mL) and 80 
μL (82 mg, 0.24 mmol, 4.0 eq.) bis-benzyl N,N-diisopropylamino phosphoramidite 20 and 
0.5 mL (0.24 mmol, 4.0 eq.) 1H-tetrazole (0.45 M in MeCN) were added. The solution 
was stirred for 20 minutes at room temperature. Progress of the reaction was monitored 
by 31P-NMR. After completion of the reaction, oxidation was achieved by addition of 41.0 
mg (0.24 mmol, 4.0 eq.) mCPBA at 0 °C. The mixture was stirred 10 min at this 
temperature and 10 min at room temperature. Solvents were removed in vacuo and the 
residue was dissolved in dichloromethane (2 mL). Crystallization from diethyl ether (ca. 1 
mL, added until the precipitate starts to form, 0 °C, overnight) yielded compound 79 (110 
mg, 0.058 mmol, 98%) as a colorless hygroscopic solid. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 11.03 (DBU), 8.84 (DBU), 7.36 - 6.97 (m, 
36H), 5.87 - 4.73 (m, 30 H), 3.42 - 3.35 (m, 23H, DBU), 2.73 - 2.71 (m, 8H, DBU), 1.94 – 
1.90 (m, 8H, DBU), 1.65 - 1.61 (m, 24H, DBU), 1.31 – 1.29 (m, 6H); 13C-NMR (126 MHz, 
298 K, CDCl3, δ/ppm): 166.4, 144.0, 136.1 - 135.9 (m), 135.7 - 135.6 (m), 135.4, 135.0, 
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134.9, 134.1, 131.8, 129.8, 129.4 - 128.7 (m), 128.5 -128.4 (m), 128.3 - 128.2 (m), 128.1 
- 128.0 (m), 127.9 - 127.8 (m), 127.6, 127.5, 74.3 – 74.1 (m), 73.3 – 73.2 (m), 72.5 – 72.4 
(m), 69.8 - 69.0 (m), 68.29 (d, J = 5.7 Hz), 67.48 (d, J = 5.7 Hz), 54.4 (DBU), 48.6 (DBU), 
47.2, 38.2 (DBU), 32.6 (DBU), 28.9 (DBU), 26.7 (DBU), 23.8 (DBU), 19.4 (DBU), 19.3 (d, 
J=3.5);* 31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -0.54, -0.95, -1.80, -2.33, -9.77 
(d, J=12.3), -9.83 (d, J=13.9), -11.80 (d, J=12.3), -12.12 (d, J=13.9); IR (neat, cm-1): 
2931.3, 1646.0, 1456.0, 1289.2, 1051.0, 1021.1, 844.7, 810.9, 739.6; Rf (SiO2, 
dichloromethane/methanol 8:1.5) 0.44; HRMS (ESI) calcd for C66H67O30P8- [(M+H)-] 
1587.1624, found 1587.1625; [α]D20 = - 3.8 (C 0.5, CHCl3). 
* 1H NMR and 13C NMR indicate the presence of TFA-DBU salt. 
 
 
Synthesis of 1,5-InsP8 (octasodium salt) 
 
 
 
Protected bis-P-anhydride 79 (30 mg, 0.016 mmol, 1.0 eq.) was dissolved in tert-
butanol/water 3:1 (1.0 mL). To this solution 11 mg (0.13 mmol, 8.0 eq.) NaHCO3 and 100 
mg (0.094 mmol, 6 eq.) Pd (10 wt. %, on carbon) were added. After 1 hour of 
hydrogenation at 180 bar in a steel autoclave, 0.4 mL water were added to the mixture 
and the hydrogenation was continued for another 2 hours. The mixture was centrifuged 
and the supernatant removed. The catalyst was washed with water (1 mL) and to this 
washing fraction, acetone (10 mL) was added. The precipitate was isolated by 
centrifugation yielding the octasodium salt of 1,5-InsP8 (11 mg, 0.011 mmol, 69%) as a 
colorless solid. 
1H-NMR (500 MHz, 298 K, D2O, water suppression, δ/ppm): 4.62 - 4.56 (m, 2H), 4.47 - 
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4.40 (m, 4H); 13C-NMR (126 MHz, 298 K, D2O, δ/ppm): 75.16 - 75.11 (m), 73.39 - 73.25 
(m), 73.04 - 72.96 (m), 72.07 - 71.97 (m), 65.84 - 65.69 (m); 31P{1H}-NMR (203 MHz, 298 
K, D2O, δ/ppm): 4.59, 3.63, 3.27, 3.19, -4.33 – (-4.47) (m, 2P), -9.13 – (-9.21) (m, 1P), -
9.74 – (-9.82) (m, 1P); 31P NMR (203 MHz, 298 K, D2O, δ/ppm): 4.59 (d, J=12.1), 3.63 (d, 
J=10.4), 3.30 – 3-16 (m), -4.33 - -4.48 (m, 2P), -9.19 – (- 9.86) (m, 2P); HRMS (ESI) 
calcd for C6H17O30P83- 272.2574, found 272.2579; calcd for C6H18O30P82- 408.8897, found 
408.8895. 
Optical rotation data was inconclusive due to very small values that were distributed 
around 0. This data is therefore not reported. 
  
  
Synthesis of 3,5-InsP8 (octasodium salt) 
 
 
 
Protected bis-P-anhydride 80 (30 mg, 0.016 mmol, 1.0 eq.) was dissolved in tert-
butanol/water 3:1 (1.0 mL). To this solution 11 mg (0.128 mmol, 8.0 eq.) NaHCO3 and 
100 mg (0.094 mmol, 5.9 eq.) Pd (10 wt. %, on carbon) were added. After 1 hour of 
hydrogenation at 180 bar in a steel autoclave, 0.4 mL water were added to the mixture 
and the hydrogenation continued for another 2 hours. The mixture was centrifuged and 
the supernatant removed. The catalyst was washed with water (1 mL) and to this 
washing fraction, acetone (10 mL) was added. The precipitate was isolated by 
centrifugation yielding the octasodium salt of 3,5-InsP8 (12 mg, 0.012 mmol, 75%) as a 
white solid. 
1H-NMR (500 MHz, 298 K, D2O, water suppression, δ/ppm): 4.59 - 4.53 (m, 2H), 4.43 (m, 
4H); 13C NMR (126 MHz, 298 K, D2O, δ/ppm): 75.4 - 75.1 (m), 73.5 - 73.3 (m), 73.3 - 
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73.1 (m), 72.2 - 72.0 (m), 66.0 - 65.7 (m); 31P{1H}-NMR (203 MHz, 298 K, D2O, δ/ppm): 
4.56, 3.52, 3.17, 3.05, -4.62 – (- 4.70) (m, 2P), -9.54 – (-9.62) (m, 1P), -9.87 – (-9.95) (m, 
1P); 31P-NMR (203 MHz, 298 K, D2O, δ//ppm): 4.55 (d, J=12.4), 3.51 (d, J=10.4), 3.20 – 
3.02 (m, 2P), -4.62 – (-4.71) (m, 2P), -9.54 – (-9.56) (m, 1P), -9.91 – (-9.96) (m, 1P); 
HRMS (ESI) calcd for C6H17O30P83- 272.2574, found 272.2579; calcd for C6H16Na2O30P82- 
430.8717, found 430.8711; calcd for C6H15Na3O30P82- 441.8627, found 441.8625; calcd 
for C6H14Na4O30P82- 452.8536, found 452.8535. 
Optical rotation data was inconclusive due to very small values that were distributed 
around 0. This data is therefore not reported. 
 
 
6.5 SYNTHESIS OF 5-PP-INSP5 AND 5-PPP-INSP5 
 
Synthesis of 16 
 
 
 
A) 2.10 g (3.34 mmol, 1.0 eq.) 14 and 1.09 g (4.01 mmol, 1.2 eq.) phosphoramidite 11 
were evaporated twice with dry MeCN (2 mL) and then dissolved in dry MeCN (5 mL). 
After addition of 9.5 mL (4.34 mmol, 1.3 eq.) 1H-tetrazole (0.45 M in MeCN), the reaction 
mixture was stirred at room temperature for 1.5 h. The mixture was cooled down (0 °C) 
and 0.9 mL (5.01 mmol, 1.5 eq.) tert-butyl hydroperoxide solution (5.5 M in decane) were 
added. The mixture was stirred at this temperature for 5 minutes, then at room 
temperature for 20 min and half of the solvents were evaporated under high vacuum. The 
solution was diluted with ethyl acetate, washed with brine (3x), dried over MgSO4 and the 
solvents were removed in vacuo. The crude material was directly used in the next step B). 
B) The crude material (3.34 g, 4.10 mmol) was dissolved in MeOH (105 mL) and DCM 
(35 mL). 282 mg (1.64 mmol, 0.4 eq.) pTsOH were added and the solution was refluxed 
for 5 minutes and then again for another 5 min. The reaction was diluted with ethyl 
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acetate and washed with saturated aqueous NaHCO3 (3x). After separation, the organic 
layer was washed with brine, dried over MgSO4 and the solvents were removed in vacuo. 
Purification was achieved by column chromatography (dichloromethane/methanol 50:1) 
yielding 1.40 g 16 as an oil (1.93 mmol, 58%, over 2 steps). 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.36 – 7.32 (m, 4H), 7.27 – 7.23 (m, 2H), 6.93 
– 6.87 (m, 6H), 4.80 – 4.72 (m, 6H), 4.34 – 4.27 (m, 1H), 4.15 – 4.07 (m, 2H), 4.04 – 3.94 
(m, 3H), 3.83 – 3.75 (m, 11H), 3.60 – 3.57 (m, 2H), 2.49 – 2.34 (m, 4H); 13C-NMR (126 
MHz, 298 K, CDCl3, δ/ppm): 159.5, 159.4, 130.3, 130.2, 129.7, 116.5, 114.0, 113.9, 79.9 
(d, J = 3.1 Hz), 78.6, 75.1, 74.0, 72.1, 62.2 (d, J = 4.8 Hz), 55.3, 19.4, 19.3; 31P{1H}-NMR 
(162 MHz, 298 K, CDCl3, δ/ppm): -1.40; IR (neat, cm-1): 3424.0, 2936.1, 2837.7, 1612.2, 
1512.9, 1246.8, 1073.2, 1025.9, 821.5, 729.0; Rf (SiO2, dichloromethane/ethyl acetate 
1:1) 0.24; HRMS (ESI) calcd for C36H43N2NaO12P [(M+Na)+] 749.2446, found 749.2441. 
 
 
Synthesis of 17 
 
 
 
Meso compound 16 (650 mg, 0.89 mmol) was dissolved in chloroform (55 mL) and 
trifluoroacetic acid (2 mL, 3.6% v/v) was added to the solution. The reaction was stirred 
at room temperature with formation of a white precipitate. After stirring the solution for 4 h, 
hexane was added and the solvents were removed in vacuo. The residue was partially 
dissolved in dichloromethane and methanol and crystallization by addition of TBME and 
hexane (0 °C, overnight) yielded compound 17 as a white solid (280 mg, 0.76 mmol, 
85%). 
1H-NMR (500 MHz, 298 K, DMSO, δ/ppm): 4.98 – 4.67 (m, 4H), 4.26 – 4.16 (m, 4H), 3.94 
– 3.88 (m, 1H), 3.71 – 3.70 (m, 1H), 3.58 – 3.54 (m, 2H), 3.34 – 3.32 (m, 1H), 3.21 – 3.18 
(m, 2H), 2.91 – 2.89 (m, 4H); 13C-NMR (126 MHz, 298 K, DMSO, δ/ppm): 118.8, 84.1 (d, 
J = 7.1 Hz), 72.9, 71.9, 71.6 (d, J = 3.0 Hz), 62.4 (d, J = 5.0 Hz), 19.4 (d, J = 7.6 Hz); 
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31P{1H}-NMR (203 MHz, 298 K, DMSO, δ/ppm): -2.45; IR (neat, cm-1): 3389.3, 3295.8, 
2360.4, 1255.4, 1045.2; HRMS (ESI) calcd for C12H19N2NaO9P [(M+Na)+] 389.0720, 
found 389.0720.  
 
 
Synthesis of 19 
 
 
 
17 (280 mg, 0.76 mmol, 1.0 eq.) and o-xylylene N,N-diisopropylamino phosphoramidite 
18 (1.83 g, 6.84 mmol, 9.0 eq.) were evaporated twice with dry acetonitrile (3-5 mL). Dry 
MeCN (60 mL) was added and the mixture cooled down (0 °C). The residue was not 
completely soluble. To this mixture 1.62 g (13.7 mmol, 18.0 eq.) 4,5- dicyanoimidazole 
(DCI) were added and the residue started to dissolve. Progress of the reaction was 
monitored by 31P-NMR. After completion of the reaction (4 h), oxidation was achieved by 
addition of 1.18 g (6.84 mmol, 9.0 eq.) mCPBA at 0 °C. The mixture was stirred for 10 
min at this temperature and 10 min at room temperature. The reaction mixture was 
diluted with DCM, washed with brine, dried over MgSO4 and the solvents were removed 
in vacuo. Crystallization from dichloromethane/diethyl ether (diethyl ether added until the 
solution becomes turbid, 0 °C, overnight) and purification by gradient column 
chromatography (ethyl acetate/methanol 1%-8%) yielded 580 mg 19 as a white solid 
(0.45 mmol, 59%). 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 7.39 – 7.25 (m, 20H), 5.71 – 5.57 (m, 5H), 
5.46 – 5.36 (m, 6H), 5.24 – 5.07 (m, 12H), 5.00 – 4.96 (m, 2H), 4.85 – 4.79 (m, 1H), 4.45 
– 4.35 (m, 4H), 2.86 – 2.75 (m, 4H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 140.4, 
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135.3, 135.2, 135.2, 134.9, 134.5, 129.6 - 129.0 (m), 117.0, 110.8, 76.5, 73.6, 69.5 - 69.3 
(m), 63.1 (d, J = 5.4 Hz), 21.1, 19.5, 19.4 (d, J = 8.3 Hz); 31P{1H}-NMR (203 MHz, 298 K, 
CDCl3, δ/ppm): -2.10 (2P), -3.14, -3.52 (2P), - 4.08; IR (neat, cm-1): 1288.2, 1225.5, 
1050.1, 1021.1, 878.4, 860.1, 731.9; Rf (SiO2, ethyl acetate/methanol 20:1) 0.22; HRMS 
(ESI) calcd for C52H54N2NaO24P6 [(M+Na)+] 1299.1384, found 1299.1383;  
 
 
Synthesis of 21 
 
 
 
Hexakisphosphate derivative 19 (100 mg, 0.078 mmol, 1.0 eq.) was evaporated twice 
with dry MeCN (0.3 mL) and then dissolved in dry MeCN (3 mL). 46.0 μL (47.0 mg, 0.31 
mmol, 4.0 eq.) DBU and 83 μL (80 mg, 0.31 mmol, 4.0 eq.) BSTFA were added. The 
solution was stirred 20 min at room temperature. After completion of the deprotection 
(checked by 31P-NMR), 80 μL MeOH and 24.0 μL (36.0 mg, 0.31 mmol, 4.0 eq.) TFA 
were added simultaneously to the solution. The mixture was stirred for 30 min and then 
evaporated to dryness. The residue was dissolved again in dry MeCN (3 mL) slowly a 
precipitate was formed. DMF (3 mL) was added and the mixture was stirred until the 
residue dissolved. 52 μL (54 mg, 0.16 mmol, 2.0 eq.) bis-benzyl N,N-diisopropylamino 
phosphoramidite 20 and 0.35 mL (0.16 mmol, 2.0 eq.) 1H-tetrazole (0.45 M in MeCN) 
were added. The solution was stirred for 20 minutes at room temperature. Progress of 
the reaction was monitored by 31P-NMR. After completion of the reaction, oxidation was 
achieved by addition of 27 mg (0.16 mmol, 2.0 eq.) mCPBA at 0 °C. The mixture was 
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stirred 10 min at this temperature and 10 min at room temperature. Crystallization by 
addition of diethyl ether (added until the precipitate starts to form, 0 °C, overnight) yielded 
compound 21 (85 mg, 0.054 mmol, 69%) as a colorless solid. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 11.01 (DBU), 8.83 (DBU), 7.39 – 7.20 (m, 
28H), 7.06 – 7.04 (m, 2H), 5.74 – 5.64 (m, 4H), 5.58 – 5.41 (m, 7H), 5.29 – 4.93 (m, 19H), 
3.35 - 3.27 (m, 7H, DBU), 2.72 - 2.70 (m, 3H, DBU), 1.87 – 1.82 (m, 3H, DBU), 1.64 - 
1.52 (m, 8H, DBU), 1.28 – 1.27 (m, 2H); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 
166.3, 162.6, 136.3 – 135.6 (m), 134.9, 129.4 – 128.8 (m), 128.4, 128.1, 127.9, 74.0, 
69.4 – 69.1 (m), 54.3 (DBU), 48.6 (DBU), 47.3, 38.2 (DBU), 32.4 (DBU), 29.0 (DBU), 
26.7 (DBU), 23.9 (DBU), 19.4 (DBU) 19.4;* 31P{1H}-NMR (162 MHz, 298 K, CDCl3, 
δ/ppm): -2.60 (2P), -3.17, -3.59 (2P), -11.08 (d, J=12.8), -12.81 (d, J=13.0); IR (neat, cm-
1): 2936.1, 1646.9, 1457.0, 1288.2, 1224.6, 1049.1, 1020.2, 977.7, 846.6, 732.8; HRMS 
(ESI) calcd for C60H60O27P7- 1429.1491, found 1429.1488.  
* 1H NMR and 13C NMR indicate the presence of TFA-DBU salt. 
  
 
Synthesis of 5-PP-InsP5 
 
 
 
Protected P-anhydride 21 (20 mg, 0.013 mmol, 1.0 eq.) was dissolved in tert-
butanol/water 3:1 (1.0 mL). To this solution 9 mg (0.104 mmol, 8.0 eq.) NaHCO3 and 80 
mg (0.078 mmol, 6 eq.) Pd (10 wt. %, on carbon) were added. After 1 hour of 
hydrogenation at 180 bar in a steel autoclave, 0.4 mL water were added to the mixture 
and the hydrogenation continued for another 2 hours. The mixture was centrifuged and 
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the supernatant removed. The catalyst was washed with water and to this washing 
fraction, acetone was added (ratio 1:8). The precipitate was isolated by centrifugation 
yielding 5-PP-InsP5 (5.4 mg, 0.006 mmol, 46%) as a white solid. 
31P{1H}-NMR (203 MHz, 298 K, D2O, δ/ppm): 1.68 (2P), 1.14, 0.79 (2P), -7.09, -9.84 – (-
9.94) (m, 1P); HRMS (ESI) calcd for C6H17O27P72- 368.9066, found 368.9071. 
 
 
Synthesis of 23 
 
 
 
Hexakisphosphate derivative 19 (100 mg, 0.078 mmol, 1.0 eq.) was evaporated twice 
with dry MeCN (0.3 mL) and then dissolved in dry MeCN (3 mL). 46.0 μL (47.0 mg, 0.31 
mmol, 4.0 eq.) DBU and 83 μL (80 mg, 0.31 mmol, 4.0 eq.) BSTFA were added. The 
solution was stirred 30 min at room temperature. After completion of the deprotection 
(checked by 31P-NMR), 80 μL MeOH and 24.0 μL (36.0 mg, 0.31 mmol, 4.0 eq.) TFA 
were added simultaneously to the solution. The mixture was stirred for 30 min and then 
evaporated to dryness. The residue was dissolved in dry DMF (1.5 mL) and the mixture 
was stirred until the residue dissolved completely. 1.4 mL (0.62 mmol, 8.0 eq.) 1H-
tetrazole (0.45 M in MeCN) were added. Then a solution of 81 mg (0.16 mmol, 2.0 eq.) 
(FmO)2PN(iPr)2 22 in DMF (1.5 mL) previously coevaporated with acetonitrile (0.2 mL) 
was added. The solution was stirred for 40 minutes at room temperature. Progress of the 
reaction was monitored by 31P-NMR. After completion of the reaction, oxidation was 
achieved by addition of 27 mg (0.16 mmol, 2.0 eq.) mCPBA at 0 °C. The mixture was 
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stirred 10 min at this temperature and 10 min at room temperature. Crystallization by 
addition of diethyl ether (added until the precipitate starts to form, 0 °C, overnight) yielded 
compound 23 (122 mg, 0.069 mmol, 88%) as a colorless solid. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 10.78 (DBU), 8.81 (DBU), 7.63 – 7.57 (m, 8H), 
7.36 – 7.06 (m, 28H), 5.74 – 5.27 (m, 13H), 5.16 – 4.96 (m, 13H), 4.39 – 4.30 (m, 4H), 
4.16 – 4.14 (m, 2H), 3.25 - 3.17 (m, 7H, DBU), 2.60 - 2.58 (m, 2H, DBU), 1.74 – 1.72 (m, 
2H, DBU), 1.48 - 1.46 (m, 7H, DBU); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 166.1, 
143.6, 143.4, 141.2, 141.1, 136.0 – 135.6 (m), 134.9, 129.4 – 128.8 (m), 127.6, 127.1, 
127.0, 125.6 (d, J = 5.6 Hz), 119.7, 74.1, 69.5 – 69.0 (m), 54.2 (DBU), 48.5 (DBU), 47.9 
(d, J = 8.1 Hz), 38.1 (DBU), 32.4 (DBU), 28.9 (DBU), 26.6 (DBU), 23.8 (DBU), 19.3 
(DBU);* 31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -1.32 (2P), -2.07, -2.33 (2P), -
10.27 (d, J=13.9), -11.70 (d, J=14.1); IR (neat, cm-1): 2942.6, 1670.1, 1646.9, 1450.2, 
1286.3, 1050.1, 1019.2, 972.9, 846.6, 732.8; Rf (SiO2, dichloromethane/methanol 8:1) 
0.24; HRMS (ESI) calcd for C74H68O27P7- 1605.2117, found 1605.2098.  
* 1H NMR and 13C NMR indicate the presence of TFA-DBU salt. 
 
Synthesis of 24 
 
 
 
Pyrophosphorylated derivative 23 (40 mg, 0.022 mmol, 1.0 eq.) was evaporated twice 
with dry MeCN (0.2 mL) and then dissolved in dry DMF (2 mL). 13.0 μL (13.0 mg, 0.088 
mmol, 4.0 eq.) DBU were added and the solution was stirred 15 min at room temperature. 
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After completion of the deprotection (checked by 31P-NMR), 0.30 mL (0.132 mmol, 6.0 
eq.) 1H-tetrazole (0.45 M in MeCN) and 15 μL (15 mg, 0.044 mmol, 2.0 eq.) bis-benzyl 
N,N-diisopropylamino phosphoramidite 20 were added. The mixture was stirred for 45 
min at room temperature and oxidation was achieved by addition of 8 mg (0.044 mmol, 
2.0 eq.) mCPBA at 0 °C. The mixture was stirred 10 min at this temperature and 10 min 
at room temperature. Crystallization by addition of diethyl ether (added until the 
precipitate starts to form, 0 °C, overnight) yielded compound 24 (30mg, 0.017 mmol, 
77%) as a sticky solid. 
1H-NMR (500 MHz, 298 K, CDCl3, δ/ppm): 10.98 (DBU), 8.98 (DBU), 7.37 – 7.18 (m, 
30H), 5.77 – 4.94 (m, 30H), 3.31 - 3.22 (m, 14H, DBU), 2.69 (5H, DBU), 1.80 – 1.79 (m, 
5H, DBU), 1.54 - 1.48 (m, 14H, DBU); 13C-NMR (126 MHz, 298 K, CDCl3, δ/ppm): 166.2, 
143.6, 138.7, 136.4 – 135.1 (m), 129.4 – 128.8 (m), 128.3 - 127.9 (m), 127.5, 127.3, 
110.0, 74.1, 69.4 – 69.1 (m), 67.3 (d, J = 5.4 Hz), 54.2 (DBU), 48.5 (DBU), 46.8, 38.1 
(DBU), 32.4 (DBU), 29.7, 28.9 (DBU), 26.7 (DBU), 23.8 (DBU), 19.3 (DBU), 19.3;* 
31P{1H}-NMR (162 MHz, 298 K, CDCl3, δ/ppm): -1.47 (2P), -2.03, -2.56 (2P), -10.81 – (-
11.22) (m, 2P), -21.09 – (-21.32) (m, 1P); IR (neat, cm-1): 3487.6, 2930.3, 2860.9, 1713.4, 
1667.2, 1573.6, 1496.5, 1437.7, 1386.6, 1285.3, 1255.4, 1092.5, 756.0, 705.8, 659.5.  
* 1H NMR and 13C NMR indicate the presence of TFA-DBU salt. 
 
Synthesis of 3-PPP-InsP5 
 
 
 
Protected P-anhydride 24 (10 mg, 0.006 mmol, 1.0 eq.) was dissolved in tert-
butanol/water 3:1 (1.0 mL). To this solution 50 mg (0.047 mmol, 8 eq.) Pd (10 wt. %, on 
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carbon) were added. After 1 hour of hydrogenation at 80 bar in a steel autoclave, 0.5 mL 
water were added to the mixture and the hydrogenation continued for another 2 hours. 
The mixture was centrifuged and the supernatant removed. The catalyst was washed 
with water and to this washing fraction acetone was added (ratio 1:8). The precipitate 
was isolated by centrifugation yielding 5-PPP-InsP5 (2.2 mg, 0.003 mmol, 50%) as a 
sticky solid. 
 
 
6.6 GENERAL PROCEDURES FOR THE DESYMMETRIZATION OF MYO-
INOSITOL 
 
Desymmetrization of diol 43 (Scheme 4.14) 
Phosphoramidite 12 (55 mg, 0.13 mmol, 1.0 eq.) was dissolved in DCM (2 mL) and 0.90 
mL (0.39 mmol, 3.0 eq.) 1H-tetrazole (0.45 M in MeCN) were added. The mixture was 
stirred at room temperature for 45 min. In another flask, diol 43 was dissolved in DCM (1 
mL). Both solutions were cooled to -78 °C. The solution containing phosphoramidite 12 
was transferred to the solution containing diol 43 via cannula. The mixture was stirred at -
78 °C and the progress of the reaction was monitored by 31P-NMR. After 1h mCPBA was 
added and the reaction mixture was allowed to warm to room temperature. The mixture 
was diluted with ethyl acetate, washed with brine, dried over MgSO2 and the solvents 
were removed in vacuo.  
 
Desymmetrization of diol 49 (Scheme 4.16) 
Phosphoramidite 12 (50 mg, 0.16 mmol, 1.5 eq.) was dissolved in acetonitrile (1.5 mL) 
and 60 µL (0.55 mmol, 5.0 eq.) pentafluorophenol were added. The mixture was stirred at 
room temperature for 1 h. After complete activation of phosphoramidite 12 (monitored by 
31P-NMR), solvents were evaporated. The residue dissolved in DMF (1.0 mL) and the 
solution cooled to -40 °C. In another flask, diol 49 was dissolved in DMF (0.5 mL) and 
transferred to the mixture containing activated phosphoramidite 12. The mixture was 
stirred at -40 °C and the progress of the reaction was monitored by 31P-NMR. 0.04 mL 
(0.22 mmol, 2 eq.) tert-butyl hydroperoxide solution (5.5 M in decane) was added and the 
reaction mixture was allowed to warm to room temperature. The mixture was diluted with 
ethyl acetate, washed with brine (3x), dried over MgSO2 and the solvents were removed 
in vacuo. 
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